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SUMMARY
It is known from the folk medicine that Cannabis may reduce pain. The aim of the pain study
was to compare analgesic effects of oral delta-9-tetrahydrocannabinol (THC, dronabinol,
Marinol‚, main psychoactive component of the Cannabis plant) and a THC-morphine
combination to morphine and placebo. This pain study was performed with 12 healthy
volunteers in four different experimental models of acute pain. Additionally, side effects and vital
functions were monitored and blood samples collected for the pharmacokinetic profiling of oral
THC. In none of the pain models THC showed a significant analgesic effect. The THC-morphine
combination showed a slight tendency to an additive effect compared to morphine alone, but
this was not statistically significant. The side effects observed with THC were mainly sleepiness
and mild to intermediate psychotropic side effects. The plasma concentrations of THC, analysed
with gas chromatography mass-spectrometry, were very low, showed a plasma peak time of 60
to 120 min with high inter-individual variation. In addition, an extensive liver first pass
metabolism could be observed leading to high metabolite-THC ratios.
In the second part of the present work the aim was to develop an application form as
alternative to the Marinol‚ capsules. The very lipophilic THC was solubilised with
Cremophor‚ RH 40 leading to a water-soluble THC formulation, which could be used as
inhalation solution for the pulmonal administration of THC. This formulation underwent an in
vitro quality assurance focussing on stability and physiological tolerability. Additionally, the
particle size of the droplets in the aerosol and the output rate of the evaluated nebuliser system
for the clinical application were determined.
In the third part of this work, the developed application form (inhalation solution) was used for
a second clinical study with eight healthy volunteers. The pharmacokinetic properties of
pulmonal THC were compared to intravenous THC and the analgesic effects were determined
comparing with pulmonal placebo. With the pulmonal application form the very low
bioavailability of oral THC could be increased up to 6-fold. Comparing the elimination half-lives,
a 5-fold decrease of the half-life after pulmonal and intravenous THC compared to oral THC
was observed, indicating that absorption is the time-determining step in the pharmacokinetic
behaviour of orally administered THC. This was also reflected by the peak plasma concentration
time, which occurred right at the end of the inhalation procedure of about 20 min (3 to 6-times
earlier than with oral THC). Peak plasma concentrations were much higher after pulmonal than
oral administration causing much less side effects, indicating that not only THC itself is
responsible for the psychotropic side effects but also the known strongly psychoactive
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11-hydroxy-THC. Metabolite-THC ratios were found to be much lower after pulmonal and
intravenous THC than after oral THC.
The most prominent side effect of pulmonal THC was the irritation of the throat and coughing
during the inhalation, which were reversible within short time after finishing the inhalation
procedure.
Despite the increased bioavailability of pulmonal THC no analgesic effect resulted,
suggesting that the bioavailability does not affect the efficacy in the pain reducing properties of
THC. We assume that the used experimental pain models, which were all models of acute pain,
were not appropriate to study the analgesic properties of THC. Further experiments are needed
to evaluate the appropriate pain tests for THC and healthy subjects. In addition, it would be very
interesting to investigate the analgesic effect of the pulmonal THC in patients suffering from
chronic and neuropathic pain.
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ZUSAMMENFASSUNG
Aus der Volksmedizin ist bekannt, dass Cannabis Schmerzen lindern kann. Das Ziel der
Schmerzstudie war es, den analgetischen Effekt von Delta-9-Tetrahydrocannabinol (THC,
Dronabinol, Marinol‚, psychoaktive Hauptkomponente der Cannabispflanze) und einer THC-
Morphin-Kombination mit Morphin und Placebo zu vergleichen. Die Schmerzstudie wurde an
12 gesunden Freiwilligen in vier verschiedenen experimentellen Akut-Schmerzmodellen
durchgeführt. Zusätzlich wurden Nebenwirkungen und Vitalfunktionen überwacht und
Blutproben für das pharmakokinetische Profiling des oral applizierten THC gesammelt. In
keinem der Schmerzmodelle zeigte THC einen signifikanten analgetischen Effekt. Die THC-
Morphin-Kombination zeigte eine leichte Tendenz zu einem additiven Effekt verglichen mit
Morphin allein. Dieser Effekt war jedoch statistisch nicht signifikant. Die unter THC
beobachteten Nebenwirkungen waren hauptsächlich Schläfrigkeit wie auch milde bis
mittelstarke psychotropische Effekte. Die Plasmakonzentrationen des THC, die mit
Gaschromatographie-Massenspektrometrie bestimmt wurden, waren sehr tief. Die maximalen
Plasmakonzentrationen wurden nach 60 bis 120 min beobachtet und zeigten eine grosse
interindividuelle Variation. Ausserdem wurde ein ausgeprägter First-pass Metabolismus, der zu
hohen Metaboliten-THC-Quotienten führte, beobachtet.
Das Ziel im zweiten Teil der vorliegenden Arbeit war es, eine alternative Applikationsform zu
den Marinol‚ Kapseln zu entwickeln. Das stark lipophile THC wurde mit Cremophor‚ RH 40
solubilisiert, was zu einer wasserlöslichen THC-Formulierung führte, die als Inhalationslösung
zur pulmonalen Verabreichung verwendet werden konnte. Diese Formulierung wurde einer In-
vitro-Qualitätssicherung unterzogen, die sich vorwiegend auf Stabilität und physiologische
Verträglichkeit konzentrierte. Zusätzlich wurden die Partikelgrösse der Tröpfchen im Aerosol
und die Freisetzungsrate des Verneblers, welcher für die klinische Applikation evaluiert worden
war, bestimmt.
Im dritten Teil der vorliegenden Arbeit wurde die entwickelte Applikationsform (Inhalations-
lösung) in einer zweiten klinischen Studie acht gesunden Probanden verabreicht. Die
pharmakokinetischen Eigenschaften von pulmonal appliziertem THC wurden mit denjenigen
einer intravenösen Applikation verglichen. Gleichzeitig wurde der analgetische Effekt mit
pulmonalem Placebo verglichen. Die sehr tiefe Bioverfügbarkeit von oral appliziertem THC
konnte mit der pulmonalen Applikationsform bis auf das Sechsfache erhöht werden. Die
Eliminationshalbwertszeiten nach pulmonaler und intravenöser Verabreichung waren im
Vergleich zur oralen Form um das Fünffache verkürzt, was darauf hindeutet, dass die
Absorption der geschwindigkeitsbestimmende Schritt im pharmakokinetischen Verhalten von
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oral verabreichtem THC ist. Dies widerspiegelte auch der Zeitpunkt der maximalen
Plasmakonzentration, der unmittelbar nach Beendigung der Inhalation (nach ca. 20 min, und
somit 3 bis 6mal schneller als nach oraler Verabreichung) erreicht wurde. Die maximalen
Plasmakonzentrationen waren viel höher nach pulmonaler als nach oraler Verabreichung und
verursachten gleichzeitig weniger Nebenwirkungen. Dies weist darauf hin, dass nicht nur THC
selber für die psychotropen Nebenwirkungen verantwortlich ist, sondern auch der stark
psychoaktive Metabolit 11-Hydroxy-THC. Die Metaboliten-THC-Quotienten waren nach der
pulmonalen und intravenösen Verabreichung viel tiefer als nach der oralen.
Die auffälligste Nebenwirkung von pulmonal appliziertem THC war die Irritation der Atem-
wege und der Hustenreiz während der Inhalation. Diese Irritation war innerhalb kurzer Zeit nach
Beendigung der Inhalation reversibel.
Trotz der verbesserten Bioverfügbarkeit von pulmonalem THC konnte kein analgetischer
Effekt gezeigt werden, was darauf hinweist, dass die Bioverfügbarkeit die Wirksamkeit nicht
beeinflusst. Dies lässt vermuten, dass die eingesetzten experimentellen Schmerzmodelle,
welche ausschliesslich Akut-Schmerzmodelle sind, zur Untersuchung der analgetischen
Eigenschaften von THC nicht geeignet waren. Weitere Experimente sind erforderlich, um
geeignete Schmerztests für THC an gesunden Probanden zu evaluieren. Es wäre ausserdem
sehr interessant, den analgetischen Effekt von pulmonal verabreichtem THC an Patienten zu
untersuchen, welche an chronischen oder auch neuropathischen Schmerzen leiden.
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INTRODUCTION AND AIM OF THE PRESENT WORK
The medicinal use of Cannabis has a very long tradition. It has been used for a variety of
symptoms including for example pain, sleeplessness, and pre-menstrual symptoms [1]. The
discovery of the endogenous cannabinoid system in the early 1990ies opened a broad field for
research helping to understand more and more the molecular mechanisms of the Cannabis
effects and the links to other modulating or regulatory systems in our body [2]. In addition, the
endogenous cannabinoid system offers a lot of new targets for drug therapy [3].
Beside the research in molecular biology, the known indications of Cannabis from the folk
medicine have to be clinically investigated. Some applications, e.g. against chemotherapy-
induced nausea and vomiting or as antianorectic drug, of D9-tetrahydrocannabinol (THC, the
main psychoactive component of the Cannabis plant) are already established. Marinol‚, a soft
gelatine capsule containing THC dissolved in sesame oil, is a FDA-registered drug, which can
be used in Switzerland for clinical research.
The analgesic effect of THC is not yet sufficiently investigated. We know from the folk
medicine and anecdotal reports that Cannabis may reduce pain. It is widely used in self-
medication to relieve pain of different origins such as back pain, headache, and migraine [4].
Several animal studies in different pain models show the antinociceptive effect of THC [5, 6].
There it has been shown that THC even potentiates the analgesic effects of morphine [7]. In
humans there are only few controlled clinical studies and the results are not convincing. This
motivated us to perform controlled clinical trials with established experimental pain tests. The
aim of the pain study was to test the antinociceptive effects of oral THC and THC combined with
morphine (THC-morphine) versus morphine and placebo in healthy subjects under experimental
pain conditions. In addition to the pain tests the adverse effects should be monitored and
plasma profiles be acquired to study the pharmacokinetics of THC and to check for a possible
correlation of the plasma concentrations with analgesia and side effects.
In the second part of this work the aim was to develop an application form as alternative to
the Marinol“ capsules. As administration route the lung was chosen. Some pharmacokinetic
studies have shown that smoked Cannabis produce early and high THC plasma levels [8, 9].
Smoking Cannabis for medical use is however not acceptable and therefore a “cold” inhalation
form according to pharmaceutical standards and preventing toxic pyrolyse by-products should
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be developed. This inhalation solution could also be an alternative preparation to be used in
further studies with THC in other indications (e.g. migraine, chronic or neuropathic pain). The
pulmonally administered inhalation solution (liquid aerosol) allows to avoid the well known
extensive liver first pass metabolism [10, 11] of oral THC. The commercially available, pressure
driven nebuliser system consisting of a Pari Master“ (producing the air pressure) coupled to a
nebuliser (either the IS-2“ or the LC-Plus“), which was already used in our laboratory in a study
with diacetylmorphine [12], should be evaluated for the THC inhalation solution. The very
lipophilic THC should be dissolved in an aqueous vehicle using an appropriate pharmaceutical
technique. The targets for the inhalation solution were the following:
- physiological tolerability (e.g. aqueous vehicle with physiological properties, well tolerable
adjuvants)
- appropriate concentration of the THC to realise the shortest possible inhalation time
- appropriate properties to be nebulised with the chosen inhalation device
- appropriate properties to produce the necessary droplet size of 2-5 mm in diameter to reach
the lower compartments of the lung
- appropriate stability of the THC in the inhalation solution to use the formulation for a
pharmacokinetic study in humans
- properties according to the standards of the European Pharmacopeia.
In the third part of this work the developed inhalation solution should be used for a second
clinical study with healthy volunteers. The aim was to investigate the pharmacokinetic properties
of pulmonal THC versus intravenous THC. In addition, the antinociceptive effect of THC should
be tested versus placebo by one of the four pain tests used in the first study. Side effects and
vital functions should be monitored.
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THEORY / LITERATURE REVIEW
1. CANNABIS SATIVA L.
1.1 Botany [13-15]
Cannabis (hemp) and Humulus (hop) are the only two genera in the family of Cannabaceae.
Cannabis sativa L. grows in all warm and temperate zones except the tropical rain forests.
Cannabis sativa L. is an annual plant with a life cycle of a few months. Plants of Cannabis
sativa grow 1 - 5 m high and are variously branched or even unbranched if planted closely
together. The whole plant is covered with minute hairs. The leaves and branches are paired at
the bottom and arranged alternating higher on the stem. The leaves have a slender stalk up to
about 6 cm long. They are pinnate in a digitate form. The 5 to 9 leaflets are mostly narrowly
lanceolate, coarsely saw-toothed, and have a long drawn-out pointed tip.
Cannabis is normally dioecious meaning that a plant has either female or male flowers.
Female plants are very leavy up to the top; male plants have the leaves on the inflorescence
fewer and much further apart. The male inflorescence is loosely arranged, much branched and
many-flowered, standing out from the leaves, with individual flowering branches up to 18 cm
long. Female inflorescences do not project beyond the leaves; they are compact, short and few-
flowered, with flowers borne in pairs. The female flowers are covered with slender hairs and
circular glands secreting drops of resin, which are produced most abundantly under hot
conditions; in nature the function of these resin glands is presumably to protect the plant from
animals.
The fruit is technically an achene. It is ellipsoid, slightly compressed, smoth, about 2.5 - 5 cm
long and 2 - 3.5 cm in diameter, grayish, brownish, or variously patterned.
1.2 Constituents of Cannabis [13, 16]
Cannabis sativa contains over 480 compounds of which more than 65 are cannabinoids
(“phytocannabinoids”). The cannabinoids are the most characteristic and most specific
components that are only occurring in the Cannabis plant. They are quite lipophilic, nitrogen-
free, mostly phenolic, and have a C21-skeleton. Biogenetically, the cannabinoids are derived
from a monoterpene and a phenol or a phenolic acid, respectively. According to the difference
in the terpene part of the molecule the cannabinoids can be classified in the following way: the
cannabigerol(1)-, the cannabichromene(2)-, the cannabidiol(3)-, the tetrahydrocannabinol(4), and
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the cannabinol(5)-type, as well as some minor cannabinoid classes. The cannabinol-type is an
artefact formed by oxidation of biogenic cannabinoids that are produced during storage or
extraction. The structures of the different cannabinoid types are presented in Figure 1.
Figure 1: Structures of the different cannabinoid types
The circular glands produce also an essential oil, which is responsible for the characteristic
smell of the hemp plant. It contains mono- and sesquiterpenes (e.g. b-caryophyllene, humulene,
caryophyllene oxide, a- and b-pinene, limonene) and phenylpropane derivatives (e.g. cis- and
trans-anethol, eugenol). Minor components of the hemp plant are other phenolic compounds
(e.g. spiroindane, dihydrostilbene, dihydrophenanthrene derivatives), flavonoids, nitrogen-
containing compounds (amines, amides), amino acids, and sugars.
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1.3 Cannabis products [13, 14, 17, 18]
Cannabis resin
The resin (“Hashish”) is collected mainly from the circular glands of the female inflorescence.
The brownish hashish is pressed to bars or cakes. The THC content of the resin is about 2 to
10 % (or even higher, up to 25 - 30 %).
Cannabis-oil (=red oil, Indian oil)
Cannabis oil is an extract of hashish prepared by solid-liquid-extraction with an organic
solvent or distillation technique. Cannabis oil can have a THC content of up to 65 %.
Cannabis herb
The herb (“Marihuana”, “Marijuana”) consists of the dried, cut, blooming or even fruit-bearing,
green tops of the female (also male) Cannabis plant. The THC content is usually 0.5 to 2 % or
even higher, up to 14 - 30 % [18].
Fatty oil of the seeds
The fatty oil of the seeds is very valuable for food because it contains a lot of essential fatty
acids. Provided that contamination during the extraction process can be avoided, it does not
contain THC.
Swiss narcotic law for Cannabis preparations
All Cannabis preparations for the production of narcotics underlay the act of narcotics and
are listed in the category of the forbidden substances [19-21]. Cannabis preparations for the
production of food (e.g. fatty oil of the seed) are part of the food regulations where specific
limitations of the THC content for each preparation are given (0.2 - 50 mg/kg) [22]. Hemp plants
for the production of fibers or oil are regulated by decrees of the Swiss Department of
Agriculture, i.e. the THC content is limited to < 0.3 % THC [23].
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2. D9-TETRAHYDROCANNABINOL (THC)
2.1 Structure
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Figure 2: Structure of THC
Figure 2 shows the structure of THC using two different numbering systems. The one
resulting in the D1-tetrahydrocannabinol is based on the monoterpene-numbering and the other
resulting in D9-tetrahydrocannabinol is based on the dihydrobenzopyran-numbering according
the IUPAC (International Union of Pure and Applied Chemistry) rules. The latter is usually used
nowadays. THC is the only biogenic, psychotropic substance without nitrogen.
2.2 Structure-activity relationship (SAR) at the cannabinoid receptor (CB-receptor) [2, 24]
In the late 1980ies the first cannabinoid receptor has been found and in 1990 the CB1-
receptor has been cloned. This was followed by the finding of the first endogenous ligand
anandamide, the cloning of the CB2-receptor, by the development of the first CB1-receptor
antagonist (SR 141716A), and by the finding of the second endogenous ligand 2-arachidonoyl-
glycerol (2-AG). The description of the endocannabinoid system follows in chapter 2.4.2
(“Pharmacodynamics of THC”).
For the binding of THC to the cannabinoid receptor CB1 different essential structure-activity
relationships have been postulated. The dihydrobenzopyran-type structure with a hydroxyl-
group at C1 and an alkyl group C3 is present in most active cannabinoids. Opening of the pyran
ring (forming cannabidiol-type compounds) lead to a complete loss of activity at CB1. The
phenolic group at the C1-position has to be free and the alkylic side chain with at least 5 carbon
atoms at position C3 is of considerable importance: elongation and branching results in
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potentiation. A stereochemical requirement for the activity on the receptor is the trans-link of the
two rings A and B at position C6a and C10a.
2.3 Chemical and physical data
Some physical and chemical properties of THC are listed in Table 1.
Table 1: Physical and chemical properties of THC
Systematic name [25] Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol
Synonym Dronabinol
Molecular weight [25] 314.45
Molecular fomula [25] C21H30O2
Boiling point [25] 200°C
Property to rotate plane polarised light [25]
† 
a[ ]D
20  - 150.5° (c = 0.53 in CHCl3)
UV max in ethanol [25] 283 nm and 276 nm
Solubility [26] Highly insoluble in water (~ 2.8 mg/L, 23°C) and 0.15 M NaCl
(0.77 mg/L, 23°C)
High solubility in ethanol, methanol
Octanol water partition coefficient [27] 12091
pKa [26] 10.6
Stability [26] Unstable in acidic solution (
† 
t1
2 = 1h at pH 1.0, 55°C)
Sensitive to light
Description [28] Yellow resinous oil, sticky at room temperature, hardens upon
refrigeration, without smell, bitter taste
2.4 Pharmacology and toxicology
2.4.1 Pharmacokinetics
Absorption and distribution [9-11, 13, 28, 29]
Inhalation of Cannabis smoke leads to a rapid absorption of THC depending on the
inhalation technique and experience in smoking. Therefore, the values for the bioavailability in
the literature are very variable (15 - 50 %). Oral administration leads to more erratic uptake as a
result of degradation of the drug by stomach acids and extensive liver first-pass metabolism. A
lipophilic vehicle can increase the absorption. The administration of THC dissolved in sesame
oil (Marinol“ capsules) leads to an almost complete absorption (90 - 95 %). But the measured
bioavailability after orally administered Marinol“ is only 10 - 20 % due to the extensive liver first-
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pass metabolism [28]. The application of THC as a prodrug (THC-hemisuccinate) in
suppositories shows more constant and a higher bioavailability compared to the oral application
form (about two fold higher) [30].
Because of their high lipophilicity, the cannabinoids rapidly penetrate the tissues and high
concentrations are found in the highly vascularised tissues shortly after drug administration.
This is reflected in the high volume of distribution of about 10 L/kg [31-33]. The main distribution
sites are liver, heart, lung, gut, kidney, spleen, mammary gland, placenta, adrenal cortex,
thyroid, pituitary gland, and brown fat. Lower concentrations are found in brain, testis, and fetus.
Once absorbed into the blood THC becomes strongly bound to protein. Only about 3 % of the
drug is in the free state. About 60 % is bound to lipoproteins (the low-density fraction), about
9 % to the blood cells, and the rest to albumin. The major monohydroxy metabolite 11-hydroxy-
D9-THC (THC-OH) is even more strongly bound with only 1 % remaining in the free state.
Metabolism [10, 11, 13]
The metabolism of the cannabinoids is very complex. For THC nearly 100 metabolites have
been identified. All cannabinoids are good substrates of the cytochrome P450 mixed-function
oxidases on account of their high lipid solubility. THC is hydroxylated at C11, at C8 and at all
positions of the alkyl side-chain. C11 is the preferred hydroxylation site in man. In humans,
cytochrome P450 isoenzyme 2C9 has been shown to catalyse the formation of the
psychoactive 11-hydroxy metabolite of D9-THC [34, 35] and cytochrome P450 3A to be
responsible for hydroxylation at the 8b-position [35]. Following the initial hydroxylation, many of
the hydroxyl groups undergo further oxidation with the major products being the formation of
carboxylic groups at C11 and C5’ (alkyl side-chain). Oxidation of the active metabolite THC-OH
leads to the inactive metabolite 11-nor-9-carboxy-THC (THC-COOH), which is in the
glucuronidated form the main metabolite found in urine. The C5’-acid undergoes b-oxidation and
related reactions result in losses of carbon atoms from the alkyl side-chain. Phase II metabolites
appear to be mainly conjugates of the phase I metabolites with glucuronic acid. The O-ester-
glucuronide of THC-COOH is the predominant phase II metabolite of THC. Another possible
pathway is the formation of conjugates with long-chain fatty acids. Although it is a phase II
reaction, it increases rather than decreases lipophilicity. These compounds, which resemble
membrane constituents, are thought to be the form in which the drug may be retained within
tissues for considerable periods of time.
Figure 3 shows the possible sites for the primary oxidation of THC. Figure 4 shows the main
metabolic pathways for THC.
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Figure 4: Main metabolic pathways for THC
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Figure 3: Sites for primary oxidation of THC
Excretion [10, 11, 13]
In common with other lipophilic drugs THC rapidly distributes between the tissues. However,
the extensive deposition in fat results in a long terminal half-life. The real elimination half-life is
very difficult to estimate due to the slow equilibration of the concentrations between plasma and
tissue. This results in very low plasma levels, which are difficult to measure. The reported half-
lives in the literature are with 1 to 4 days very variable. The complete elimination time may well
reach up to 5 weeks.
THC is excreted both in urine and feces as metabolites. Feces are the preferred route in
humans, with about 80 % of the excreted dose. THC undergoes an extensive enterohepatic
cycle, which also contributes to the slow elimination. Most urinary metabolites are acids. The
main metabolite found in urine is the THC-COOH glucuronide, which, normalised to the
creatinine concentration, can be used for the detection and monitoring of drug abuse.
2.4.2 Pharmacodynamics
Cannabinoid receptors and the endogenous cannabinoid system [36, 37]
As mentioned in chapter 2.2 mammalian tissues contain two types of cannabinoid receptors,
CB1 and CB2, both coupled to their effector systems through Gi/o proteins. CB1 receptors are
present in the brain, the spinal cord, and in certain peripheral tissues. Some central and
peripheral CB1 receptors are located at nerve terminals where they probably modulate
neurotransmitter release when activated. CB2 receptors are expressed primarily by immune
tissues, for example leukocytes, spleen, and tonsils. The discovery of CB1 and CB2 receptors
was followed by the detection of endogenous cannabinoid-receptor ligands. Arachidonoyl-
ethanolamide (anandamide) and 2-AG are the most important ones and there is evidence that
both agonists can act as neuromodulators or neurotransmitters. Experiments with isolated blood
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vessels have shown that anandamide and methanandamide (but no other ligand of the CB
receptors) activate vanilloid receptors on sensoric neurons [38]. These findings indicate that
anandamide is also an endogenous ligand for vanilloid receptors and therefore the vanilloid
receptors represent possibly a cannabinoid CB3 receptor.
The cannabinoid receptors and their endogenous ligands constitute what is now often
referred to as “the endogenous cannabinoid system” or “endocannabinoid system”. The
endocannabinoid system seems to play a fundamental physiological role in the regulation and
modulation of processes in the central nervous system (neutrotransmitter release) and in the
periphery (such as modulation of neurotransmitter release/action of autonomic and sensory
fibers), as well as in the control of immunological, gastrointestinal, reproductive, and
cardiovascular performance [2]. All these functions and the links to neurotransmitter systems
are not yet fully understood.
Several selective synthetic agonists and antagonists have been synthesised for both CB
receptors and are available for basic and clinical research.
Possible biosynthetic and catabolic pathways for anandamide are presented in Figure 5.
Figure 5: Possible biosynthetic and catabolic pathways for anandamide modified from Di Marzo and Petrocellis [2].
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Therapeutic potential [39]
THC or Cannabis preparations are used for a broad spectrum of symptoms. But the data of
the efficacy are often very limited. Well established is the antiemetic and anti-vomiting effect in
chemotherapy-induced nausea and the appetite stimulating, weight increasing effect, e.g. in
cancer, aids or Alzheimers disease patients. For these indications Marinol“ is registered and
used in the USA. Newer studies show a quite good effect of THC or Cannabis preparations (e.g.
standardised extracts) in spasticity, moving disorders, and pain in patients suffering from
multiple sclerosis, spinal cord injuries, or Tourette syndrome. THC is antiasthmatic and lowers
intraocular pressure in glaucoma. Some first studies and case reports show THC effects against
allergy, pruritus, inflammations, infections, epilepsy, depressions, bipolar disorders, anxiety,
addiction, and withdrawal syndromes. Some basic research has been done in different fields:
autoimmune diseases, cancer, neuroprotection, fever, and high blood pressure.
2.4.3 Side effects and toxicology
Acute toxicology [40]
The acute toxicity of THC is very low. The oral LD50 dose in rats was determined as 800 to
1900 mg/kg. No lethal doses could be determined in dogs (up to 3000 mg/kg administered) and
monkeys (up to 9000 mg/kg). Also in men no deaths directly linked to toxic somatic effects of
Cannabis have been reported so far. Nevertheless, there are different acute effects of
Cannabis. Normally a Cannabis-“high” is reported to be a pleasant, relaxing experience. On the
contrary there are reports of dysphoric reactions that can also lead to panic attacks. Overdosing
can produce fear of death. Cannabis causes dose dependent sleepiness, mental clouding,
dizziness, and confusion. It impairs cognitive functions, memory, attention, ability to react, and
motor functions, and therefore also the ability to drive a vehicle.
Chronic toxicology [40, 41]
Many chronic effects of Cannabis have been described. The main risk of long-term Cannabis
consumption consists of the mucous membrane damaging effect of the pyrolysis products when
inhaling the smoke of a Cannabis cigarette (“joint”). There are indications that heavy Cannabis
users can show slight impairment of cognitive functions and memory. THC is able to induce
“temporal disintegration”, which is defined as a difficulty in regaining, coordinating, and serially
indexing those memories, perceptions, and expectations that are relevant to the attainment of
some goal [42]. Consuming Cannabis can trigger a latent schizophrenia in vulnerable persons
without increasing the incidence of schizophrenia. The chronic toxic effects on the immune and
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endocrine system are inconsistent. Also the data concerning the influence on fertility are
contradictory. There is no evidence of an impairment of these functions in man. On the other
hand, there are strong indications that Cannabis can cause disturbance in the development of
subtle cerebral functions in a fetus of a Cannabis consuming pregnant woman resulting in
impaired cognitive functions in the child. A teratogenic effect of Cannabis is unlikely.
Tolerance [43]
Tolerance is developed within short time against the receptor mediated effects of Cannabis
such as the psychotropic and cardiovascular effects as well as the cognitive and psychomotor
side effects. Heavy chronic Cannabis consumers report a mild withdrawal syndrome when they
suddenly stop taking Cannabis, characterised by nervous agitation, hyperhydrosis, and lack of
appetite. However, the Cannabis dependence is mainly considered as psychological and not
somatic. The risk for Cannabis abuse in the therapeutic context is low.
Somatic side effects [40]
Acute side effects are hyposalivation (atropine-like effect), increase in heart rate, reddening
of the eyes, orthostatic hypotension. Further rare side effects are headache, nausea, and
vomiting. Hyposalivation and the decrease in the flood of tears can increase the risk of
infections of the upper respiratory tract and the eyes.
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3. CANNABIS AND PAIN
3.1 Animal data
Several animal studies have shown the analgesic effect of THC in different pain models [5, 6,
44]. In mice, subcutaneously (s.c.) and orally (p.o.) administered THC enhanced the
antinociceptive effect of s.c. and p.o. morphine in the tail-flick and also in the paw-pressure test
[45]. Again in mice, an inactive p.o. dose of THC (20 mg/kg) enhanced the antinociception of
opioids 2.2- (for morphine) to 25.8-fold (for codeine, shift in ED50) in the tail-flick test [7].
3.2 Human data
There are few experimental pain studies and they do not clearly show an analgesic effect of
THC. The results are controversial. Smoked Cannabis increased pressure pain tolerance in
Cannabis-naïve and Cannabis-experienced subjects compared to placebo (THC-extracted
Cannabis) [46]. In a radiant heat test experienced Cannabis users reported a mild
antinociceptive effect when smoking Cannabis cigarettes [46]. In thermal pain p.o. THC showed
in healthy subjects with moderate side effects a reduction of pain and in subjects experiencing a
“bad trip” hyperalgesia [48]. In the transcutaneous electrical stimulation pain model, smoked
Cannabis had no analgesic effect, it even produced a slight hyperalgesia [49].
In clinical pain again, only few trials have been conducted and the results were equivocal
[50]. Oral doses of 15 and 20 mg THC resulted in a significant reduction of cancer pain [51]. In
another clinical study, the analgesic potency of THC in cancer pain was compared with codeine.
The analgesic effect of 20 mg p.o. THC corresponded to that of 120 mg p.o. codeine [52]
whereas i.v. administered THC did not affect pain tolerance thresholds in dental surgical pain
[53]. In a double-blind, placebo-controlled, crossover trial on a chronic pain patient suffering
from familial Mediterranean fever five doses of 10 mg p.o. THC (as standardised Cannabis
preparation, containing 5.75% THC) per day did not reduce pain [54]. However, it significantly
reduced the need for morphine (10 mg per dose) given as escape medication indicating an
additive effect of THC on morphine. A case report study showed that smoked Cannabis, in low
doses not causing psychotropic side effects, reduced the required opioid doses for pain
management in chronic neuropathic pain in three patients by 60 to 100 % [55].
Some patients claim that Cannabis (e.g. smoked or ingested as cookie) is more effective
than pure THC (e.g. dronabinol, Marinol“) for a variety of symptoms, including nausea and
vomiting, wasting syndrome, and muscle spasticity [56, 57]. However, most of these assertions
are based on patient reports and surveys, and have not been verified by controlled clinical trials
[58]. To the best of our knowledge, no comparative data exist of the analgesic effect of THC and
Cannabis. A recent study compared the subjective effects of orally administered and smoked
Theory / Literature Review 15
____________________________________________________________________________________
THC alone and THC within Cannabis preparations (brownies and cigarettes) [58]. THC and
Cannabis in both application forms produced similar, dose-dependent subjective effects, and
there were few reliable differences between the “THC-only” and the “Cannabis” conditions. In
studies on healthy volunteers and a multiple sclerosis patient it was shown that cannabidiol
(CBD) reduces the psychotropic effects of THC [59, 60] and a Cannabis-based medicinal
extract [61], respectively. This could explain anecdotal reports from patients who prefer the
milder forms of Cannabis containing significant levels of CBD [61]. A review of the antianxiety
effects and the pharmacology of CBD is given by Partland and Russo [62] and Mechoulam et al.
[63].
4. INHALATION
4.1 Physiology of the lung [64]
The lung is the organ of respiration. Its function is to maintain blood gases (nominal values of
partial pressure for O2 = 90 mm Hg, and for CO2 = 40 mm Hg) exchanging the CO2 of the
erythrocytes with O2 in the alveoles and so arterialising the blood. The lung divides
dichotomously for about 23 generations until it reaches the alveolar sacs, which number
approximately 300 millions and covers some 70 m2. Distributed over this surface is 80 mL of
blood in the alveolar capillaries, through which O2 is given up and absorbed. The conducting
airways are surrounded by smooth muscles and are innervated. They are also lined with
specialised cells: some of which produce mucus, others who carry cilia. Together they form an
escalator carrying mucus and deposited inhaled material upwards to maintain the lung in a
sterile condition. The alveolated surface is covered with a surfactant lining (about 0.5 nm thick)
which determines the normal compliance (distensibility) of the parenchyma.
4.2 Inhalation therapy [65, 66]
The administration of drugs directly into the respiratory tract is widely regarded as the
method of choice for treating respiratory diseases. In addition, there has been an increase in
utilising the airways and the respiratory membrane surface as a portal of entry into the body for
drugs that otherwise would not be absorbed (for example because of acidic degradation of
peptides such as insulin or desmopressin in the stomach) or for those drugs that suffer
extensive liver first-pass metabolism after oral administration. Although some drug metabolism
(e.g. by cytochromes P450) also takes place in the respiratory tract, this metabolism is of minor
importance, because the presence of these enzymes and their capacity therefore are much
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lower than in the liver. Some inhaled drugs are metabolised then in the lung, others are
absorbed very rapidly and therefore do not undergo a metabolism in the lung.
A crucial point in the drug administration via the respiratory tract is the particle size of the
inhaled droplets (liquid aerosol) or solid particles (powder aerosol). For a maximal absorption
the high surface region of the alveolar compartment, which is also highly vascularised, has to be
reached. Particles with a size of 2 - 5 mm are able to deposit in the alveoli. Particle with a size of
5 - 10 mm get to the upper parts of the lung, the bronchioli, and particles > 10 mm will deposit in
the extrathoracic regions. Studies showed that deposition could be maximised in the lower
regions of the lung by inhaling slowly and holding the breath for up to 20 seconds [67].
4.3 Novel liquid-based inhalation technology [68]
Drugs can either be administered in solid or liquid form to the lungs. Steroids in the therapy
of asthma are usually powders and are administered with special devices (e.g. Turbohaler‚,
Diskhaler‚). The today’s conventional liquid inhalation devices are on one hand the pressurised
metered dose inhalers (pMDI’s) and on the other hand the nebulisers. pMDI’s are hand-held
and deliver the drug in one breath or a few breaths. The drug is either suspended or dissolved
in a propellant, which is pressurised until it liquefies in a canister. Releasing a metered volume
of the fluid through a control valve causes the propellant to expand and evaporate and leaves
the drug in the form of a high velocity aerosol. The limitations are the high exit velocity of the
drug aerosol which can lead to high levels of oropharyngeal impaction, and the need for users
to coordinate the pMDI valve actuation with their breathing manoeuvre.
The nebulisers are generally larger fixed devices and deliver the drug over many breaths
sometimes taking several minutes. They traditionally use compressed air directed through the
liquid drug formulation in the form of a high velocity jet to produce a fine mist of droplets from an
aqueous solution of the drug. Using a baffle arrangement, inhalable droplets are permitted to
pass into the inhaled air stream while oversized droplets are filtered and recycled. The specific
limitations of nebulisers are: relatively long treatment times, poor dose efficiency (due to
residual volumes), and often lack of portability. Nebulisers of the newest generation are smaller
and some even portable.
Novel liquid-based inhalation devices have been developed in the last few years. They can
be grouped into three types: mechanical, vibrational, and electrostatic.
Mechanical devices usually use air compressed by a spring to aerolise a drug formulation.
The Respimat“ of Boehringer Ingelheim is a small, pocket-sized device (dimensions similar to a
traditional pMDI) and contains the drug in an appropriate formulation without environment-
polluting propellant. The drug is loaded and nebulised with a mechanical rotation of the lower
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half of the device by the patient. Another example is the AERx‘ from Aradigm, which is a hand-
held battery powered inhalation device. It utilises a unit dose of drug stored in a blisterpack.
When loaded by the user a piston compresses the blister, a heat seal is opened, and the drug is
forced through a polymeric nozzle plate producing the aerosol. This device is controlled by a
microprocessor.
Vibrational devices can either be ultrasonically driven or membrane-vibrated. The Premaire‘
from Sheffield Pharmaceuticals is a pocket-sized ultrasonic nebuliser. The device utilises an
ultrasonic atomising horn, which vibrates at an ultrasonic frequency and aerosolises a liquid
dose into a fine, low-speed aerosol mist. Vibrating-membrane devices use a perforate
membrane in contact with a reservoir of fluid, which vibrates at ultrasonic frequencies. Jets of
fluid are drawn through the holes in the membrane where surface tension and hydrodynamic
effects then break these jets into a steam of precisely controlled droplets. Examples for this
technology are the Touch Spray“ from ODEM LTD, the e-Flow“ from PARI GmbH, and
AeroDose“ from Aerogen.
An example for the electrostatic technology is the Mystic‘ device from Battelle Pulmonary
Therapeutics. It uses electrohydrodynamic nebulisation, which is a process of turning a liquid
into a spray of fine droplets using a strong electric field.
Most of the novel liquid devices have been shown to be capable of delivering considerably
more of the emitted dose to the lung and of minimising oropharyngeal impaction, compared with
conventional devices, because of the much greater control of the droplet size and a much
lower-velocity aerosol than pMDIs.
5. SOLUBILISATION [69, 70]
Solubilisation is a process to increase the solubility of lipophilic drugs in water (e.g. lipophilic
vitamins, hormones). For this purpose surface-active substances are used to dissolve the drugs
into clear, eventually opalescent solutions. These so called surfactants are amphiphilic
substances consisting of hydrophilic as well as lipophilic parts within the molecule. There are
three groups of surfactants: the anionic surfactants (the surfactant molecule is negatively
charged forming a salt with e.g. sodium ions), the cationic surfactants (the surfactant molecule
is negatively charged forming a salt with e.g. chloride), and the non-ionic surfactants (without
charge). In pharmaceutical technology mainly the non-ionic type is used. Added in a certain
concentration (the critical micelle concentration, CMC) into water, they have the property to form
micelles in solution. Micelles are molecular aggregates of surfactant molecules with the
incorporated drug, called association colloids. These particles are usually 5 - 15 nm in diameter,
spherical in shape in a surfactant concentration near the CMC and mostly laminar in a higher
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surfactant concentration underlying a continuous dynamic equilibrium. Another characteristic
property, beside the CMC, of each surfactant is the hydrophilic-lipophilic-balance (HLB),
characterising the amphiphilic properties of non-ionogenic surfactants. Surfactants with an HLB
of 1 to 10 are predominantly lipophilic whereas surfactants with an HLB of 10 to 20 are
predominantly hydrophilic. The HLB can be calculated with the following equation:
† 
HLB =  20 1- S
A
Ê 
Ë 
Á 
ˆ 
¯ 
˜ 
S: Saponification number of the ester
A: Acid number of the acid
Thus the non-ionogenic surfactants can be classified with the HLB system. Table 2 gives an
overview.
Table 2: Classification of surfactants using the HLB system [70]
HLB Use Example (HLB) of the nonionic surfactant family
0 – 3 Antifoaming agent Sorbitan trioleate, Span“ 85 (1.8)
3 – 8 Water in oil emulsifier Sorbitan mono-oleate, Span“ 80 (4.3)
7 – 9 Wetting agent Sorbitan mono-palmitate, Span“ 40 (6.7)
8 – 19 Oil in water emulsifier Polyoxyethylene-20-sorbitan-mono-stearate, Tween“ 60 (14.9)
13 – 16 Detergent Polyoxyethylene-4-sorbitan-mono-laurylate, Tween“ 21 (13.3)
14 – 19 Solubilising agent Polyoxyethylene-20-sorbitan-mono-oleate Tween“ 80 (15)
The capacity of a certain surfactant to solubilise a drug can be increased using the
cosolvation method. Alcohols, mainly polyols (e.g. glycerol, sorbitol), incorporate into the
palisade layer of the micelle forming hydrogen bonds with the micelle constituents. The micelle
stabilising effect increases with the number of hydroxyl groups of the co-solubiliser.
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MATERIALS AND METHODS
1. PHARMACODYNAMIC STUDY WITH ORAL THC (PAIN STUDY)
1.1 Quality assurance of clinical test preparations
Quality assurance was done with the Marinol‚ capsules, which were used by the Pharmacy
of the University hospital to prepare the test substances for the pharmacodynamic study.
Quality assurance was also done with THC-hemisuccinate suppositories, which were used for a
spasticity study at the REHAB (Rehabilitation Center for Spinal Cord Injury and Head Injury,
Basel).
1.1.1 Marinol® (THC, dronabinol; capsules)
Standards, chemicals, and solvents
Table 1: Standards for the quality assurance of Marinol‚
Abbreviations Name Lot-No. Supplier
THC D9-Tetrahydrocannabinol 135.1B25.6L4 Lipomed, Arlesheim, CH
THC-d3 (-)-D9-THC-d3 FYC-30965-21-A Radian, Austin, USA
All solvents and chemicals used were of HPLC or analytical quality obtained from Merck AG,
Basel (CH) or Fluka Chemie AG, Buchs (CH).
Instrumentation
The gas chromatography-mass spectrometry system (GC-MS) consisted of a HP GC 5890
Series II gas chromatograph with a 7673 autosampler and a G1512A autosampler controller, a
HP 5972 mass-selective detector (MSD), a Vectra 486/66 XM computer with Chemstation
Software G1046A Rev. A.00.00 (HP 1989-1994).
Method
Sample preparation
Three Marinol“ capsules (soft gelatine capsules with sesame oil as vehicle, Unimed
Pharmaceuticals, Inc., Deerfeld, IL, USA; provided by the Swiss Federal Office for Public
Health) were randomly sampled from the batch Lot. 990468B (exp. Febr. 2001) used for the
pain study. 1000 mL of ethanol were added to one capsule (containing 10 mg THC) in a 5 mL
sample vial with screw cap. The capsule was then punctured several times with a sharp wire.
After sonicating for 10 min (the capsule and the oil was not dissolved) the extract was
Materials and Methods 20
____________________________________________________________________________________
centrifuged for 5 min at 1500 rpm. 100 mL of the supernatant was diluted to 10.0 mL with
ethanol. 30 mL of this solution and 30 mL of the internal standard solution containing 100 ng/mL
D9-THC-d3 (in ethanol) were transferred into a GC vial insert and vortexed.
Chromatographic conditions
Column DB-5 MS column (J&W Scientific, Folsom, CA, provided by MSP,
Köniz, CH), 25 m x 0.2 mm I.D., film-thickness 0.33 mm
Carrier gas Helium
Constant flow 0.2 mL/min
Oven 170 °C (1.0 min) to 250°C at 8.0 °C/min; 250 °C (20.0 min)
Injection volume 1 mL, splitless
Injector temperature 250 °C
Transfer line temperature 280 °C
Detection mode Full scan monitoring (50 to 650 m/z)
Validation
Peak identification (selectivity / specificity)
Chromatographic selectivity: The retention times of the analyte and the internal standard
were identified with the corresponding standards. A blank run was performed using an extract of
an aliquot of the capsule matrix (sesame oil) to exclude any interferences.
Spectroscopic selectivity: The identity of the signal was determined with characteristic ions
for the analyte and the internal standard, respectively. Additionally, the spectra were compared
to the spectra of the online library [71].
Calibration and linear range
The quantification of THC was done with internal standard method using the ratio of the
characteristic and intensive ion of THC (m/z  314) and the corresponding ion of the internal
standard THC-d3 (m/z  317). Calibration was done with the standards dissolved in ethanol in the
concentrations of 30, 50 and 70 µg/mL. The constant concentration of the internal standard was
50 mg/mL. Each calibrator was measured twice.
Recovery
The recovery was not determined. It was assumed that 100 % of the THC was extracted from
the sesame oil matrix with the chosen method.
Materials and Methods 21
____________________________________________________________________________________
Intra- and interday precision and accuracy
The intraday precision was determined preparing and measuring 4 samples for each
concentration (30, 50, and 70 µg/mL) within the same day. Mean, (absolute and relative)
standard deviation (SD and RSD), and accuracy were calculated.
The interday precision was determined preparing and measuring 6 samples for each
concentration (30, 50, and 70 µg/mL) at different days within 1 month. Mean and (absolute and
relative) standard deviation (SD and RSD) were calculated.
1.1.2 THC-hemisuccinate suppositories (rectal THC-HS)
The content of THC-hemisuccinate (THC-HS) in suppositories used in a spasticity study at the
REHAB Basel was determined.
Standards, chemicals, and solvents
The THC-hemisuccinate (THC-HS) was originally synthesised by ElSohly Laboratories (ELI),
Inc., Oxford MS, USA, and provided by Prof. M. ElSohly, Oxford MS [2].
THC-hemiglutarate (THC-HG) was synthesised in our laboratory according to the method of
ELI used for the preparation of THC-HS [72].
All solvents and chemicals used were of HPLC- or analytical quality obtained from Merck AG,
Basel (CH) or Fluka Chemie AG, Buchs (CH).
Instrumentation
HPLC HP 1090-system consisting of a Hewlett-Packard (HP) 1090M Series II Liquid
chromatograph with a 1040 autosampler, a 1040M photodiode array detector (DAD), a Vectra
486/66 XM computer with HPLC Chemstation Rev. A.03.03. Software (HP 1990-1995).
Method
Sample preparation
The total weight of the suppository was determined and an aliquot of 200 mg taken for the
quantitative analysis. The sample and 10.0 mL internal standard solution, containing 270 mg/mL
of THC-HG in methanol, were added to a 10 mL sample vial with screw cap and heated at 50 °C
for 5 min shaking vigorously (vortexed and sonicated alternately). Then the vial was put into ice
to let the suppository matrix precipitate. 10 mL of the supernatant was then injected into the
HPLC.
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Chromatographic conditions
Stationary phase: 124 x 4 mm I.D. LiChroCART“ column, packed with LiChrospher“
100 RP-18, particle size 5 mm and a 8 x 4 mm I.D. precolumn,
packed with the same material (Merck AG, Basel, CH)
Solvent A: Bidistilled water containing 5.5 % (v/v) acetic acidMobile phase:
Solvent B: Methanol
Gradient: 0-10 min, 85 % B, isocratic
Run time: 10 min; post run time: 15 min
Flow: 1.1 mL/min
Oven temperature: 45 °C
Detection: Quantification wavelength for THC-HS and THC-HG (IS): 280 nm
(Online registration of the UV spectra from 190-350 nm (DAD))
Calibration
For the quantification of the THC-HS content of the suppositories the internal standard
method was used (THC-HG). Calibrators were prepared in methanol using 4 different
concentrations as presented in Table 2.
Table 2: Calibrators for the quantification of THC-HS: concentration of the analytes and ratios of the amounts
Calibrator Amount of THC-HS [mg/mL] Amount of THC-HG (IS) [mg/mL] Ratio (THC-HS/THC-HG)
1 160 550 0.2909
2 405 370 1.0946
3 600 480 1.2500
4 590 170 3.4706
1.2 Subjects and study design (pain study)
Twelve healthy volunteers participated in this randomised, placebo-controlled, double-blind,
crossover study which was carried out in the pain laboratory of the Department of
Anaesthesiology at the University Hospital of Bern. The subjects were informed about the risks
of the study, gave their written informed consent, and were paid for participating. Exclusion
criteria were past or existing drug abuse (including alcohol and prescription drugs; Cannabis
and opiate immunoassay urine tests before each session), known or suspected hypersensibility
to cannabinoids or opioids, pregnancy (urine test before first session), and positive past history
of any psychiatric disorders. The subjects were not allowed to take analgesics, alcohol and
caffeinated beverages 48 h before and during the study, and were asked to refrain from driving
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up to 12 h after the study. The study has been approved by the Ethics Committee of the Faculty
of Medicine, University of Bern, the Intercantonal Drug Control Office (IKS), and the Federal
Office for Public Health (study protocol, volunteer information etc. see appendices I). Each
subject received either 20 mg THC (dronabinol, Marinol“), 30 mg morphine hydrochloride
(Schweizerhall Pharma, Basel, CH), a mixture of 20 mg THC and 30 mg morphine
hydrochloride, or placebo as a single oral dose on empty stomach. The blinding of the test
medications was performed by enclosing the 20 mg- or placebo Marinol® capsules in another,
dark-coloured gelatine capsule, and adding either 30 mg mannitol or 30 mg morphine. The
30 mg morphine capsules were similarly prepared. Caffeine free beverages were allowed 1 h,
and light, but not standardised meals 3 h post-dosing. The between-session washout phases
were at least 7 days. To get the subjects familiar and comfortable with the testing procedures
(reaction test, 4 pain tests including cold-, heat-, pressure-, and electrical stimulation-test,
described later), each session began with a training phase. Then the baselines were recorded
and the pain tests performed in a random order every hour up to 8 h post drug. Pressure and
heat pain were not determined at time points 5, 6, and 7 h post drug to prevent pulp and skin
damage. Side effects were monitored before each set of pain tests. Blood (5-10 mL) was
collected in all four sessions through a peripheral vein catheter at baseline, 0.5, 1, 2, 4, and 8 h
post drug. The heparinised blood samples were centrifuged and the plasma instantly deep-
frozen and stored at -20 °C until analysis.
1.3 Pain tests
Pressure
Pressure pain tolerance thresholds were determined on the center of the pulp of the second
and third finger of the right hand with an electronic pressure algometer (Somedic AB,
Stockholm, S) [73-75]. A probe with a surface area of 0.28 cm2 was used, and the pressure
increase rate was set to 30 kPa sec-1. Pain tolerance was defined as the point when the subject
felt the pain as intolerable. For determination of the tolerance thresholds, the mean of two
consecutive measurements was used.
Heat
The computer-driven Thermotest (Somedic AG, Stockholm, S) was used [76, 77]. A
thermode with a surface of 25 x 50 mm was applied to the volar surface of the forearm, in the
middle of a line joining the elbow to the wrist fold. The temperature of the thermode was
continuously increased from 30 to a maximum of 52 °C at a rate of 2.0 °C sec-1. The subject was
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asked to press a button when perceiving the heat as painful (pain detection) and when feeling
the heat as intolerable and not wanting the heat to be further increased (pain tolerance). At that
point the temperature was recorded and the thermode cooled to 30 °C. The thermode was also
cooled to 30 °C in the case when the tolerance threshold was not reached at 52 °C. 52 °C was
then considered as pain tolerance threshold. Three consecutive measurements were performed
for both pain detection and tolerance thresholds. The average of the last two values were
computed and evaluated for data analysis.
Cold
A standardised 2-min ice water test (ice cold immersion test) was used [75, 78, 79]. Before
immersion, the skin temperature on the thenar of the left hand was measured. The left hand
was then immersed in ice-saturated water (0.6 ± 0.2 °C). If pain was considered as intolerable
(pain tolerance) before 2 min had elapsed, the subject could withdraw the hand. Perceived pain
intensity was rated continuously with an electronic visual analogue scale (VAS), and recorded
on a computer. Peak pain (maximal VAS score), area under the pain intensity-time curve, and
mean pain (mean VAS score) were determined. If the hand was withdrawn before the end of
2 min, pain intensity was considered to be maximal until the end of the 2-min period (for
calculation of the area under the curve (AUC)).
Transcutaneous electrical stimulation (single, repeated)
Two bipolar surface Ag/AgCl-electrodes (Dantec, Skovlunde, DK) were placed on the shaved
skin of the shin, 14 cm distal to the patella. The electrode surface was 7 x 4 mm, the distance
between the two electrodes 1.5 cm. A train of 5 square-wave impulses was delivered from a
computer-controlled constant current stimulator (University of Aalborg, DK). Each of these
impulses lasted 1 msec. The whole duration of the train of 5 impulses was 25 msec, so they
were perceived as a single stimulus. For the single electrical stimulation this train was given
once, and for the repeated electrical stimulation this train was repeated 5 times, at the same
intensity and a frequency of 2 Hz (i.e. every 0.5 sec) [80, 81]. The current intensity was
increased stepwise 1 mA until the stimulus was perceived as painful. For the single electrical
stimulation the pain detection threshold was defined as the minimum stimulus intensity eliciting
a subjective pain. For the repeated electrical stimulation the pain detection threshold was
defined as the minimum stimulus intensity eliciting a subjective increase in perception during the
5 stimulations, so that the last 1-2 impulses are perceived as painful.
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1.4 Monitoring of side effects and vital functions
A 10-cm VAS (see appendix I) was used to asses sedation, psychological (euphoria,
hallucinations, disorientation, altered perception etc.) and somatic side effects (heart and
digestive problems). The episodes of vomiting were noted. Haemoglobin oxygen saturation
(pulse oximetry), blood pressure, and heart rate were recorded. To determine the reaction time,
a 1000 Hz tone was delivered from a computer with random intervals of 3-8 sec, and
simultaneously a timer was started. The volunteer was told to press a button as fast as possible
after the tone. The reaction time was defined at the time from the tone until the subject pressed
the button. The mean value of five consecutive measurements was calculated.
1.5 Determination of morphine and -metabolites in plasma by high performance liquid
chromatography with photodiode array (HPLC-DAD) and fluorescence detection (HPLC-
FLD)
Standards, chemicals, and solvents
Table 3: Standards for the quantification of morphine and its metabolites
Abbreviations Name Lot-No. Supplier
M-HCl Morphine hydrochloride 408038 Hänseler AG, Herisau (CH)
M6G Morphine-6-b-D-glucuronide 57.1B11.2 Lipomed, Arlesheim (CH)
M3G Morphine-3-b-D-glucuronide 51F-3831 Sigma, Buchs (CH)
EM Ethylmorphine hydrochloride 101101 Grogg Chemie, Bern (CH)
Bidistilled water, Department of Clinical Research, University of Bern (CH)
Acetonitrile gradient grade (ACN), LiChrosolv‚, Merck AG, Basel (CH)
Trifluoroacetic acid for UV-Spectroscopy (TFA), Uvasol‚, Merck AG, Basel (CH)
Methanol LiChrosolv“, Merck AG, Basel (CH).
All other solvents and chemicals used were of HPLC- or analytical quality obtained from
Merck AG, Basel (CH) or Fluka Chemie AG, Buchs (CH).
Instrumentation
The HPLC HP 1090-system consisted of a Hewlett-Packard (HP) 1090M Series II Liquid
chromatograph with a 1040 autosampler, a 1040M photodiode array detector (DAD), a 1046A
fluorescence detector (FLD), and a Vectra 486/66 XM computer with HPLC Chemstation Rev.
A.03.03. Software (HP 1990-1995).
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Method
Sample preparation
The plasma samples were purified with solid phase extraction (SPE) columns of the type
Chromabond C-18 ec, 3 mL, 500 mg. The sample preparation was done using an ASPEC
robotic system (Automatic Sample Preparation with Extraction Columns; Gilson, Villiers
Le Bel, F) according to the scheme presented in Table 4.
Table 4: SPE of the plasma samples for the sample preparation of the morphine session, modified method of
Bourquin et al. [82]
Conditioning Methanol
ACN 40 % (V/V) in phosphate buffer 0.01 M, pH 2.1
Bidistilled water
10 mL
5 mL
10 mL
Loading of the sample Plasma
Internal standard (EM 0.001 % (w/v))
Carbonate buffer 0.5 M, pH 9.3
‡ an aliquot of 4.1 mL (corresponding 1.0 mL plasma) was
loaded onto the column
1.5 mL
150mL
 4.5 mL
Washing Carbonate buffer 0.005 M, pH 9.3
Bidistilled water
ACN 40 % (v/v) in phosphate buffer 0.01 M, pH 2.1
20 mL
0.5 mL
0.35 mL
Elution ACN 10 % (v/v) in phosphate buffer 0.01 M, pH 2.1
ACN 70 % (v/v) in phosphate buffer 0.01 M, pH 2.1
1 mL
1 mL
A new batch of SPE columns resulted in slightly different extraction properties, which made a
further optimisation of the extraction procedure necessary. The extraction was consequently
manually done according to the scheme presented in Table 5. This alternative extraction
method was used for the plasma samples of the THC-morphine session, which were after that
analysed with HPLC-FLD.
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Table 5: SPE of the plasma samples for the sample preparation of the THC-morphine session
Conditioning Methanol
ACN 40 % (v/v) in phosphate buffer 0.01 M, pH 2.1
Bidistilled water
10 mL
5 mL
10 mL
Loading of the sample Plasma
Internal standard (EM 0.001 % (w/v))
Carbonate buffer 0.5 M, pH 9.3
‡ this mixture was loaded completely onto the column
1.0 mL
100mL
3.0 mL
Washing Carbonate buffer 0.005 M, pH 9.3
Bidistilled water
ACN 40 % (v/v) in phosphate buffer 0.01 M, pH 2.1
20 mL
0.4 mL
0.25 mL
Elution ACN 10 % (v/v) in phosphate buffer 0.01 M, pH 2.1
ACN 70 % (v/v) in phosphate buffer 0.01 M, pH 2.1
1 mL
1.2 mL
The eluate was evaporated under nitrogen at 43 °C, redissolved in 120 mL of bidistilled water
containing 0.05 % TFA (mobile phase A of the chromatographic system), and sonicated for
10 min. The extract was filtrated through an Eppendorff pipette tip containing a small piece of
Kleenex‚ into a 200 mL vial insert and 12 mL of the filtrate injected onto the HPLC-column.
Chromatographic conditions
HPLC-DAD
Stationary phase: 125 x 2 mm I.D. column, packed with Nucleosil-50 EC, particle
size 5 mm and a 8 x 3 mm I.D. precolumn, packed with Nucleosil-
120 C8, particle size 3 mm, (both Macherey-Nagel, Oensingen,
CH)
Mobile phase: Solvent A: Bidistilled water containing 0.05 %  (v/v) TFA
Solvent B: ACN containing 0.05 %  (v/v) TFA
Gradient: 0-1 min, 3.5 % B isocratic; 1-6 min, 3.5-13 % B linear; 6-7 min, 13-
15 % B linear; 7-20 min, 15 % B isocratic; 20-21 min, 15-100 % B
linear; 21-24 min, 100 % B isocratic; 24-25 min, 100-3.5 % B
linear
Run time: 25 min; post run time: 15 min
Flow: 330 mL/min
Oven temperature: 45 °C
Detection: Wavelength for the quantification of morphine, its metabolites, and
the internal standard (EM): UV 210 nm
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the internal standard (EM): UV 210 nm
(online recording of the UV spectra from 190-350 nm (DAD))
HPLC-FLD
Stationary phase: 125 x 2 mm I.D. column, packed with Spherisorb-80 ODS-1 (C18),
particle size 3 mm and a 8 x 3 mm I.D. precolumn, packed with
Spherisorb-80 ODS-1 (C18), particle size 3 mm, (both Macherey-
Nagel, Oensingen, CH)
Mobile phase: Solvent A: Bidistilled water containing 0.05 %  (v/v) TFA
Solvent B: ACN containing 0.05 %  (v/v) TFA
Gradient: 0-5.5 min, 4 % B isocratic; 5.5-9 min, 4-15 % B linear; 9-9.2 min,
15-25 % B linear; 9.2-18 min, 25 % B isocratic; 18-19 min, 25-
100 % B linear; 19-21 min, 100 % B isocratic; 21-22 min, 100-4 %
B linear
Run time: 22 min; post run time: 15 min
Flow: 300 mL/min
Oven temperature: 40 °C
Detection: Wavelength for the quantification of morphine, its metabolites, and
the internal standard (EM): 343 nm (excitation wavelength:
227 nm, 220 Hz; response time 1.0 sec)
343 nm quantification wavelength (amplification factor: 15)
Validation
Peak identification (selectivity / specificity):
HPLC-DAD:
Chromatographic selectivity: The peaks of the analytes (M, M6G, M3G) and the internal
standard (EM) were assigned by the corresponding standards. Negative- (extracted blank
plasma) and positive-control samples (spiked and extracted blank plasma) were analysed to
exclude any interferences.
Spectroscopic selectivity: The identity of the signal was determined by comparing the UV-
spectra in the range of 205-325 nm with the spectra of the standards. The recorded UV-spectra
were also used for the peak purity check.
HPLC-FLD:
Chromatographic selectivity: The peaks of the analytes (M, M6G, M3G) and the internal
standard (EM) were assigned by the corresponding standards. Negative- (extracted blank
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plasma) and positive-control samples (spiked and extracted blank plasma) were analysed to
exclude any interferences.
Spectroscopic selectivity: The identity of the signal was determined by using dual detection
comparing the UV-spectra in a range of 205-325 nm and the fluorescence (detection at 343 nm
after excitation at 227 nm) with the spectra of the standards. The recorded UV-spectra were
also used for the peak purity check.
Calibration and linearity (HPLC-DAD and HPLC-FLD)
Blank plasma was spiked with different concentrations of standards. After the sample
preparation with SPE the samples were analysed using the described method. For each analyte
calibrators of 20, 50, and 100 ng/mL were used. In addition a calibrator of 500 ng/mL was used
for M and M6G, and a calibrator of 1000 ng/mL for M3G. The concentration of the internal
standard (EM) was 1000 ng/mL.
Recovery and precision
For the determination of the recovery blank plasma was spiked 5 times with different
concentrations of analytes (20-100 ng/mL). The samples were prepared and analysed with the
described method. For the interday precision blank plasma was spiked with 20 ng/mL of each
analyte, prepared, and analysed at 5 different days within a month.
Limit of detection and limit of quantification
The limit of detection (LOD) and the limit of quantification (LOQ) were determined with spiked
blank plasma. The LOD was defined at the concentration where the peaks could be clearly
integrated with a signal to noise ratio of 3 to 1. The LOQ was defined at the concentration where
a control sample of 20 ng/mL (HPLC-DAD) and 10 ng/mL (HPLC-FLD), respectively, was within
the range of ± 20 % of the calibration.
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1.6 Determination of THC and -metabolites in plasma by gas chromatography mass-
spectrometry (GC-MS)
Standards, chemicals, and solvents
Table 6: Standards for the quantification of THC and its metabolites
Abbreviations Name Lot-No. Supplier
THC D9-Tetrahydrocannabinol 135.1B25.6L4 Lipomed, Arlesheim, CH
THC-d3 (-)-D9-THC-d3 FYC-30965-21-A Radian, Austin, USA
THC-OH (±)-11-Hydroxy-D9-THC 34703-81B Radian, Austin, USA
THC-OH-d3 (±)-11-Hydroxy-D9-THC-d3 31534-49A Radian, Austin, USA
THC-COOH (±)-11-nor-9-Carboxy-D9-THC 31533-70A Radian, Austin, USA
THC-COOH-d3 9-Carboxy-11-nor-D9-THC-5‘-H3 3983-59 Research Triangle Institute, NC, USA
b-Glucuronidase, Type IX-A, Escherichia choli, from Sigma, Fluka Chemie AG, Buchs (CH),
N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) with 1 % trimethylchlorosilane (TMCS) from
Fluka Chemie AG, Buchs (CH). All other solvents and chemicals used were of GC or analytical
quality obtained from Merck AG, Basel (CH) or Fluka Chemie AG, Buchs (CH).
The immunoaffinity resin slurry was obtained from ElSohly Laboratories, Inc., Oxford, MS, USA.
Instrumentation
The GC-MS system consisted of a HP GC 5890 Series II gaschromatograph with a 7673
autosampler and a G1512A autosampler controller, a HP 5972 mass-selective detector (MSD),
a Vectra 486/66 XM computer with Chemstation Software G1046A Rev. A.00.00 (HP 1989-
1994).
Method
Hydrolysis and extraction procedure for the plasma samples
The preparation of the plasma samples was done using an immunoaffinity extraction
procedure [83]. In a 10 mL sample vial with screw cap 0.5 mL of plasma was spiked with 25 mL
of a methanolic solution containing 1 mg/mL of THC-d3, THC-OH-d3, and THC-COOH-d3. To
each vial 2 mL of 0.1 M potassium phosphate buffer (pH 6.8) was added followed by 200 mL of a
25’000 units/mL solution of b-glucuronidase in the same buffer (a total of 5’000 units). The vial
was then vortexed, closed tightly, and incubated at 37 °C for 16 h. After cooling the sample to
room temperature 1 mL of immunoaffinity resin slurry was added. The tubes were closed tightly,
placed on a test tube mixer operated at a speed of 30 rpm, and mixed for 45 min. The mixture
was poured into a frit filter cartridge (preconditioned with 3 mL of methanol and 3 mL of
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bidistilled water) that was positioned onto a vacuum manifold (Adsorbex SPU, model EM 6500,
series 5055, 16-2-1988, Merck, Darmstadt, D) and the liquid was allowed to pass through under
a slight vacuum. The resin was washed with 3 mL of phosphate saline buffer (pH 7.0), two times
with 3 mL of bidistilled water, followed by 3 mL of 10 % acetone in bidistilled water, and then
dried under vacuum for 2 min. The elution of the analytes was performed using 5 portions of
0.5 mL methanol, allowing the solvent to flow through under gravity into a 10 mL tube. The
eluate was then evaporated to dryness at 45 °C under nitrogen. The residue was derivatised
with 60 mL of BSTFA containing 1 % TMCS and by heating at 70 °C for 30 min. After cooling to
room temperature, the samples were transferred to GC vial inserts and the vials were capped.
The trimethylsilyl (TMS) derivatives (dissolved in the excess of derivatisation reagent) were
directly injected on the GC-MS.
Chromatographic Conditions
Column DB-5 MS column (J&W Scientific, Folsom, CA; provided by MSP,
Köniz, CH), 25 m x 0.2 mm I.D., film-thickness 0.33 mm
Carrier gas Helium
Constant flow 0.2 mL/min
Oven 200 °C (0.5 min) to 280 °C at 30.0 °C/min, 280 °C (13.5 min)
Injection volume 2 mL, splitless
Injector temperature 250 °C
Transfer line temperature 280 °C
Detection mode Single ion monitoring (SIM, the ions are listed in Table 7)
Table 7: Monitored ions for the quantification of THC and its metabolites (TMS derivatives)
Analyte Quantitation ion Qualifying ion
THC-TMS 371 343
THC-d3-TMS 374 389
THC-OH-TMS2 371 474
THC-OH-d3-TMS2 374 377
THC-COOH-TMS2 371 488,473
THC-COOH-d3-TMS2 374 491
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Validation
Peak identification (selectivity / specificity):
Chromatographic selectivity: The peaks of the analytes (THC, THC-OH, THC-COOH) were
assigned by the corresponding standards and deuterated standards (THC-d3, THC-OH-d3, THC-
COOH-d3). Negative- (extracted blank plasma) and positive-control samples (spiked and
extracted blank plasma) were analysed to exclude any interferences.
Spectroscopic selectivity: Peak identification was performed in the SIM mode by the qualifyer
ions listed in Table 7.
Calibration and linearity
Blank plasma was spiked with different concentrations of standards. After extraction the
samples were analysed using the described method. For each analyte calibrators of 100, 20,
and 10 ng/mL were used. In addition to that a calibrator of 2 ng/mL was used for THC and THC-
OH. For THC-COOH two additional calibrators, 200 and 500 ng/mL, were used. The
concentration of the internal standards was 50 ng/mL each.
Recovery, intra- and interday precision, and accuracy
For the determination of the recovery 5 samples of blank plasma were spiked with 20 ng/mL
of each analyte. The samples were analysed as described above, and the area under the peaks
were compared with the areas of identically concentrated standard solutions.
For the determination of the intraday precision, 5 samples of blank plasma were spiked with
20 ng/mL of each analyte and prepared within the same day according to the method described
above. Mean, standard deviation (SD and RSD), and accuracy were calculated.
For the determination of the interday precision, 5 samples of blank plasma were spiked with
20 ng/mL of each analyte, and analysed at 5 different days within a month.
Limit of detection and limit of quantification
The LOD and the LOQ were determined with spiked blank plasma. The LOD was defined at
the concentration where the peaks could be clearly integrated with a signal to noise ratio of 3 to
1. The LOQ was defined at the concentration where a control sample of 2 ng/mL for THC and
THC-OH and 10 ng/mL for THC-COOH, respectively, was within the range of ± 20 % of the
calibration.
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1.7 Statistical analysis
Statistical analysis was performed independently for each pain test. Differences of the
baseline values in the four different sessions of each volunteer were excluded with the
Friedman’s test. Then for each session the mean results of all subjects and time-points were
calculated. The three verum sessions were then compared to the placebo session using the
Wilcoxon signed ranks test. P < 0.05 was considered as significant.
1.8 Calculation of the pharmacokinetic parameters
For the calculation of the pharmacokinetic parameters the TopFit software (version 2.0) was
used [84]. The data were evaluated as mean of the 12 volunteers. Non-compartmental analysis
was performed for the calculation of the parameters (half-life, AUC).
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2. DEVELOPMENT OF WATER SOLUBLE THC FORMULATIONS
2.1 Extraction, purification, and quality assurance of THC from extract ELB-11-98 for the
in vitro experiments
Standards, chemicals, and solvents
Table 8: Standards for the development of water soluble THC formulations
Abbreviations Name Lot-No. Supplier
THC D9-Tetrahydrocannabinol 135.1B25.6L4 Lipomed, Arlesheim, CH
THC-d3 (-)-D9-THC-d3 FYC-30965-21-A Radian, Austin, USA
Petroleum ether, boiling range 40-80 °C, (extra pure, containing n-hexane), Merck AG, Basel
(CH); diethylether, Merck AG, Basel (CH).
All other solvents and chemicals used were of HPLC or analytical quality obtained from Merck
AG, Basel (CH) or Fluka Chemie AG, Buchs (CH).
Extract ELB-11-98: Ethanolic extract of Swiss Cannabis prepared earlier in our lab for analytical
purposes.
Instrumentation
The GC-MS system consisted of a HP GC 5890 Series II gaschromatograph with a 7673
autosampler and a G1512A autosampler controller, a HP 5972 mass-selective detector (MSD),
and a Vectra 486/66 XM computer with Chemstation Software G1046A Rev. A.00.00 (HP 1989-
1994).
The HPLC HP 1090-system consisted of a Hewlett-Packard (HP) 1090M Series II Liquid
chromatograph with a 1040 autosampler, a 1040M photodiode array detector (DAD), and a
Vectra 486/66 XM computer with HPLC Chemstation Rev. A.03.03. software (HP 1990-1995).
The column chromatography (CC) fractions were collected with a LKB fraction collector, LKB
7000 Ultro Rac, LKB Produkter AB, Bromma (S).
The medium pressure chromatograhy (MPLC) system consisted of a Büchi chromatography
pump (type: B-681) with a Büchi fraction collector (type: B-684), Büchi AG Flawil (CH).
Qualitative and quantitative characterisation of the extract ELB-11-98 with GC-MS
A methanolic solution (sonicated for 30 sec at room temperature) of the extract ELB-11-98
with a concentration of 240 ng/mL was used for the quantitative and qualitative characterisation.
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30 µL of this solution was mixed with 30 µL of the internal standard solution (100 µg/mL THC-d3)
and injected into the GC-MS.
Chromatographic conditions GC-MS
Column DB-5 MS column (J&W Scientific, Folsom, CA), 25 m x 0.2 mm
I.D., film-thickness 0.33 mm
Carrier gas Helium
Constant flow 0.2 mL/min
Temperature program 170 °C (1.0 min) to 250 °C at 8.0 °C/min, 250 °C (20.0 min)
Injection volume 1 mL, splitless
Injector temperature 250 °C
Transfer line temperature 280 °C
Detection mode Full scan monitoring (50 to 650 m/z)
For the quantification of THC in the extract ELB-1-98 three calibrators were used: 80, 53, and
26.7 µg/mL of THC (each with 50 µg/mL internal standard).
For the identification of other peaks their mass spectra were compared with those of the
online library [71] and literature [85].
Starting experiments with thin layer chromatography (TLC)
TLC was used to monitor the fractionation of the following CC and MPLC purification of the
extract ELB-11-98, respectively.
Chromatographic conditions
Stationary phase High performance thin layer chromatography (HPTLC) silica gel
60 plates 254, 5 x 10 cm, (Merck, Darmstadt, D)
Mobile phase Petroleum ether / diethylether (1:1), saturated atmosphere
Spot volume 2 mL
Visualisation UV at 254 nm
Spraying with anisaldehyde reagent1 followed by heating (80 °C
for 30 min)
                                                 
1  Anisaldehyde reagent: 0.5 mL of anisaldehyde, 10 mL of glacial acetic acid, 85 mL of methanol,
5 mL of conc. sulfuric acid.
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Purification of the extract ELB-11-98 with column chromatography (CC) and medium
pressure liquid chromatography (MPLC)
In a first step 300 mg of the extract ELB-11-98 were purified using an open column according
to the conditions described below. The collected fractions were screened with TLC and the THC
containing fractions were pooled. After evaporation of the solvents with the vacuum distiller,
purity was checked with GC-MS. In a second step, follow-up purification was done with MPLC
according to the conditions described below. Again the collected fractions were screened,
pooled, the solvent evaporated, and the purified THC analysed with GC-MS and additionally
HPLC-DAD (methods described below).
Chromatographic conditions for CC
Column and stationary phase Length: 40 cm, diameter: 3 cm, filled with silica gel 60,
0.063-0.200 mm (Merck, Darmstadt (D) 1.07734.1000) in
petroleum ether / diethylether 95:5;
after each run the column was refilled completely with new
silica gel.
Mobile phase 200 mL petroleum ether / diethylether 95:5
300 mL petroleum ether / diethylether 80:20
Flow 1 drop/sec
Sample volume 300 mg extract ELB-1-98 dissolved in 10 mL petroleum
ether / diethylether 95:5
Forerun 200 mL
Fractionation 50 fractions (6 mL each) with the fraction collector
Monitoring TLC
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Chromatographic conditions for MPLC
Column and stationary
phase:
Length: 45 cm, diameter: 3.5 cm (+ precolumn: length 10 cm,
diameter 1 cm), filled with 130 g of LiChroprep“ Si 60, 25-40 mm
(Merck, Darmstadt, D), Art.Nr. 1.09390.1000) in petroleum ether /
diethylether 95:5;
after each run a washing procedure (described below) was
performed and after 5 runs the column was completely refilled
with new silica gel.
Mobile phase: 300 mL of petroleum ether / diethylether 95:5
100 mL of petroleum ether / diethylether 90:10
300 mL of petroleum ether / diethylether 80:20
200 mL of petroleum ether / diethylether 50:50
200 mL of diethylether
250 mL of methanol
‡ washing
‡ washing
‡ washing
Flow: ‡ Pressure 1.5 bar
‡ 5 mL/min
Sample  volume: 300 mg of prepurified extract dissolved in 10 mL of petroleum
ether / diethylether 95:5
Forerun: 90 mL
Fractionation: 60 fractions (6 mL each) with the fraction collector
Monitoring: TLC
Quality assurance with GC-MS and HPLC
To monitor the efficiency of the extraction and to characterise the quality of the obtained THC
GC-MS and HPLC-DAD was used. For GC-MS the sample concentration was 150 µg/mL and
for HPLC-DAD 120 µg/mL.
Chromatographic conditions for GC-MS
The conditions were the same as for peak identification in the extract ELB-11-98.
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Chromatographic conditions for HPLC-DAD
Stationary phase: 124 x 4 mm I.D. Spherisorb“ ODS I column, particle size 3 mm
and a 8 x 4 mm I.D. precolumn, packed with the same material
(both Macherey-Nagel AG, Oensingen, CH)
Mobile phase: Solvent A: Bidistilled water containing 0.05 % (v/v) formic
acid
Solvent B: ACN containing 0.05 % (v/v) formic acid
0-15 min, 60 % B isocratic
Run time: 15 min; post run time: 15 min
Flow: 1.0 mL/min
Oven temperature: 40 °C
Injection volume: 10 mL
Detection: DAD 210 nm
Online recording of the UV spectra from 190-350 nm (DAD)
Materials and Methods 39
____________________________________________________________________________________
2.2 Development and validation of the THC inhalation solution
Standards, chemicals, and solvents
Table 9: Standards for the quantification of THC in the developed water soluble THC formulations
Abbreviations Name Lot-No. Supplier
THC D9-Tetrahydrocannabinol 135.1B48.1L1 Lipomed, Arlesheim, CH
phen Phenanthren 11015AU Aldrich, Schnellendorf, D
Table 10: Chemicals for the preparation of the inhalation solution
Abbreviations Name Lot-Nr. Supplier
- Purified THC out of the extract ELB-
11-98 (the ethanolic extract of Swiss
Cannabis prepared earlier in our lab
for analytical purposes)
- -
THC D9-Tetrahydrocannabinol, dronabinol 300.802 THC Pharm, Frankfurt am Main
(D)
Cremophor® RH 40, Polyoxyl 40
Hydrogenated Castor Oil (Ph. Eur.)
54-2535 BASF GmbH, Ludwigshafen (D)
Cremophor® EL, Polyoxyl 35
Hydrogenated Castor Oil (Ph. Eur.)
80-4326 BASF GmbH, Ludwigshafen (D)
Alcohol benzylicus (Ph. Eur.) 2002.02.0379 Hänseler AG, Herisau (CH)
NaAsc Sodium ascorbate (USP) 1167110 Pharmacy of the University
Hospital, Bern (CH)
NaH2PO4 Sodium dihydrogen phosphate
dihydrate (Ph. Eur.)
010008 Pharmacy of the University
Hospital, Bern (CH)
EtOH Ethanolum absolutum 412613/1
62100
Fluka Chemie AG, Buchs (CH)
Bidistilled water, Department of Clinical Research, University of Bern (CH);
methanol LiChrosolv“, Merck AG, Basel (CH).
All other solvents and chemicals were of HPLC or analytical quality obtained from Merck AG,
Basel (CH) or Fluka Chemie AG, Buchs (CH).
Instrumentation
The HPLC HP 1090-system consisted of a Hewlett-Packard (HP) 1090M Series II Liquid
chromatograph with a 1040 autosampler, a 1040M photodiode array detector (DAD), and a
Vectra 486/66 XM computer with HPLC Chemstation Rev. A.03.03. software (HP 1990-1995).
Certoclav, heating plate (Jura type 1074), light bulb (TUNGSRAM, 100 watt, 235-245 V, E27,
"dim", Austria)
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HPLC method
Sample preparation
To 100 mL of the respective formulation 100 mL of internal standard solution containing
2 mg/mL of phen in EtOH were added and diluted to 1.0 mL. 10 mL were then injected on the
HPLC-DAD.
Chromatographic conditions (modified from the method of Brenneisen et al. [86])
Stationary phase 125 x 4 mm I.D. column, packed with Spherisorb ODS I, particle
size 3 mm and a 8 x 4 mm I.D. precolumn, packed with the same
material (Macherey-Nagel, Oensingen, CH)
Mobile phase Solvent A: Bidistilled water containing 1 % (V/V) acetic acid
Solvent B: Methanol
0-16 min, 77.5 % B isocratic; post run time: 15 min
Flow 0.6 mL/min
Oven temperature 40 °C
Detection Wavelength for the quantification of THC with the internal
standard method (phen as internal standard): UV 230 und
280 nm; online recording of the UV spectra from 190-350 nm
(DAD)
Validation
Peak identification (selectivity / specificity)
Chromatographic selectivity: The peaks of THC and the internal standard phen were
assigned by the corresponding standards. Adjuvants were tested for interference.
Spectroscopic selectivity: The identity of the signal was determined by comparing the UV
spectra in a range of 205-325 nm with the spectra of the standards. The recorded UV spectra
were also used for the peak purity check.
Calibration and linearity
The calibrators were prepared using standard solutions. Concentrations of 1000, 500, 250,
and 100 µg/mL of THC were used. The internal standard concentration was 200 µg/mL.
Intra- and interday precision and accuracy
For the determination of the intra- and interday precision standard solutions were used. For
the intraday precision 4 samples of each concentration (1000, 500, 250, and 100 mg/mL) were
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prepared and measured within the same day. Mean, standard deviation (SD, RSD), and
accuracy were calculated.
For the interday precision (SD, RSD) 5 samples of each concentration (1000, 500, 250, and
100 mg/mL) were prepared at different days within 1 month and analysed.
Limit of quantification and limit of detection
The LOQ and the LOD were not determined because the method was used for the
quantification of the THC content in galenic formulations and therefore the concentration range
not critical.
Pilot solubilisation experiments
The solubilisation experiments were all done using 1.8 mL-GC vials and making 1 mL-
formulations. The solvent of an aliquot of the ethanolic THC stock solution (containing 5 mg/mL
of THC) was evaporated under nitrogen at room temperature to get the necessary amount of
pure THC. The appropriate amount of Cremophor® was then added and the mixture heated to
63 °C for 20 min in a water bath. The aqueous phase was heated separately. After that the two
phases were mixed together and shaken vigorously until a clear solution was obtained. The
solutions were then allowed to cool, examined for residues of THC, and finally analysed with the
HPLC method described before. The THC peak areas were compared with those of the
ethanolic THC standard solution.
The different solubilisation experiments are summarised in Table 11.
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Table 11: Solubilisation experiments
Experiment THC [mg/mL] Solvent Cremophor® RH 40
concentration in % [w/v]
Cremophor® EL
concentration in % [w/v]
1 Bidistilled water - -
1 EtOH - -
1 5 -
1 10 -
1 15 -
1 - 5
1 - 10
1
1
Bidistilled water
- 15
2 EtOH - -
2 2.5 -
2 5 -
2 10 -
2 - 2.5
2 - 5
2
2
Bidistilled water
- 10
3 EtOH - -
3 2.5 -
3 5 -
3 10 -
3 - 2.5
3 - 5
3
3
Bidistilled water
- 10
3 7.5 -
3 5 -
3 4 -
3 3 -
3 2 -
4
3
Bidistilled water
1 -
Follow-up experiments with different pH in the heat stress test
To compare the stability of the formulation the next experiments were done at different pH
conditions, buffered and not buffered, followed by a stress test in the certoclav (stress test
conditions described below). The THC concentration was set to 3 mg/mL, Cremophor‚
concentrations to 5 %. The buffer capacity2 (b) of the phosphate buffer was 0.03 each time. The
formulations at 4 different pH values (6.0, 6.8, 7.4, and 8.0), buffered and non-buffered,
                                                 
2  Equation to calculate the buffer capacity b:
† 
b =  2.3 C 
Ka H3O +[ ]
Ka  +  H3O +[ ]( )
2
C: total buffer concentration
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respectively, were compared by analysing the following variables before and after the stress
test with the described HPLC method: area of the THC and the cannabinol peaks (CBN,
degradation product of THC due to oxidation), and the ratio of the areas.
Conditions of the stress tests
Heat
The formulations in the 1.8 mL GC vials were capped and left in the certoclav at 1 bar,
121 °C, 20 min steam. After this treatment the vials were shaken for 5 min to re-emulsify the two
separated phases. After cooling to room temperature the samples were analysed using the
described HPLC method.
Light
The formulations in the 1.8 mL GC vials were capped and put on a piece of plastic (distance
to the table: 6 cm) covered with a white sheet of paper. In a distance of 45 cm the lamp was
installed containing a 100 W light bulb. The measured temperature on the piece of plastic was
27 °C and the measured light intensity 12 500 lux. The test time was set to 6 and 24 h,
respectively. After cooling to room temperature the samples were analysed using the described
HPLC method.
Statistical experiment
A statistical experiment was done using a factorial 23-design [87, 88]. The null hypothesis
(H0) was that there is no influence of the adjuvants on the stability of the formulations and that
there are no interactions between the adjuvants leading to additional influence on the stability of
the formulations. The factors and levels of the 23-design were defined as listed in Table 12.
Table 12: Definition of factors and levels for the 23-design
LevelsFactors
+ -
A pH (buffered) 8.0 7.4
B Cremophor® RH 40 conc. [% w/v] 6 3
C NaAsc conc. [% w/v] 0.2 0.05
Basing on these definitions the scheme presented in Table 13 was arranged for the
experiments.
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Table 13: Scheme for the 23-design
Level of the factors Level of the interactions
A B C AB AC BC ABC
(1) - - - + + + -
a + - - - - + +
b - + - - + - +
ab + + - + - - -
c - - + + - - +
ac + - + - + - -
bc - + + - - + -
abc + + + + + + +
Symbols: a, b, c Upper level of the factors A, B, and C (not marking the lower level)
(1) All factors on the lower level
This scheme led to the different formulations for the statistical experiment. The composition
of the 8 experiments is presented in Table 14.
Table 14: Formulations for the statistical experiment (3mg/mL THC added)
No. pH buffered Cremophor® RH 40 concentration
in % [w/v]
NaAsc concentration (antioxidant)
in % [w/v]
(1) 7.4 3 0.05
a 7.4 6 0.05
b 8.0 3 0.05
ab 8.0 6 0.05
c 7.4 3 0.2
ac 7.4 6 0.2
bc 8.0 3 0.2
abc 8.0 6 0.2
The THC concentration was set to 3 mg/mL. All the formulations were analysed immediately
after preparation, after the heat stress test, and finally after the light stress test (6 h and 24 h)
with the described HPLC method. Statistical assessment was done using Yates-analysis [87].
The endpoint was the ratio of the peak areas of THC and CBN, respectively, after the stress
tests.
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Final formulation with adjuvants
The final formulation with all adjuvants (buffer, antioxidant, conservant) is presented in
Table 15.
Table 15: Final formulation of the THC inhalation solution
Component Amount [% (w/v)]
THC 30.0 mg 0.3
Cremophor® RH 40 500.0 mg 5.0
NaAsc 5.0 mg 0.05
Benzyl alcohol 100.0 mg 1.0
Phosphate buffer (pH 7.4, 84.2 mM) to 10.0 mL
The THC and the Cremophor® RH 40 were heated together in a water bath at 63 °C for
10 min. Two third of the phosphate buffer, also heated to 63 °C, were then incorporated in the
mixture by shaking. After cooling to room temperature the benzyl alcohol, the NaAsc, and the
remaining phosphate buffer were added to the mixture. The clear, yellowish solution was then
sonicated for 30 s and finally filtrated through a 0.22 mm filter under aseptic conditions.
Quality assurance of the final formulation (in vitro)
Stability
Quantification of the THC content was done every 4 to 9 days using the described HPLC
method.
Viscosity
The measurement of the viscosity was done by the pharmacy of the University Hospital Bern
according to the standards of the European Pharmacopeia [89]. The measurement was carried
out with the placebo solution.
Osmolality
The measurement of the osmolality was done by the pharmacy of the University Hospital
Bern according to the standards of the European Pharmacopeia [89].
pH
The pH value of the formulation was determined three times using a potentiometer.
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Particle size distribution
The measurement was performed with a Malvern Mastersizer X equipped with a 100 mm
lens. For the calculation of the particle size Malvern Software with the algorithm for volume
distribution, polydisperse aerosol, and the 2QAA-model representing water in air was used. To
minimise light scattering the room was darkened during the measurements. Temperature and
humidity remained constantly at 23 °C and 40 %, respectively. For the sample analysis the
solution was nebulised continuously into the laser beam and continuously removed by a
vacuum cleaner. The obscuration was held on a value of approximately 10-30 %. The particle
size distribution was determined with the vehicle solution with both nebulisers (n = 10) and with
the THC solution with the LC-Plus nebuliser (n = 5).
Output rates
For the determination of the output rate of THC from the pressure driven PARI‚ Master
coupled to the LC Plus nebuliser the conditions developed earlier by our group were used [12]
(Figure 1). The PARI‚ Master was connected to the tubing followed by the interrupter and the
nebuliser (either the LC-Plus- or the IS-2-nebuliser) equipped with an inspiratory valve (LC-
Plus). The nebuliser was connected to a PARI filter set containing a filter pad collecting the
aerosol. The filter set was coupled with an expiratory valve filled with a bowl of glass wool to
collect the small amount that is not retained by the filter pad. This valve was then again
connected with the adult’s mouthpiece (with a second expiratory valve) leading to a 3 L hand
pump representing the lung and simulating the “breathing” (3 Liter Calibrated Syringe, Sensor
Medics Corporation, Yorba Linda, CA, USA; provided by the Dept. of Pneumology, University
Hospital, Bern).
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Figure 1: Scheme of the experimental arrangement for the determination of the output rate
Samples of 2 mL (n = 3) and 3 mL (n = 3) were nebulised with each of the nebulisers. The
inhalation was simulated manually with the hand pump (velocity 1 breath/10 sec, simulating
optimal inhalation). The filter pad and the glass wool which collected the aerosol were then
extracted using the following procedure: the filter pad and the bowl of glass wool were
lyophilised for 15 h, transferred to a 200 mL beaker, and 20 mL of ethanol added. After
sonicating for 5 min the filter pad and the bowl of glass wool were again extracted with 30 mL of
ethanol. The two extracts were combined, evaporated to a volume of about 2 mL, and rediluted
to 10.0 mL. Then to 1.0 mL of this extract 100 mL of the internal standard solution containing
2 mg/mL phen in ethanol were added. 10 mL were injected into the HPLC-DAD.
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2.3 Preparation and validation of the THC injection solution
Standards, chemicals, and solvents
Table 16: Chemicals for the preparation of the injection solution
Abbreviations Name Lot-No Supplier
THC D9-Tetrahydrocannabinol,
Dronabinol
300.802 THC Pharm, Frankfurt am Main
(D)
Tween® 80 Polysorbatum 80 (Ph. Eur.) 020077 Pharmacy of the University
Hospital, Bern (CH)
NaAsc Sodium Ascorbate (USP) 1167110 Pharmacy of the University
Hospital, Bern (CH)
NaCl Sodium chloride (Ph. Eur.) 010042 Pharmacy of the University
Hospital, Bern (CH)
EtOH Ethanolum absolutum 412613/1 62100 Fluka Chemika AG, Buchs (CH)
Bidistilled water, Department of Clinical Research, University of Bern (CH).
All other solvents and chemicals used were of HPLC or analytical quality obtained from Merck
AG, Basel (CH) or Fluka Chemie AG, Buchs (CH).
Composition and preparation of the THC injection solution
The THC injection solution was prepared using the formulation of Olsen et al. [90] adding
NaAsc as an antioxidant for better stability. The composition of the formulation is presented in
Table 17.
Table 17: Composition of the THC injection solution
Component Amount [% (w/v)]
THC 10.0 mg 0.1
EtOH abs. 500.0 mL 5.0
Tween® 80 150.0 mg 1.5
NaAsc 10.0 mg 0.1
NaCl solution (0.9 % w/v) to 10.0 mL
The THC was dissolved in the EtOH and Tween® 80, then added to NaAsc dissolved in 1 mL
of the NaCl solution. The remaining sodium chloride solution was finally added to the mixture.
The clear, yellowish solution was then sonicated for 30 sec and filtrated through a 0.22 mm filter
under aseptic conditions.
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Quality assurance of the injection solution
Stability
Quantification of the THC content was done every 3 to 9 days using the described HPLC
method.
Osmolality
The measurement of the osmolality was done by the pharmacy of the University Hospital
Bern according to the standards of the European Pharmacopeia [89].
pH
The pH value of the formulation was determined three times using a potentiometer.
Sterility
The absence of microbial contaminants was confirmed by the pharmacy of the University
Hospital Bern using the method of the European Pharmacopeia [89].
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3. PHARMACOKINETIC STUDY WITH PULMONAL AND INTRAVENOUS THC
3.1 Subjects and study design (pharmacokinetic study)
Eight healthy volunteers were admitted to this randomised, placebo controlled (only
inhalation), double-blind, crossover study which was carried out in the Clinical Investigation Unit
(CIU) of the University Hospital of Bern. The subjects were informed about the risks of the
study, gave their written informed consent, and were paid for participating. Exclusion criteria
were past or existing drug abuse (including alcohol and prescription drugs; Cannabis urine test
before each session), known or suspected hypersensibility to cannabinoids, pregnancy (urine
test before first session), positive past history of any psychiatric disorders, and lung diseases.
Each subject had to pass the lung function tests including vital capacity and forced expiratory
volume in one second. The subjects were not allowed to take analgesics, alcohol, and
caffeinated beverages 48 h before and during the study and were asked to refrain from driving
up to 24 h after the study. The study was approved by the Local Ethics Committee, the Swiss
Agency for Therapeutic Products (Swissmedic), and the Federal Office for Public Health (study
protocol, volunteer information etc. see appendix II). In the first and second session, each
subject received randomly and double-blinded either the THC (0.053 mg/kg b. wt.) or the
placebo inhalation aerosol. In the third session THC was administered i.v. (0.053 mg/kg b. wt.)
over a time period of 2 min. The between-session washout phases were at least 7 days. To
familiarize the subjects with the pain test and the VAS, each session began with a training
phase, during which the subjects performed a pain test and a 5-min inhalation training with the
placebo aerosol. This was followed by the recording of the baseline (vital functions, side effects
scores, and pain test). After administration of the THC and placebo preparations vital functions
and side effects were recorded and ice water pain determined at 20, 40, 60, 120, 240, and
480 min. Blood (5 mL) was collected in all three sessions through a peripheral vein catheter at
baseline, 5, 10, 20, 40, 60, 120, 240, and 480 min after administration of the test medications.
The heparinised blood samples were centrifuged and the plasma instantly deep-frozen and
stored at - 20 °C until analysis.
3.2 Inhalation procedure
The pressure-driven inhalation device PARI‚ Master and the PARI‚ LC-plus nebuliser with
interrupter were used. The subjects were instructed to inhale deeply with a breath frequency of
1 breath per 10 sec waiting 3 to 5 sec before expiration. The subjects were instructed to
continue until all the inhalation solution had been inhaled. Inhalation time and any residue left in
the nebuliser compartment were measured.
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3.3 Composition and preparation of the clinical test substances
Verum inhalation solution
The verum inhalation solution was prepared using the composition and method described in
chapter 2.2 ("Development and validation of the THC inhalation solution"), 1 to 2 weeks before
the respective sessions.
Placebo inhalation solution
The placebo inhalation solution was exactly prepared like the verum solution only lacking the
THC, 1 to 2 weeks before the respective sessions.
Injection solution
The injection solution was prepared using the composition and method described in
chapter 2.3 ("Preparation and validation of the THC injection solution") 1 to 2 weeks before the
respective sessions.
3.4 Pain test
The same cold test as in the first pain study (ice cold immersion test, described in chapter
1.3 “Pain tests”) was used.
3.5 Monitoring of side effects and vital functions
A 10-cm VAS (see appendix II) was used to asses psychological and somatic side effects,
such as sedation, euphoria, anxiety, nausea, vertigo, headache, irritation of airways etc..
Haemoglobin oxygen saturation (pulse oximetry), blood pressure, and heart rate were recorded.
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3.6 Determination of THC and -metabolites in plasma by gas chromatography mass-
spectrometry (GC-MS)
Standards, chemicals, and solvents
Table 18: Standards for the quantification of THC and its metabolites
Abbreviations Name Lot-No Supplier
THC D9-Tetrahydrocannabinol 135.1B48.1L1 Lipomed, Arlesheim, CH
THC-d3 D9-THC-d3 315.1B1.1L1 Lipomed, Arlesheim, CH
THC-OH (±)-11-Hydroxy-D9-THC 34703-81B Radian, Austin, USA
THC-OH-d3 (±)-11-Hydroxy-D9-THC-d3 31534-49A Radian, Austin, USA
THC-COOH (±)-11-nor-9-Carboxy-D9-THC 31533-70A Radian, Austin, USA
THC-COOH-d3 (±)-11-nor-9-Carboxy-D9-THC-D3 35002-42B Radian, Austin, USA
b-Glucuronidase, Type IX-A from Escherichia choli, Sigma, Buchs (CH);
N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA) with 1 % trimethylchlorosilane (TMCS) from
Fluka Chemie AG, Buchs (CH).
All other solvents and chemicals used were of HPLC or analytical quality obtained from Merck
AG, Basel (CH) or Fluka Chemie AG, Buchs (CH).
Instrumentation
The GC-MS system consisted of a HP GC 5890 Series II gaschromatograph with a 7673
autosampler and a G1512A autosampler controller, a HP 5972 mass-selective detector (MSD),
and a Vectra 486/66 XM computer with Chemstation Software G1046A Rev. A.00.00 (HP 1989-
1994).
Method
Hydrolysis and extraction procedure for the plasma samples
The hydrolysis of the plasma samples was done using the method of Feng et al. [83]. In a
10 mL tube 0.6 mL of plasma was spiked with 30 mL of a methanol solution containing 1 mg/mL
THC-d3, THC-OH-d3, and THC-COOH-d3. To each tube 2.44 mL of 0.1 M potassium phosphate
buffer (pH 6.8) followed by 200 mL of a 25’000 units/mL solution of b-glucuronidase in the same
buffer (a total of 5’000 units) were added. The tube was then vortexed, capped, and incubated
at 37 °C for 16 h. The sample was cooled to room temperature and extracted automatically with
an ASPEC XL (Automatic Sample Preparation with Extraction columns) robotic system
equipped with a Dilutor 402 (Gilson, Villliers Le Bel, F), using the method of Moeller et al. [91]
and Bakerbond C18 SPE columns (Stehelin & Cie AG, Basel, CH) (Table 19).
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Table 19: SPE of the plasma samples
Conditioning Methanol
Bidistilled water
6 mL
3 mL
Sample An aliquot of 2.725 mL (corresponding to 0.5 mL plasma) of
the hydrolysed mixture was loaded onto the column 2.725 mL
Washing Bidistilled water
0.25 M Acetic acid
Bidistilled water
Acetone
3 mL
3 mL
3 mL
0.075 mL
Drying Air 2 mL
Elution Acetone
Acetone
Acetone
0.5 mL
0.5 mL
0.5 mL
The eluate was evaporated to dryness at 50 °C under nitrogen. The residue was then
derivatised using the method of Feng et al. [83]. 60 mL of BSTFA containing 1 % TMCS was
added to the residue and vortexed. The tube was capped and heated at 70 °C for 30 min. The
sample was then cooled to room temperature, transferred to a GC vial insert, capped, and
injected into the GC-MS.
Chromatographic conditions
Column DB-5 MS column (J&W Scientific, Folsom, CA, provided by MSP,
Köniz, CH), 25 m x 0.2 mm I.D., film-thickness 0.33 mm
Carrier gas Helium
Constant flow 1.2 mL/min
Temperature program 200 °C (0.5 min) to 280 °C at 5.0 °C/min, 280 °C (5 min)
Injection volume 2 mL, splitless
Injector temperature 250 °C
Transfer line temperature 280 °C
Detection mode SIM monitoring (the ions are listed in Table 20)
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Table 20: Monitored ions for the quantification of THC and its metabolites (TMS derivatives)
Analyte Quantitation ion Qualifying ion
THC-TMS 371 343
THC-d3-TMS 374 389
THC-OH-TMS2 371 474
THC-OH-d3-TMS2 374 377
THC-COOH-TMS2 371 488, 473
THC-COOH-d3-TMS2 374 491
Validation
Peak identification (selectivity / specificity):
Chromatographic selectivity: The peaks of the analytes (THC, THC-OH, THC-COOH) and
the corresponding deuterated internal standards (THC-d3, THC-OH-d3, THC-COOH-d3) were
assigned by standards. Negative control - (extracted blank plasma) and positive control-
samples (spiked blank plasma) were analysed to exclude any interferences.
Spectroscopic selectivity: Peak identification was performed in the SIM mode by the qualifyer
ions listed in Table 20.
Calibration and linearity
Blank plasma was spiked with different concentrations of standards. After extraction the
samples were analysed using the described method. For each analyte the following calibrators
were used in duplicates: 0.4, 1, 2, 5, 10, 20, 40, and 100 ng/mL plasma. For THC, additional
calibrators containing 200 and 300 ng/mL plasma were used. The concentration of the internal
standards was 50 ng/mL each.
Recovery, intra- and interday precision, and accuracy
For the determination of the recovery 6 samples of blank plasma were spiked with different
concentrations (2-150 ng/mL) of each analyte. The samples were prepared and analysed with
the described method, and the area of the respective peaks compared with the area of the
peaks of a standard measured without sample preparation.
For the determination of the intraday precision 5 samples of blank plasma were spiked with 4
and 100 ng/mL of each analyte, respectively, then extracted and analysed within the same day
according to the described method. Mean, standard deviation (SD, RSD), and accuracy were
calculated.
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For the determination of the interday precision 5 samples of blank plasma were spiked with
4  and 100 ng/mL of each analyte, respectively, and analysed at 5 different days within one
month.
Limit of detection and limit of quantification
The LOD and LOQ were determined with spiked blank plasma. The LOD was defined as the
concentration where the peaks could be clearly integrated with a signal to noise ratio of 3 to 1.
The LOQ was defined as the concentration where a control sample of 0.4 ng/mL was within the
range of ± 20 % of the calibration.
3.7 Calculation of the pharmacokinetic parameters
Plasma concentrations versus time were used to estimate pharmacokinetic parameters,
including plasma peak concentrations (Cmax), time to reach peak plasma concentration (tmax),
and area under the concentration-time curve (AUC). Based on a non-compartment model, all
pharmacokinetic parameters were assessed by use of standard calculation procedures
performed by the TopFit‚ (version 2.0) computer software [84]. AUC up to the time
corresponding to the last measurable concentration (AUC0-tlast) was calculated by numeric
intergration using the linear trapezoidal rule. Values for C0 (extrapolated) were determined by
linear regression of the logarithmically transformed concentration values back to the time point
0. The value of the elimination rate constant, lz, was determined by using TopFit‚ software,
applying a non-compartmental analysis technique that focused on the terminal linear phase of
semilogarithmic plots of the individual plasma concentration-time data. The elimination half-life
(t1/2) was calculated using the following equation: t1/2 = 0.69315/lz. The bioavailability (F) of
inhaled THC compared to i.v. THC was calculated using the following equation: F =
(AUCinhal./AUCi.v.)/(dosei.v./doseinhal.). The clearance (CL) and volume of distribution (Vz) were
calculated using the i.v. data and the following equations: CL = dosei.v./AUCi.v.; Vz = CL/lz.
A second analysis of the i.v. data was done with the PKAnalyst‚ software (Version 1.0) [92]
using a two-compartment model (model # 8, two compartments with bolus input and first-order
output, micro-constants as input) for the fitting. Clearance CL and distribution volume Vz were
manually calculated using the following equations: CL = dose / AUC0-480min, Vz = CL / elimination
rate constant.
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RESULTS
1. PHARMACODYNAMIC STUDY WITH ORAL THC (PAIN STUDY)
1.1 Quality assurance of clinical test preparations
1.1.1 Marinol® (THC, dronabinol; capsules)
Validation
Peak identification (selectivity / specificity)
The blank run showed no interferences at the retention times of the analyte and the internal
standard. Retention time and ions for THC were 20.3 min (20.0 - 21.0 min) and m/z 314, 299,
and 271, respectively. Retention time and ions for THC-d3 were 20.4 min (20.0 - 21.0 min) and
m/z 317, 302, and 274, respectively.
Calibration and linearity
Table 1 shows the data of the calibration.
Table 1: Calibration data for the quantification of THC in Marinol“ capsules
Analyte Retention time [min] m1) b1) Correlation coefficient r
THC 20.3 0.0223 - 0.0829 0.9994
1)y = mx + b; x: amount of THC; y: ratio of the areas under the peak
The calibration was linear in the concentration range of 30 to 70 mg/mL THC. The present
method was consequently used to determine the THC content of the Marinol“ capsules used in
the pain study.
Recovery
The recovery was not determined. It was assumed that 100 % of the THC was extracted
from the capsule and the sesame oil matrix.
Intra- and interday precision and accuracy
Table 2 shows the results for the intraday precision and the accuracy. Table 3 shows the
results for the interday precision.
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Table 2: Intraday precision and accuracy for the quantification of THC in Marinol‚ capsules
Added THC
[mg/mL]
Found
[Mean, mg/mL]
SD
[mg/mL, n = 4]
RSD
[%, n = 4]
Accuracy
[%]
30 29.01 0.55 1.1 - 3.3
50 51.60 1.17 1.6 3.2
70 70.01 2.94 2.7 0.01
Table 3: Interday precision for the quantification of THC in Marinol‚ capsules
Added THC
[mg/mL]
SD
[mg/mL]
RSD
[%]
30 (n = 6) 0.74 2.6
50 (n = 6) 0.46 4.1
70 (n = 6) 0.85 1.2
Limits of detection and quantification
The LOD and LOQ were not determined because the method was used for the quantification
of the THC content in the 10 mg-Marinol“ capsules and therefore the range of the concentration
far above the LOD/LOQ.
Quality assurance of Marinol®
Table 4 shows the results of the quality assurance of the Marinol“ capsules used in the pain
study.
Table 4: Quality assurance of 10 mg-Marinol“ capsules
Measured THC content in mg Difference to the declared content of 10 mg
Capsule 1 10.8 mg + 8.0 %
Capsule 2 10.9 mg + 9.0 %
Capsule 3 11.0 mg + 10.0 %
The THC content of the three capsules was in the ± 10 % range of the declared content and
thus in agreement on the regulations of the European Pharmacopeia [89].
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1.1.2 THC-hemisuccinate suppositories (rectal THC-HS)
Calibration
The calibration data are presented in Table 5.
Table 5: Calibration data for the quantification of THC hemisuccinate in suppositories
Analyte Retention time [min] m1) b1) Correlation coefficient r
THC-HS 4.47 1.0685 0.0217 0.9994
1)y=mx + b; x: ratio of amount of the concentrations (THC-HS vs. THC hemiglutarate); y: ratio of the areas
under the peak
Results of the quality assurance
The analysis of 6 suppositories showed that a high amount of the THC-HS was already
hydrolysed. The results are presented in Table 6.
Table 6: THC-HS quantification in suppositories
Sample Type / Lot THC-HS content
[mg]
% of the declared
content
Comment
1 5 mg / VSu0698 3.0 60 % out of the tolerated limits
of ± 10%1)
2 5 mg / VSu0698 3.1 62 % out of the tolerated limits
of ± 10%
3 10 mg / VSu0798 7.8 78 % out of the tolerated limits
of ± 10%
4 10 mg / VSu0798 9.4 94 % within the tolerated limits
of ± 10%
5 20 mg / VSu0898 17.8 89 % out of the tolerated limits
of ± 10%
6 20 mg / VSu0898 16.9 mg 85 % out of the tolerated limits
of ± 10%
1) Prescribed limits of the European Pharmacopeia: ± 10 % [89]
The THC-HS content of the suppositories of batch 1 - 3 and 5 - 6 were not within the ± 10 %
range of the declared content and thus not in agreement of the regulation of the European
Pharmacopeia [89]. In consequence, batch 1-3 and 5-6 could not be used for clinical purposes
within the REHAB Basel project due to significant hydrolysis of THC-HS to THC.
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1.2 Subjects and study design
The subjects were all Cannabis-naïve. Six females (21 - 38 years; 70 ± 8 kg b.wt.) and
6 males (18 - 47 years; 74 ± 7 kg b.wt.) were admitted.
1.3 Pain tests
Pressure
In the pressure test, where pain tolerance thresholds were measured, no significant
analgesic effect of THC was observed compared to placebo (Figure 1). On the other hand,
morphine alone increased the pain tolerance threshold significantly compared to placebo
(p = 0.01).
Heat
As shown in Figure 2 and 3, THC did not produce any analgesic effect in the heat test,
neither alone nor in combination with morphine. Morphine alone had no effect.
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Figure 1: Pain tolerance of THC, morphine, THC-morphine, and placebo in the pressure test: values > 100 %
of baseline (mean ± SEM) indicate analgesia, values < 100 % hyperalgesia.
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Figure 2: Pain detection threshold of THC, morphine, THC-morphine, and placebo in the heat test: values
> 100 % of baseline (mean ± SEM) indicate analgesia, values < 100 % hyperalgesia.
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Figure 3: Pain tolerance threshold of THC, morphine, THC-morphine, and placebo in the heat test: values
> 100 % of baseline (mean ± SEM) indicate analgesia, values < 100 % hyperalgesia.
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Cold
Figure 4 represents the area under the pain-intensity time curve (total pain, AUP) in the cold
test (ice cold immersion test). The AUP’s of THC and THC-morphine showed no significant
difference compared to placebo. Morphine alone significantly (p = 0.014) reduced AUP,
whereas THC alone increased AUP, an effect completely neutralised when combining THC with
morphine. This hyperalgesia was not significant. The same effect was observed for the mean
pain value. The peak pain value was significantly reduced by morphine (p = 0.017) and the
THC-morphine combination (p = 0.046), but not with THC alone.
Transcutaneous Electrical Stimulation (single, repeated)
In the single mode of the transcutaneous electrical stimulation (Figure 5) no significant
analgesic effect of THC and THC-morphine was observed. However, a slightly additive effect of
THC in combination with morphine compared to morphine alone at most of the observation
points could be seen. Morphine significantly increased the pain detection threshold value
(p = 0.008). In the repeated mode (Figure 6) THC in combination with morphine was again
additively effective in the pain detection compared to morphine alone and even produced a
statistically significant analgesic effect compared to placebo (p = 0.042). Morphine alone
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Figure 4: Pain tolerance of THC, morphine, THC-morphine, and placebo in the ice cold immersion test; values
> 100 % of baseline (mean ± SEM) indicate hyperalgesia, values < 100 % analgesia.
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showed again a significant increase of the pain detection threshold value compared to placebo
(p = 0.004). THC alone did not significantly reduce pain. It again caused a slight, not significant
hyperalgesia in the second part of the session (time point 4 to 8 h post drug) compared to
placebo.
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Figure 5: Pain detection threshold of THC, morphine, THC-morphine, and placebo after single transcutaneous
electrical stimulation; values > 100 % of baseline (mean ± SEM) indicate analgesia, values < 100 %
hyperalgesia.
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Figure 6: Pain detection threshold of THC, morphine, THC-morphine, and placebo after repeated transcuta-
neous electrical stimulation; values > 100 % of baseline (mean ± SEM) indicate analgesia, values
< 100 % hyperalgesia.
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1.4 Monitoring of side effects and vital functions
The side effects, summarised in Table 7, were usually mild. Most of the subjects felt sleepy
and confused after the administration of THC and THC-morphine. They also reported altered
inner and outer perception, feelings of anxiety and aggression. Interestingly, the euphorigenic
and hallucinogenic effects of THC were reduced when combining with morphine (Figures 7 & 8).
Table 7: Psychological and somatic side effects (peak VAS %, mean ± SEM of all subjects) after THC, morphine,
 THC-morphine, and placebo (n = 12)
Placebo THC Morphine THC-Morphine
Side effect
f1 VAS [%] f1 VAS [%] f1 VAS [%] f1 VAS [%]
Sleepiness 12 70 ± 31 12 82 ± 20 12 64 ± 33 12 85 ± 20
Euphoria 1 66 ± 0 9 54 ± 34 3 16 ± 11 5 21 ± 29
Irritation 1 12 ± 0 5 44 ± 34 1 6 ± 0 5 28 ± 31
Anxiety 0 - 4 54 ± 43 0 - 3 22 ± 32
Tenseness and aggressiveness 1 10 ± 0 4 57 ± 39 2 14 ± 5 2 49 ± 66
Confusion and disorientation 1 2 ± 0 7 58 ± 31 0 - 8 13 ± 9
Change of inner perception 2 16 ± 4 10 66 ± 30 5 19 ± 9 9 61 ± 37
Change of outer perception 0 - 8 53 ± 28 0 - 4 41 ± 36
Hallucinations 0 - 6 64 ± 29 0 - 5 39 ± 37
Strange thoughts, ideas, moods 0 - 7 51 ± 40 1 13 ± 0 3 43 ± 50
Nausea 0 - 5 25 ± 17 3 27 ± 7 6 11 ± 8
Headache 2 23 ± 8 6 63 ± 28 5 33 ± 33 5 36 ± 29
Difficulties in breathing 0 - 6 30 ± 33 2 18 ± 17 4 22 ± 23
Heart problems (tachycardia) 0 - 6 48 ± 37 0 - 1 97 ± 0
Digestive problems 0 - 5 25 ± 19 3 13 ± 12 4 8 ± 6
Dry mouth 5 21 ± 20 12 76 ± 28 8 31 ± 22 10 51 ± 37
Vertigo 3 6 ± 2 11 51 ± 35 5 12 ± 10 9 34 ± 33
Vomiting 0 - 0 - 4 - 2 -
Orthostatic disorder 0 - 0 - 1 - 2 -
1 f: Frequency of side effect per 12 subjects
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Figure 7: Side effect "euphoria" (VAS %, mean ± SEM) after THC, morphine, THC-morphine, and placebo.
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Figure 8: Side effect "hallucinations" (VAS %, mean ± SEM) after THC, morphine, THC-morphine, and
placebo.
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The reaction time was not significantly impaired by any of the test preparations (Figure 9).
Systolic (116 ± 4 to 101 ± 3 mm Hg) as well as diastolic blood pressure (65 ± 3 to 54 ± 2 mm Hg)
decreased significantly only after THC-morphine compared to placebo. With 63 ± 3 to 87 ± 4
THC alone increased significantly the heart rate, whereas the haemoglobin oxygen saturation
was only significantly reduced after THC-morphine.
1.5 Determination of morphine and -metabolites in plasma by HPLC-DAD and HPLC-FLD
Validation
Peak identification (selectivity / specificity)
HPLC-DAD:
Blank and positive control samples showed no interferences with the analytes and the
internal standard. The retention times of the analytes are presented in Table 8, paragraph
“Calibration and linearity”.
HPLC-FLD:
Blank and positive control samples showed no interferences with the analytes and the
internal standard. The retention times of the analytes are presented in Table 9, paragraph
“Calibration and linearity”.
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Figure 9: Reaction time % of baseline (mean ± SEM) after THC, morphine, THC-morphine, and placebo.
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Calibration and linearity
HPLC-DAD:
Table 8 gives an overview of the calibration results.
Table 8: Calibration data for the quantification of morphine and its metabolites in plasma (HPLC-DAD)
Analyte Retention time [min] m1) b1) Correlation coefficient r
M3G 2.75 1.35664 0.06873 0.9999
M6G 3.81 1.63370 -0.00779 0.9988
M 4.40 1.28137 0.01607 0.9985
1) y = mx + b; x: ratio of the concentrations; y: ratio of the areas under the peak
The data show linearity in the calibrated range of 20 to 500 ng/mL for M and M6G and 20 to
1000 ng/mL for M3G, respectively.
HPLC-FLD:
Table 9 gives an overview of the calibration results.
Table 9: Calibration for the quantification of morphine and its metabolites in plasma (HPLC-FLD)
Analyte Retention time [min] m1) b1) Correlation coefficient r
M3G 5.15 0.79240 0.00799 0.9992
M6G 7.28 0.26299 0.00485 0.9997
M 9.59 0.54045 0.00171 0.9995
1) y = mx + b; x: ratio of the concentrations; y: ratio of the areas under the peak
The data show linearity in the calibrated range 20 to 500 ng/mL for M and M6G and 20 to
1000 ng/mL for M3G, respectively. The current method was used for the acquisition of
pharmacokinetic data and therefore the range of calibration had to be selected in order to
include the highest plasma levels of the morphine metabolites as well as the lowest plasma
levels of the analytes in the elimination phase. Different experiments showed a LOQ of
20 ng/mL (DAD) and 10 ng/mL (FLD), respectively, for each of the analytes. The upper LOQ
was equal to the highest calibrator (1000 ng/mL).
Recovery and precision
Table 10 shows the results for the two quantification methods.
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Table 10: Recovery and precision of the quantification of morphine and its metabolites in plasma
Analyte Recovery [%]
HPLC-DAD (n = 5)
Recovery [%]
HPLC-FLD (n = 5)
Precision (RSD, %; n = 5)
HPLC-DAD
Precision (RSD, %; n = 5)
HPLC-FLD
M3G 68.4 66.3 6.3 7.4
M6G 87.3 65.7 9.7 9.8
M 67.3 46.1 7.5 8.3
IS 87.3 42.8 - -
Limit of detection
The LOD was found to be 20 (DAD) and 10 ng/mL (FLD), respectively. At this concentration
levels the peaks could clearly be detected and integrated.
Limit of quantification
The LOQ was 20 (DAD) and 10 ng/mL (FLD), respectively, corresponding to the lowest
calibrator.
Plasma levels
The measured morphine plasma concentrations after oral administration of 30 mg of
morphine alone ranged from 0 to 11.2 ± 2.2 ng/mL peaking at 60 min. The M6G plasma
concentrations were 16.5 ± 6.8 to 97.5 ± 14.4 ng/mL, mostly peaking at 120 min. The M3G
levels were 98.7 ± 23.2 to 707.8 ± 64.2 ng/mL, with peaks from 60 to 120 min. Figure 10 shows
the mean morphine, M6G, and M3G plasma concentrations after the oral administration of
morphine plotted against time on a semilogarithmic scale.
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After oral administration of THC-morphine the morphine, M6G, and M3G levels were 0 to
14.1 ± 3.3, 13.3 ± 5.8 to 143.3 ± 12.3, and 129.4 ±16.3 to 561.8 ± 46.5 ng/mL, respectively.
Figure 11 shows the mean morphine, M6G, and M3G plasma concentrations after the oral
administration of THC-morphine plotted against time on a semilogarithmic scale.
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Figure 10: Plasma concentration of morphine and its main metabolites M6G and M3G after oral administration
(n=12).
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1.6 Determination of THC and -metabolites in plasma by GC-MS
Validation
Peak identification (selectivity / specificity)
Blank and positive control samples showed no interferences with the analytes and the
internal standard (for a typical chromatogram see appendix III). The corresponding retention
times and ions are summarised in Table 11.
Table 11: Retention times and monitored ions for THC and its metabolites (TMS derivatives)
Analyte Retention time [min] Quantitation ion Qualifying ion
THC-TMS 8.27 (8.25-8.30) 371 343
THC-d3-TMS 8.23 (8.20-8.25) 374 389
THC-OH-TMS2 11.53 (11.51-11.56) 371 474
THC-OH-d3-TMS2 11.48 (11.46-11.50) 374 377
THC-COOH-TMS2 14.57 (11.55-11.60) 371 488, 473
THC-COOH-d3-TMS2 14.50 (14.48-15.53) 374 491
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Figure 11: Plasma concentration of morphine and its main metabolites M6G and M3G after oral administration in
combination with THC (n=12).
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Calibration and linearity
Table 12 gives an overview of the calibration results.
Table 12: Calibration data for the quantification of THC and its metabolites in plasma (TMS derivatives)
Analyte Retention time [min] m1) b1) Correlation coefficient r
THC-TMS 8.27 0.0577 0.0823 0.9983
THC-OH-TMS2 11.53 0.0464 0.0413 0.9992
THC-COOH-TMS2 14.57 0.0216 0.1568 0.9995
1) y = mx + b; x: ratio of the concentrations; y: ratio of the areas under the peak
The data show good linearity in the calibration range of 2 to 100 ng/mL for THC and THC-OH
and 10 to 500 ng/mL for THC-COOH, respectively. The current method was used for the
acquisition of pharmacokinetic data and therefore the range of calibration had to be selected in
order to include the highest plasma levels of THC and its metabolites as well as the lowest
plasma levels of the analytes in the elimination phase. Different experiments showed a LOQ of
2 ng/mL for THC and THC-OH and 10 ng/mL for THC-COOH, respectively. The upper LOQ was
equal to the highest calibrator (100 and 500 ng/mL, respectively).
Recovery, intra- and interday precision, and accuracy
Table 13 summarises the results of the intraday precision. Table 14 shows the results of the
recovery and the interday precision.
Table 13: Intraday precision and accuracy for the quantification of THC and its metabolites in plasma (TMS
derivatives)
Analyte Conc. added
[ng/mL]
Conc. found [mean, ng/mL]
(n = 5)
SD [ng/mL] RSD [%] Accuracy [%]
THC-TMS 20 19.76 0.95 4.80 - 1.2
THC-OH-TMS2 20 19.96 0.25 1.26 - 0.2
THC-COOH-TMS2 20 20.99 0.54 2.59 + 4.9
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Table 14: Recovery and interday precision for the quantification of THC and its metabolites in plasma
(TMS derivatives)
Analyte Recovery [%] (n = 5) Precision (RSD %; n = 5)
THC-TMS 84.4
THC-d3-TMS 87.3
3.96
THC-OH-TMS2 89.6
THC-OH-d3-TMS2 90.5
4.35
THC-COOH-TMS2 85.2
THC-COOH-d3-TMS2 87.3
6.96
Limit of detection
The LOD was found to be 2 ng/mL for THC-TMS and THC-OH-TMS2 and 10 ng/mL for THC-
COOH-TMS2, respectively. At these concentration levels the peaks were clearly detectable and
could be integrated.
Limit of quantification
The LOQ was 2 ng/mL for THC-TMS and THC-OH-TMS2 and 10 ng/mL for THC-COOH-
TMS2, respectively, corresponding to the lowest calibrator.
1.7 Plasma levels and phamacokinetics
The measured THC plasma concentrations after oral administration of 20 mg of THC ranged
from 1.1 ± 0.9 to 7.2 ± 1.8 ng/mL, with a maximum at 60 or 120 min. The THC-OH plasma
concentrations were 0.3 ± 0.3 to19.7 ± 1.8 ng/mL, mostly peaking at 120 min, and the THC-
COOH levels were 1.7 ± 1.7 to 241.4 ± 19.3 ng/mL, peaking at 120 or 240 min. Figure 12 shows
mean THC, THC-OH, and THC-COOH plasma concentrations after the oral administration of
THC plotted against time on a semilogarithmic scale.
The ratio of the parent drug THC to its psychoactive metabolite THC-OH was at most time
points 0.5 - 1 to 1.
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After oral administration of THC-morphine the THC, THC-OH, and THC-COOH levels were
4.0 ± 1.4 to 6.7 ± 2.1, 0.2 ± 0.2 to 7.9 ± 2.4, and 0 to 134.7 ± 18.8 ng/mL, respectively.
Figure 13 shows mean THC, THC-OH, and THC-COOH plasma concentrations after the oral
administration of THC-morphine plotted against time on a semilogarithmic scale.
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Figure 12: Plasma concentration of THC and its main metabolites THC-OH and THC-COOH after oral
administration (n=12).
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Table 15 gives an overview of the pharmacokinetic parameters of orally administered THC
calculated with the plasma concentration time curve data of the mean of the twelve volunteers.
Table 15: Pharmacokinetic parameters of orally administered THC
Parameter THC THC-morphine
tmax [min] 120 30
Cmax [ng/mL] 7.19 6.66
t1/2 [min] 299 367
AUC0-480min [ng⋅min/mL] 1377 2076
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Figure 13: Plasma concentration of THC and its main metabolites THC-OH and THC-COOH after oral
administration in combination with morphine (n=12).
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2. DEVELOPMENT OF WATER SOLUBLE THC FORMULATIONS
2.1 Extraction, purification, and quality assurance of THC from extract ELB-11-98 for the
in vitro experiments
Quantitative and qualitative characterisation of the extract ELB-11-98 with GC-MS
The quantification of THC in the extract ELB-11-98 resulted in a THC content of 42 %.
Impurities were characterised as very small amounts of other cannabinoids such as cannabinol
(CBN), cannabidiol (CBD), cannabigerol (CBG) etc. Presumably there were also some organic
solvent residues and some substances not detectable by GC-MS present.
Pilot experiments with TLC
The TLC system showed a good separation of the different components of the ethanolic THC
extract with an Rf of THC of 0.7. Due to the insufficient visualisation of the analytes with UV light
at 254 nm, HPTLC plates were sprayed with anisaldehyde reagent and heated. The spots then
showed a red to purple colour.
Purification of the extract ELB-11-98 with CC and MPLC
The purification with CC yielded in pre-purified THC-fractions with a THC content of 75 to
85 %. The average yield was 46 %. The follow-up purification with MPLC led to THC fractions
with a THC content of 95 %. The average yield of the purest THC fractions was 70 %.
Quality assurance with GC-MS and HPLC
The GC-MS chromatogram of the pure THC fractions showed either no or only minor (0-1 %)
contaminating by-products. The HPLC chromatogram showed only minor (1.36 - 3.3 %)
contamination, too. The THC content of 95 % was sufficient enough for the further use in the in
vitro experiments.
2.2 Development and validation of the THC inhalation solution
Validation of the HPLC method
Peak identification (selectivity / specificity)
The adjuvants showed no interferences with THC and the internal standard. The retention
time for the THC is presented in Table 16.
Calibration and linearity
Table 16 gives an overview of the calibration results.
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Table 16: Calibration data for the quantification of THC in water soluble THC formulations
Analyte Retention time [min] m1 b1 Correlation coefficient r
THC 6.90 0.05804 0.00074 0.9999
1 y = mx + b; x: ratio of the concentrations; y: ratio of the areas under the peak
The calibration graph was linear in the concentration range of 100 to 1000 mg/mL THC.
Intra- and interday precision and accuracy
Table 17 shows the results of the intraday precision and Table 18 for the interday precision.
Table 17: Intraday precision of the quantification of THC in water soluble THC formulations
Concentration of THC
[mg/mL]
Mean [mg/mL] SD [mg/mL]
(n = 4)
RSD [%] Accuracy [%]
1000 1002.5 8.44 0.84 + 0.25
500 500.7 4.20 0.84 + 0.14
250 247.8 1.90 0.77 - 0.88
100 99.7 2.47 2.47 -0.27
Table 18: Interday precision of the quantification of THC in water soluble THC formulations
Concentration of THC [mg/mL] SD [mg/mL] (n = 5) RSD [%]
1000 2.04 0.20
500 7.99 1.61
250 1.19 0.48
100 2.42 2.42
Limit of quantification and limit of detection
The determination of LOQ and LOD was not necessary because the method was used for
the quantification of THC in galenic formulations where the concentration was far above the
LOQ and LOD.
Pilot solubilisation experiments
The experiment with pure water showed insoluble residues at the bottom of the vial, a turbid
solution, and the AUC of the THC peak was about 0.4 % of that of the ethanolic reference
solution (= 100 %).
In the first series of experiments with the solubilisers and the lowest THC concentration
(1mg/mL) the resulting solutions were clear, no residue could be seen in the GC vial, and the
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AUC of the THC peaks were comparable to that of the ethanolic reference solution. There was
no difference between the single experiments. Both types of Cremophor® (EL and RH 40) in
each concentration (5, 10, and 15 %) were able to fully solubilise the THC. In the next series the
THC concentration was therefore increased to 2 mg/mL and the Cremophor® concentrations
were decreased to 2.5, 5, and 10 %. The formulations with 2.5 % of the solubilisers showed
residues at the bottom and at the wall of the GC vial. The AUC of the THC peaks were
nevertheless not much decreased compared to that of the ethanolic reference solution. The
formulations with 5 % of the Cremophors® showed again very small residues at the wall of the
GC vial which could be due to incomplete covering of the THC with the solubiliser during the
heating process. The AUC of the THC peaks were comparable to that of the ethanolic reference
solution. The formulations with 10 % of the solubilisers formed a clear solution with no residues
and the AUC of the THC peaks were again comparable to that of the ethanolic reference
solution. To determine the limit of solubilisation, the THC concentration was once more
increased to a level of 3 mg/mL, and the solubiliser concentrations were left constant at 5 and
10 %, respectively. The formulations with Cremophor® RH 40 showed clear solutions. A very
small residue remained at the wall of the GC vial in the 5 % Cremophor® formulation which
could be again due to the incomplete inclusion of the THC by the solubiliser during the heating
process. The AUC of the THC peaks were comparable to that of the ethanolic reference
solution. The formulations with Cremophor® EL showed a different result. The 10 % formulation
produced a clear solution with no residues. The 5 % formulation showed small residues at the
wall of the GC vial and a decreased AUC of the THC peak compared to the ethanolic reference
solution.
To complete the solubilisation experiments another series was done only with the better
solubiliser, the Cremophor® RH 40, to determine the limit of the solubilisation rate with a THC
concentration of 3 mg/mL. Up to a Cremophor® concentration of 3 % the solubilisation of the
THC was incomplete. With 4, 5, and 7.5 % of Cremophor® RH 40 the solution was clear and
there was no residue seen neither at the bottom nor at the wall of the GC vial. To be sure of a
complete solubilisation process 25 % more solubiliser were added, and the further experiments
done with a solubiliser concentration of 5 % to solubilise 3 mg/mL THC.
Follow-up experiments with different pH in the heat stress test
The results of these experiments are summarised in Figure 14. The buffered formulations
showed an advantage in stability compared to the non-buffered formulations. This result was
very clear in the formulations with Cremophor® EL. When comparing the buffered formulations,
Cremophor® RH 40 showed an advantage in stability compared to Cremophor® EL. Comparing
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the different buffered formulations with Cremophor® RH 40 with the different pH, the formulation
with pH 8.0 showed the lowest decrease of the ratio of THC vs. its oxidation product cannabinol
(CBN). These results indicated a better stability in not acidic pH ranges. Garret and Hunt [26]
reported a rapid degradation in acidic solution (t  
† 
1
2
= 1 h at pH 1.0, 55°C). For the next
experiments, the formulations with Cremophor“ RH 40 at pH 7.4 and 8.0 were further examined
and optimised.
Statistical experiment
To investigate the influence of different adjuvants on the stability of the formulation, a
factorial design experiment (a 23-design) was carried out.
The Yates-analysis after the heat stress test is presented in Table 19.
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Figure 14: Ratio of THC/CBN (AUC of the peaks in the HPLC chromatogram) normalised to the value before the
heat stress test of the different formulations. Grey bars represent non-buffered formulations, black
bars buffered formulations.
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Table 19: Yates-analysis after the heat stress test
Factors Interactions
A B C AB AC BC ABC
Endpoint
(THC/CBN)
(1) - - - + + + - 5.9718
a + - - - - + + 5.7937
b - + - - + - + 5.7775
ab + + - + - - - 4.6848
c - - + + - - + 5.9368
ac + - + - + - - 5.8125
bc - + + - - + - 5.6944
abc + + + + + + + 4.7284
4A 4B 4C 4AB 4AC 4BC 4ABC4-fold effect
-2.3611 -2.6296 -0.0557 -1.7563 0.1805 -0.0235 0.0729
(4A)2 (4B)2 (4C)2 (4AB)2 (4AC)2 (4BC)2 (4ABC)2Sum of squares
5.5748 6.9148 0.0031 3.0846 0.0326 0.0006 0.0053
(4A)2/
(4ABC)2
(4B)2/
(4ABC)2
(4C)2/
(4ABC)2
(4AB)2/
(4ABC)2
(4AC)2/
(4ABC)2
(4BC)2/
(4ABC)2
Fcalc
1051.85 1304.68 0.58 582.00 6.15 0.11
Significance:
Fcalc > Ftab1)
Fcalc >
Ftab
*
Fcalc >
Ftab
*
Fcalc <
Ftab
n.s.
Fcalc >
Ftab
*
Fcalc <
Ftab
n.s.
Fcalc <
Ftab
n.s.
1) Ftab = 161.44 (degrees of freedom: 1, 1; p-value: 0.05)
The statistical analysis showed that the two factors A and B had a significant effect on the
stability of the formulation. Also the interaction between the two factors A and B had a
significant effect on the stability. No changes of the statistical results in the Yates-analysis were
found after the additional first and second light stress test respectively (data not shown).
The endpoint values of the 8 different experiments showed a negative influence of the upper
level of the two factors A and B on the stability of the formulations, meaning that pH 7.4 and the
lower concentration of the solubiliser (3 %) showed better stability. The amount of the added
antioxydant (NaAsc) showed no significant influence on the stability of the formulation.
Development of the final THC inhalation solution
The findings of the statistical experiments lead to the following conclusions for the final
composition of the formulation: lower concentration of the solubiliser (3 %), physiological pH 7.4,
lower concentration of NaAsc 0.05 %. To be sure of a complete solubilisation process 25 %
more solubiliser (5 %) and a conservant (benzylalcohol) in adequate concentration was added
leading to the final formulation as presented in Table 20.
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Table 20: Final formulation of the THC inhalation solution
Component Amount [%, w/v]
THC 30.0 mg 0.3
Cremophor® RH 40 500.0 mg 5.0
NaAsc 5.0 mg 0.05
Benzylalcohol 100.0 mg 1.0
Phosphate buffer (pH 7.4, 84.2 mM) ad 10.0 mL
Quality assurance
Appearance
The THC inhalation solution was clear, yellowish, and free of floating particles.
Stability
The THC content of the inhalation solution, stored at 4 °C and protected from light, was
within the ± 5 % range during 83 days. The results are presented in Figure 15.
Figure 15: Stability of the inhalation solution (THC-content in % of the initial value) stored at 4°C and protected
from light.
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Viscosity
The dynamic viscosity was 1.578 mPas (n = 4).
Osmolality
The osmolality was 550 mOsm/kg (n = 3).
pH
The pH was 7.40 (n = 3).
Particle size distribution
Table 21 lists the results of the measurement of the particle size. Figure 16 shows the
distribution of the particle size.
Table 21: Particle size of the aerosolised THC inhalation solution
Nebuliser system PARI Master / IS-2 nebulizer PARI Master / LC-Plus nebulizer
Placebo solution
Particle size [mm] (median ± SD, n = 10)
2.5 ± 0.14 3.5 ± 0.27
Verum solution
Particle size [mm] (median ± SD, n = 5)
n.d. 3.8 ± 0.32
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Figure 16: Particle size distribution of the two different nebulisers measured with either verum or placebo
solution (median with its 10- and 90-percentiles, respectively; A: IS-2 nebuliser, placebo solution;
B: LC-Plus nebuliser, placebo solution; C: LC-Plus nebuliser, verum solution).
Output rates and output time
Table 22 shows the results of the output rates and output times of the two different
nebulisers tested.
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Table 22: Output rates and output times of THC nebulised with the two different nebulisers
Nebuliser system PARI Master / LC-Plus nebuliser
Concentration 3 mg/mL THC
Volume nebulised 2 mL 3 mL
Output rates [%]
(mean ± SD, n = 3)
62.4 ± 3.2 64.5 ± 6.0
Output time [min]
(mean ± SD, n = 3)
9.5 ± 0 14.2 ± 0.3
Nebuliser system PARI Master / IS-2 nebuliser
Concentration 3 mg/mL THC
Volume nebulised 2 mL 3 mL
Output rates [%]
(mean ± SD, n = 3)
57.1 ± 1.0 60.6 ± 3.6
Output time [min]
(mean ± SD, n = 3)
12.8 ± 0.8 21.7 ± 0.8
Consequently, for the clinical study we decided to use the LC-Plus nebuliser because of the
higher output rate, the shorter output time, and the appropriate particle size distribution.
2.3 Preparation and validation of the THC injection solution
Quality assurance
Stability
The THC content of the injection solution, stored at 4 °C and protected from light, was within
the ± 5 % range at least during one month. The results are presented in Figure 17.
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Figure 17: Stability of the injection solution (THC-content in % of the initial value) stored at 4°C and protected from
light.
Osmolality
The osmolality was 321 mOsm/kg (n = 3).
pH
The pH was 7.40 (n = 3).
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3. PHARMACOKINETIC STUDY WITH PULMONAL AND INTRAVENOUS THC
3.1 Subjects
The subjects were all Cannabis-naïve and non-smokers. Four females (26 - 35 years; 60 ± 8
kg b.wt.) and 4 males (27 - 50 years; 80 ± 5 kg b.wt.) were included. All of the subjects showed
normal vital capacity and normal forced expiratory volume in one second in the lung function
tests.
3.2 Preparation of the clinical test preparations
The properties of the 2 formulations were according to the standards of the European
Pharmacopeia. The i.v. formulation passed the sterility test.
3.3 Pain test
Figure 18 shows the results of the ice water test (ice cold immersion test) plotted as mean of
the eight subjects. No significant analgesic effect of pulmonal or i.v. THC compared to placebo
could be observed.
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Figure 18: Pain tolerance of i.v THC, pulmonal THC, and pulmonal placebo in the ice cold immersion test;
values > 100 % of baseline (mean ± SEM) indicate hyperalgesia, values < 100 % analgesia.
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3.4 Monitoring of side effects and vital functions
The observed psychological and somatic side effects are listed in Table 23.
Table 23: Psychological and somatic side effects (peak VAS %, mean ± SEM of all subjects) after pulmonal and
i.v. THC, and pulmonal placebo (n = 8)
Placebo (pulmonal) THC (pulmonal) THC (intravenous)
Side effect
f1 VAS [%] f1 VAS [%] f1 VAS [%]
Sleepiness 5 50 ± 16 % 8 64 ± 8 % 7 86 ± 4 %
Euphoria 3 19 ± 8 % 5 51 ± 16 % 7 57 ± 14 %
Irritation 1 4 ± 0 % 3 15 ± 5 % 6 38 ± 13 %
Anxiety 2 6 ± 1 % 1 14 ± 0 % 6 45 ± 13 %
Tenseness and aggressiveness 1 5 ± 0 % 2 9 ± 2 % 6 45 ± 13 %
Confusion and disorientation 2 6 ± 0 % 4 33 ± 20 % 8 80 ± 6 %
Change of inner perception 2 9 ± 2 % 5 42 ± 18 % 8 87 ± 3 %
Change of outer perception 1 6 ± 0 % 3 31 ± 17 % 8 65 ± 9 %
Hallucinations  - - 2 27 ± 25 % 7 52 ± 15 %
Strange thoughts, ideas, moods 1 6 ± 0 % 1 15 ± 0 % 6 47 ± 11 %
Nausea  - - 4 26 ± 7 % 7 46 ± 14 %
Headache 1 20 ± 0 % 5 40 ± 14 % 8 48 ± 10 %
Difficulties in breathing   - - 5 24 ± 10 % 5 59 ± 17 %
Irritation of the throat, coughing 2 7 ± 3 % 8 70 ± 9 % 3 27 ± 20 %
Irritation of the upper resp. tract  - - 5 53 ± 19 % 4 30 ± 17 %
Heart problems (tachycardia)  - - 3 8 ± 1 % 8 45 ± 13 %
Digestive problems  - - 2 7 ± 3 % 5 36 ± 16 %
Dry mouth 2 19 ± 12 % 3 24 ± 13 % 8 83 ± 10 %
Vertigo 1 10 ± 0 % 5 38 ± 6 % 8 75 ± 8 %
Vomiting 0 - 0 - 0 -
Orthostatic disorder 0 - 0 - 0 -
1 f: Frequency of side effects per 8 subjects
In the THC inhalation session all subjects reported irritation of the throat and coughing during
the inhalation (partly impairing inhalation efficiency) (Figure 19). This adverse effect was
reversible within 30 min after finishing inhaling. It was not observed in the placebo inhalation
session. The psychotropic effects of the THC aerosol were usually very mild. The i.v. application
caused much more prominent side effects, i.e. strong psychotropic symptoms, increased heart
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rate, and dry mouth. Figure 20 shows the hallucinogenic effect of i.v. THC and pulmonal THC
vs. pulmonal placebo.
Blood pressure was not changed by any of the test preparations, whereas both pulmonal and
i.v. THC increased heart rate significantly compared to placebo (data not shown).
0
10
20
30
40
50
60
70
80
90
100
0 20 40 60 120 240 480
Time [min]
VA
S 
in
 %
 [m
ea
n 
± 
SE
M
]
i.v. THC pulmonal THC pulmonal Placebo
Figure 19: Side effect "irritation of the airways, coughing" (VAS %, mean ± SEM) after i.v. THC, pulmonal THC,
and pulmonal placebo.
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3.5 Determination of THC and -metabolites in plasma by GC-MS
Validation
Peak identification (selectivity / specificity)
Blank and positive control samples showed no interferences with the analytes and the
internal standard (for a typical chromatogram see appendix IV). The corresponding retention
times and ions are summarised in Table 24.
Table 24: Retention times and monitored ions for THC and its metabolites (TMS derivatives)
Analyte Retention time [min] Quantitation ion Qualifying ion
THC-TMS 11.87 (11.85 - 11.93) 371 343
THC-d3-TMS 11.85 (11.80 - 11.88) 374 389
THC-OH-TMS2 15.39 (15.36 - 15.44) 371 474
THC-OH-d3-TMS2 15.36 (15.32 - 15.40) 374 377
THC-COOH-TMS2 17.44 (17.40 - 17.48) 371 488, 473
THC-COOH-d3-TMS2 17.40 (17.36 - 17.44) 374 491
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Figure 20: Side effect "hallucinations" (VAS %, mean ± SEM) after i.v. THC, pulmonal THC, and pulmonal
placebo.
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Calibration and linearity
To reach sufficient linearity two calibration curves for THC, from 0.4 to 20 and 20 to
300 ng/mL plasma were determined. Table 25 gives an overview of the calibration results.
Table 25: Calibration data for the quantification of THC and its metabolites in plasma (TMS derivatives)
Analyte Retention time [min] m1) b1) Correlation coefficient r
THC-TMS (0.4 - 20 ng/mL) 11.87 1.3918 0.0111 0.9994
THC-TMS (20 - 300 ng/mL) 11.87 1.3455 0.1851 0.9984
THC-OH-TMS2 15.39 1.1193 0.0107 0.9988
THC-COOH-TMS2 17.40 1.1988 0.0106 0.9992
1) y = mx + b; x: ratio of the concentrations; y: ratio of the areas under the peak
The data show good linearity in the calibration range of 0.4 to 20 ng/mL for the lower
concentrations of THC and in the range of 20 to 300 ng/mL for the higher concentrations of
THC. The method was linear in the calibrated concentration range of 0.4 to 100 ng/mL for THC-
OH and THC-COOH. The current method was used for the aquisition of plasma profiles and
therefore the range of calibration had to include the highest plasma levels of THC and -
metabolites as well as the lowest plasma levels in the elimination phase. Different experiments
showed a LOQ of 0.4 ng/mL for THC, THC-OH, and THC-COOH. The upper LOQ was
corresponding to the highest calibrators (300 ng/mL for THC and 100 ng/mL for the
-metabolites).
Recovery, intra-and interday precision, and accuracy
Table 26 summarises the data of the intraday precision and Table 27 of the recovery and the
interday precision.
Table 26: Intraday precision and accuracy of the quantification of THC and its metabolites in plasma (TMS
derivatives)
Analyte Conc. added
[ng/mL]
Conc. found [Mean
ng/mL] (n = 5)
SD [ng/mL] RSD [%] Accuracy [%]
THC-TMS 4 4.08 0.17 4.10 + 2.1
THC-TMS 100 103.05 1.09 1.06 + 3.1
THC-OH-TMS2 4 4.04 0.22 5.50 + 1.0
THC-OH-TMS2 100 102.77 1.13 1.11 + 2.8
THC-COOH-TMS2 4 4.02 0.17 4.15 + 0.5
THC-COOH-TMS2 100 102.30 1.45 1.42 + 2.3
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Table 27: Recovery and interday precision of the quantification of THC and its metabolites in plasma
(TMS derivatives)
Precision [RSD, %] (n = 5)Analyte Recovery [%] (n = 6)
4 ng/mL plasma 100 ng/mL plasma
THC-TMS 91.3
THC-d3-TMS 90.6
9.83 3.90
THC-OH-TMS2 87.6
THC-OH-d3-TMS2 86.8
4.11 2.85
THC-COOH-TMS2 77.9
THC-COOH-d3-TMS2 76.3
9.09 3.75
Limit of detection
The LOD was found to be 0.4 ng/mL for THC and -metabolites. At this concentration level the
peaks were clearly detectable and could be integrated.
Limit of quantification
The LOQ was 0.4 ng/mL for THC and -metabolites, corresponding to the lowest calibrator.
3.6 Plasma levels and pharmacokinetics
Figure 21 and 22 show the plasma profiles of THC and its two metabolites THC-OH and
THC-COOH following pulmonal and i.v. administration, respectively. The mean plasma level of
pulmonal THC after 10 min was 18.7 ± 7.4 ng/mL (mean ± SEM) with a mean duration of the
inhalation procedure of 23 ± 3 min. As can be seen in Figure 21, the peak plasma levels of
18.9 ± 5.0 ng/mL were measured at 20 min. Then, the plasma concentrations decreased rapidly
to 6.1 ± 4.0 ng/mL after 1 h and 2.4 ± 1.7 ng/mL after 2 h. Peak plasma levels of the two main
metabolites THC-OH and THC-COOH were 1.38 ± 0.31 ng/mL occurring at 40 min and
10.0 ± 2.85 ng/mL mostly peaking at 120 min, respectively.
The plasma levels 5 min after the i.v. injection of THC (0.053 mg/kg b.wt.) ranged from 81.6
to 640.6 ng/mL (271.5 ± 61.1 ng/mL) (Fig. 22). Then, the plasma levels decreased rapidly to a
mean concentration of 95.6 ± 28.2 ng/mL at 10 min, 38.3 ± 10.6 ng/ml at 20 min,
20.1 ± 5.3 ng/mL after 1 h, and 9.0 ± 3.0 ng/mL at 2 h. Peak plasma levels of THC-OH and THC-
COOH were 9.13 ± 0.84 ng/mL occuring at 5 or 10 min and 36.66 ± 3.75ng/mL occuring at
60 min, respectively. Figure 23 shows the mean THC plasma concentrations after the i.v. and
pulmonal administration plotted against time on a semilogarithmic scale.
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The ratio of THC to its psychoactive metabolite THC-OH was at most time points 2 - 15 to 1
for pulmonal and 5 - 10 to 1 for i.v. THC, respectively.
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Figure 21: Plasma concentration of THC and its main metabolites THC-OH and THC-COOH after pulmonal THC
(n=8).
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Figure 22: Plasma concentration of THC and its main metabolites THC-OH and THC-COOH after i.v. THC
(n=8).
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Figure 23: THC plasma concentration after i.v. and pulmonal administration (n=8).
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Table 28 a and 28 b summarise the pharmacokinetic parameters for i.v. and pulmonal THC
calculated with the TopFit software [84]. Table 29 presents the results of an alternative
calculation of the i.v. data using the PKAnalyst software [92] fitted for a two-compartment
model.
Table 28a: Pharmacokinetic parameters of i.v. and pulmonal THC
Subject Intravenous THC Pulmonal THC
No Gender Dose
[mg]
AUC0-480
[ng*min*mL-1]
Dose
[mg]
AUC0-480
[ng*min*mL-1]
Bioavailability F
[%]
Half-life
t1/2
[min]
1 f 3.3 5560.5 3.71 2527.7 40.4 43
2 m 4.2 3434.3 2.98 693.6 28.5 46
3 m 4.24 4556.3 4.08 2596.8 59.2 64
4 m 4.53 5824.3 4.56 1256.5 21.4 41
5 f 2.4 19244.9 2.34 67.9 0.4 18
6 f 2.92 3402.5 2.97 527.8 15.3 44
7 f 3.5 10506.8 3.29 361.3 3.7 84
8 m 4.0 2588.1 4.03 1580.6 60.6 31
Mean ± SEM (f & m) 6889.8 ± 1967.1 1201.5 ± 342.1 28.7 ± 8.2 46 ± 7
Mean ± SEM (f) 9678.7 ± 3518.4 871.2 ± 560.3 14.9 ± 9.1 47 ± 14
Mean ± SEM (m) 4100.9 ± 701.9 1531.9 ± 399.5 42.4 ± 10.2 45 ± 7
Table 28b: Pharmacokinetic parameters of i.v. THC
Subject Intravenous THC
No Gender Distribution volume Vz
[L]
Clearance CL
[mL/min]
Half life t1/2
[min]
Elimination rate
constant lz [* 10-2]
1 f 98.6 570 120 0.578
2 m 89.2 1220 51 1.370
3 m 66.3 930 49 1.400
4 m 51.7 777 46 1.500
5 f 30.8 174 133 0.566
6 f 65.1 857 53 1.320
7 f 40.7 333 185 0.813
8 m 121.0 1540 54 1.280
Mean ± SEM (f & m) 70.4 ± 10.8 800.1 ± 158.5 73 ± 12 1.100 ± 0.140
Mean ± SEM (f) 58.8 ± 15.1 483.5 ± 148.7 95 ± 17 0.820 ± 0.180
Mean ± SEM (m) 82.1 ± 15.1 1116.8 ± 168.4 50 ± 2 1.390 ± 0.050
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Table 29: Pharmacokinetic parameters of i.v. THC fitted to a two-compartment model
Subject Intravenous THC
No Gender Dose
[mg]
AUC0-480
[ng*min*mL-1]
alpha
t1/2 [min]
beta t1/2
[min]
Elimination
rate constant
lz [* 10-2]
Correlation Distribution
Volume Vz
[L]
Clearance
CL
[mL/min]
1 f 3.3 7166.8 1.66 99.2 0.699 0.999703 65.9 460.5
2 m 4.2 3717.1 2.58 48.3 1.436 0.999897 78.7 1129.9
3 m 4.24 5638.9 1.93 40.6 1.706 0.999970 44.1 751.9
4 m 4.53 6538.8 2.29 41.6 1.665 0.999983 41.6 692.8
5 f 2.4 16655.6 3.25 62.8 1.110 0.999974 13.1 144.1
6 f 2.92 3706.9 2.20 42.4 1.634 0.999925 48.2 787.7
7 f 3.5 9376.3 2.88 61.4 1.129 0.999785 33.1 373.3
8 m 4.0 2458.1 3.01 43.0 1.612 0.999923 100.9 1627.3
Mean (f & m)
(SEM)
6907.3
(1598.8)
2.47
(0.20)
54.0
(7.1)
1.373
(0.128
0.999895
(0.000035)
53.2
(9.8)
745.9
(164.3)
Mean
(SEM, f)
9266.4
(2737.4)
2.50
(0.35)
66.5
(11.9)
1.141
(0.191)
0.999847
(0.000062)
40.1
(11.2)
441.4
(133.3)
Mean
(SEM, m)
4588.2
(922.2)
2.45
(0.23)
43.4
(1.7)
1.605
(0.059)
0.999943
(0.000020)
66.3
(14.3)
1050.5
(215.3)
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DISCUSSION AND CONCLUSIONS
1. PHARMACODYNAMIC STUDY WITH ORAL THC (PAIN STUDY)
A multimodel, well established experimental pain test battery [93-95] was used to cover
different types of pain. On one hand the more superficial pain in the electrical stimulation and
heat test, and on the other hand the more deep pain in the pressure and cold test (ice cold
immersion test). An oral formulation of THC (dronabinol) registered in some countries under the
trade mark of Marinol“, was used although this administration route was not ideal in a
pharmacokinetic point of view. The 8-h study period enabled to register also effects at time
points where mainly the metabolites were present in the plasma.
THC did not produce any analgesia after pressure stimulation. Interestingly, it seemed even
to antagonise morphine analgesia. This could be the result of a hyperalgesic effect of THC that
has not been detected with THC alone, but appeared when THC was combined with morphine.
In the heat test (pain tolerance threshold) THC produced a significant hyperalgesia. One
problem in this test was the temperature limit of 52°C. Some volunteers had already a baseline
of 52°C. A similar hyperalgesic effect of THC on thermal pain was also reported in habitual
Cannabis users participating in a pain study with Cannabis cigarettes [96]. Heat pain was
recently found to be inadequate for detecting opioid-induced analgesia [95].
Hyperalgesia after THC was also observed with the cold test. Interestingly, the combination
with morphine totally reversed this effect to an analgesic effect, which was comparable to that of
morphine. The cold test is well established to measure opioid-induced analgesia, but it is
unclear whether it is also suited for non-opioid analgesics. Jones et al. showed the opiate
sensitivity of the cold test but also the apparent insensitivity of the model for non-steroidal anti-
inflammatory drugs [78]. We assume that hyperalgesia measured in the cold test was due to an
outlier, which also caused the wide variability.
The results of both the single and the repeated transcutaneous electrical stimulation showed
a tendency to an additional analgesic effect of the THC-morphine combination compared to
morphine alone. In the repeated mode the analgesic effect of THC-morphine was even
statistically significant.
Our findings indicate that the analgesic effect of THC and morphine, which was in all our
experiments gender-independent, is much influenced by the pain model used.
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Luginbuhl et al. [95] also reported that the experimental pain profile differed for substances like
alfentanil, xenon, and nitrous oxide. This illustrates the benefit of a multimodel stimulation in the
investigation of the analgesic properties of new drugs. None of the experimental pain tests used
in this study produces inflammation or tissue damage. Different animal studies have shown an
increased analgesic effect of THC in models of inflammatory pain [97]. It has previously been
reported that in rats cannabinoid CB1 receptors are upregulated in chronic neuropathic pain and
therefore could lead to an increased analgesic effect of THC in chronic pain [98]. In a
retrospective study with patients suffering from chronic pain of different origins, 3 out of 6
patients could reduce their pain to a satisfactory level with a dose of THC of 5 to 20 mg/day,
whereas the other 3 patients had to stop the medication due to lack of analgesia or intolerable
side effects [99]. Therefore, we cannot rule out that THC would have an analgesic effect after
induction of inflammation, tissue or nerve damage. However, up to now no adequate test
models for healthy subjects are available.
The side effects of THC were common and normally not severe. There was one volunteer
out of twelve who reported disliking very much the psychotropic effects of THC. We assume that
a strong aversion to the psychotropic effect leads to a discomfort and therefore possibly also to
increased sensitivity to pain. This phenomenon could be observed in the ice cold immersion test
where one subject showed a nice correlation between hyperalgesia and anxiety. Von
Graffenried et al. [100] found anxiety (and also other psychological factors like mood) to be a
factor that might be responsible for the unreliable results obtained in experimentally induced
pain in man especially for mild analgesics. If anxiety towards pain tests played a role, even
when not using psychotropic drugs, anxiety feelings produced by the psychotropic THC could
have an additional influence on the outcomes of pain tests. Many of the psychotropic side
effects of THC (euphoria, hallucinations, confusion etc.) were lowered when combining with
morphine. On the other hand THC was also influencing the side effects of morphine. Nausea
and vomiting was decreased in the combination session compared to the morphine session.
This could be due to the well-known antiemetic effect of THC [101]. The reduction of this
common side effect of opioids would be a great benefit in the therapy of chronic pain. Although
the subjects were Cannabis-naïve the typical psychotropic side effects of THC made the true
blinding of the study impossible. A psychoactive placebo could be used to improve the blinding,
but the inactivity of the placebo regarding the investigated parameters should be determined.
To reach optimal sensitivity in the determination of the plasma concentration of THC and its
two main metabolites THC-OH and THC-COOH, an immunoaffinity extraction procedure with
specific antibodies for THC and -metabolites after enzymatic hydrolysis was used followed by
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derivatisation and analysis with GC-MS [83]. The very specific extraction procedure produced
samples, which were almost free of impurities.
Although THC is almost completely absorbed (90-95 %) after oral administration [28, 31] the
plasma profiles after 20 mg THC are characterised by very low levels of THC and high levels of
the two main metabolites THC-OH and THC-COOH. The levels were similar to those measured
in an earlier study after administration of oral THC [30]. Due to the combined effects of
extensive first pass hepatic metabolism, pre-systemic elimination in the gut, and high lipid
solubility (volume of distribution V = 10 L/kg b.wt.), only 10 to 20 % of an oral dose is reaching
the systemic circulation [28, 31]. The metabolites were detectable already 30 min post drug
indicating the rapid liver first pass metabolism. The microsomal hydroxylation is catalised by
cytochrome P450 isoenzymes [11]. THC-OH is psychoactive whereas the dominating
metabolite THC-COOH is inactive. In glucuronidated form the latter is the main urinary excretion
product of THC [10]. A correlation between the THC plasma levels and the pharmacological
profiles could only be observed related to the side effects. It is not known whether THC-OH has
analgesic properties, too.
These very low plasma levels after 20 mg p.o. THC did not allow to perform the
pharmacokinetic analysis by using the individual plasma curves (except for AUC, Cmax, tmax).
Therefore, it was based on the plasma concentration time curve out of the mean data of the
twelve volunteers.
The analysis of the plasma samples for the quantification of morphine and its main
metabolites M6G and M3G caused a lot of problems. The change to a new batch of SPE
columns resulted in a complete loss of the recovery of the analytes and made further
optimisation of the extraction procedure inevitable. Recovering the analytes as much as
possible unfortunately lead to increased matrix effects and chromatographic interferences. To
separate these impurities from the analytes the HPLC column and the detecting system had to
be changed.
The plasma profiles after the administration of 30 mg morphine showed only low levels of
morphine, but high (M6G) to very high (M3G) concentrations of its glucuronidated metabolites.
Like THC, phase-II biotransformation by first pass metabolism starts within minutes after
administration. M3G is the dominating urinary excretion product of morphine [102], but only
M6G exhibits analgesic effects [103].
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2. DEVELOPMENT OF WATER SOLUBLE THC FORMULATIONS
To investigate whether another application form with a better bioavailability than the oral
formulation could increase the analgesic effect of THC, an inhalation solution of THC was
developed. To get optimal physiological tolerability the aim was to develop an aqueous
inhalation solution. Due to the very low water solubility of the drug [26], we had to add a
solubiliser to the formulation in order to get the necessary THC concentration. For this purpose
Cremophors“ were evaluated, for clinical use approved solubilisers for topical or oral application
forms.
First experiments showed good solubilisation properties for Cremophor“ RH 40 and
Cremophor“ EL. By adding 5 % of the solubiliser a THC concentration of 3 mg/mL could be
achieved. The inclusion of the THC by the solubiliser in the heating process turned out to be a
very crucial step in the production of the micellar solution regarding the completeness of the
solubilisation.
The stress tests with the buffered and non-buffered formulations at four different pH values
showed differences in the stability of THC. As known from literature [26] THC was less stable
under acidic conditions than in formulations with higher pH. Buffered formulations showed great
advantages in the stability of the THC compared to the non-buffered solutions. In addition to
that the formulations with Cremophor“ RH 40 showed slight advantages in stability than the
formulations basing on Cremophor“ EL. These findings and also the fact that Cremophor“ RH
40 has much better properties concerning taste and odour (not soapy) lead to the decision to
perform the further experiments with Cremophor“ RH 40 only.
To further investigate the influence of the solubiliser, the pH, and the addition of an
antioxidant on the stability of THC in the aqueous formulation, a statistical experiment was
carried out. The 23-design [69, 88] with additional Yates-analysis allowed to investigate the
influence of the different factors on the chosen endpoint, in this case the stability of the THC
(expressed as THC/CBN ratio; CBN being the oxidative degradation product of the THC). The
analysis showed a significant advantage of the lower concentration of the solubiliser and the
physiological pH compared to pH 8, whereas the concentration of the sodium ascorbate did not
influence the stability of the formulation. The antioxidant was added because both the THC and
the solubiliser are sensitive to oxygen. The chemically compatible benzylalcohol was added as
a conservant.
For the use in the pharmacokinetic study this formulation, consisting of THC, Chremophor“
RH 40, sodium ascorbate, and benzylalcohol in phosphate buffer at physiological pH, had to
undergo an in vitro quality assurance. The tests according to the European Pharmacopeia [89]
(pH, osmolality, viscosity, etc.) showed acceptable results for clinical purposes. An appropriate
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stability resulted when storing the solution at 4°C and protected from light. The THC content
stayed in the ± 5 % range for over 80 days that allowed to prepare the solutions some weeks in
advance of the trial.
For the pulmonal application of a drug the particle size of the droplets in the aerosol
produced by the nebuliser system is of crucial importance. The analysis of the particle size
distribution with laser diffractometry was performed with two nebulisers used already in earlier
studies with opiates [12]. The IS-2 and the LC-Plus nebuliser, both pressure driven and coupled
to the Pari Master apparatus (producing the air pressure), showed both the necessary median
particle size smaller than 5 mm in diameter. This droplet dimension is needed to reach the lower
compartments of the lung [66]. The determination of the output rate and time was then the next
important step to examine if the concentration of 3 mg/mL inhalation solution would be sufficient
to administer the target dose of 4 mg/75 kg b.wt. in a time which would be appropriate for the
use in the clinical study. The LC-Plus nebuliser showed with 63 % a slightly higher output rate
than the IS-2 nebuliser (59 %). However, with the LC-Plus resulted a much shorter output time
(4.75 min/mL) than with the IS-2 nebuliser (7 min/mL). Consequently, taken all this parameters
in account, the LC-Plus nebuliser was used for the study.
For the determination of the absolute bioavailability of THC a THC injection solution was
prepared using the formulation of Olsen et al. [90] and adding sodium ascorbate as a stabiliser.
The THC inhalation solution could not be used due to the risk of an anaphylactic reaction when
injecting Cremophor“ intravenously [104].
3. PHARMACOKINETIC STUDY WITH PULMONAL AND INTRAVENOUS THC
(PHARMACOKINETIC STUDY)
The pulmonal application of nebulised THC seems to be a promising mode for the clinical
use of THC. The pulmonal bioavailability of 28.7 ± 8.2 % reached with our application device
was significantly higher compared to the oral administration, where the bioavailability was found
to be 5 to 20 % [8, 9, 31]. Some volunteers even showed a bioavailability of over 40 %. Most of
the subjects reached plasma levels comparable to those of i.v. THC at 10 and 20 min. Peak
plasma levels of THC were already observed before the end of the inhalation procedure.
Regarding the plasma concentrations of the THC metabolites THC-OH and THC-COOH,
similar patterns for pulmonal and i.v. THC were observed. The THC to THC-OH ratios found in
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the present study, 5 - 10 to 1 (i.v. THC) and 2 - 15 to 1 (pulmonal THC), and in an earlier study
[105], 0.5 - 1 to 1 (oral THC), confirm the findings reported by Wall et al. for i.v. THC [31]. The
significantly lower formation of the psychoactive THC-OH after pulmonal THC, due to the
absent first pass metabolism, results in remarkably less intensive psychotropic side effects
compared to oral THC. This is an important fact regarding the development of future THC
application forms.
The plasma concentration time plot of the i.v. administration showed first a distribution phase
with a very rapid decrease of the THC plasma levels followed by the elimination phase with a
much longer terminal plasma elimination half-life, compatible with a two-compartment
elimination kinetic, which has been described before for THC by Wall et al. [31] and Huestis [9].
Similar pharmacokinetic data were obtained when using the two- and non-compartment
calculation model for the i.v. data. The results were in agreement with those from earlier studies
(reviewed by Grothenhermen [29]).
The placebo aerosol was very well tolerated indicating a good tolerability of the vehicle with
the adjuvants used for the solubilisation and stabilisation of the formulation. Nevertheless,
irritation of the airways and coughing after pulmonal THC was observed for all subjects,
meaning that THC itself caused these adverse effects. Coughing impaired the inhalation
procedure and therefore most likely also the bioavailability, which would probably be higher with
a less irritating formulation of THC. The irritations were reversible within a short time after the
end of inhalation indicating no lasting damage of the mucosa. This particular effect of THC was
also demonstrated by Tashkin et al. [106]. It is very difficult to hypothesise what happens when
the THC containing micelles get in contact with the surface of the airways. We assume that the
micelles release the THC due to diluting effects of the surfactant and mucus and therefore THC
is able to irritate. As the micellar formulation used in this study did not prevent mucosa irritation,
other techniques should be tested, for example the use of liposomes or microencapsulation.
Among other adverse effects in the inhalation session were very mild psychotropic symptoms
and headache. Higher Cmax and very rapid increase of the concentration in the central nervous
system were responsible for the more pronounced adverse effects of i.v. THC, which were
mainly of psychotropic nature.
THC did not reduce pain in the ice water test, as it was the case in our preceding pain study
with oral THC [105]. As postulated before [105], this indicates that not the low oral bioavailability
of THC is responsible for the lack of analgesia. It is assumed, that the ice water test is not the
right model to determine an analgesic effect of THC.
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4. SUMMARY OF PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES
OF ORAL, PULMONAL, AND INTRAVENOUS THC
After pulmonal THC much higher plasma levels resulted than after oral THC. The
bioavailability of pulmonal THC showed an up to six-fold increase compared to the oral
application form used in the first pain study. The elimination half-life of oral THC was much
longer (5-fold increase) than after i.v. or pulmonal THC indicating that absorption is the time-
determining step in the pharmacokinetics of oral THC. A further disadvantage of the oral
administration was the plasma peak time. The highest THC plasma concentrations were found
at 60 or 120 min post drug indicating a quite high inter-individual variability. With pulmonal THC
peak plasma concentrations resulted already 20 min post drug, actually at the end of the
inhalation procedure, in all of the eight subjects. Peak plasma concentrations were much higher
after pulmonal than oral administration causing much less side effects indicating that not only
THC itself is responsible for the psychotropic side effects but also the known strongly
psychoactive metabolite THC-OH.
Despite the increased bioavailability of pulmonal THC no analgesic effect could be provoked
suggesting that the bioavailability does not affect the efficacy in the pain reducing properties of
THC. We assume that our experimental pain models, which were all models of acute pain, were
not the right ones for studying the analgesic properties of THC. Further experiments are needed
to evaluate the appropriate pain tests for THC and healthy subjects.
5. OUTLOOK
The THC inhalation solution could be an ideal formulation for the rapid onset of action. The
novel liquid-based inhalation devices (see “Theory and Literature Review”, chapter 4.3) would
be suitable for its administration.
To achieve a better tolerable formulation other pharmaceutical techniques are required for
the solubilisation of THC in an aqueous vehicle. Micro- or nanoemulsions could be used or even
nanoencapsulation of THC. When using nanoencapsulation, THC would be dissolved in a
suitable vehicle oil which then would be encapsulated by a special technique forming particles
of a few nanometers in diameter. THC would be absorbed within these nanocapsules  not
getting into contact with the surface of the airways.
An easy to handle, pocket-sized and portable inhalation device would be an option to further
study the therapeutic potential of pulmonal THC. The pulmonal aerosol should be the
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application form of first choice in acute pain situations, like migraine or spasms, where a rapid
onset of action is of great therapeutic relevance.
It can be disputed whether the right experimental pain models were used to measure the
analgesic effect of THC and whether THC reduces acute pain actually. Therefore THC should
be tested too with other pain models, such as models for chronic pain (nowadays not available),
or to investigate the effect in patients suffering from chronic or neuropathic pain.
Referneces 103
____________________________________________________________________________________
REFERENCES
[1] Fankhauser, M., Haschisch als Medikament, Dissertation, University of Bern (1996).
[2] Di Marzo, V. and De Petrocellis, D., The endogenous cannabinoid signalling system: chemistry,
biochemistry and physiology. Intern J Sci – Biol Chem, 1: 1-27 (1997)
[3] Di Marzo, V., Bisogno, T., and De Petrocellis, L., Endocannabisnoids: new targets for drug
development. Curr Pharm Design, 6(13): 1361-1380 (2000)
[4] Ogborne, A.C., Smart, R.G., Weber, T., and Birchmor-Timney, C., Who is using cannabis as a
medicine and why: an exploratory study. J Psychoactive Drugs, 32(2): 435-443 (2000).
[5] Vivian, J.A., Kishioka, S., Butelman, E.R., Broadbear, J.,Lee, K.O., and Woods, J.H., Analgesic,
respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys:
antagonist effects of SR 141716A. J Pharmacol Exp Ther, 286(2): 697-703 (1998).
[6] Smith, F.L., Fujimori, K., Lowe, J., and Welch, S.P., Characterization of delta-9-THC and
anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem and Behav,
60(1): 193-191 (1998).
[7] Cichewicz, D.L., Martin, Z.I., Smith, F.L., and Welch, S.P., Enhancement of mu opioid
antinociception by oral delta-9-tetrahydrocannabinol: dose-response analysis and receptor
identification. J Pharmacol Exp Ther, 289(2): 859-867 (1999).
[8] Ohlsson, A., Lindgren, J.E., Wahlen. A., Agurell, S., Hollister, L.E., and Gillespie, H.K., Plasma
delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous
administration and smoking. Clin Pharmacol Ther, 28(3): 409-416 (1980).
[9] Huestis, M., Pharmacokinetics of THC in inhaled and oral preparations. In Marihuana and
medicine. Nahas, G.G., Sutin, K.M., Harvey, D.J., and Agurell, S., Eds., Humana Press, Totowa,
NJ, 1999, pp 105-116.
[10] Brenneisen, R., Pharmakokinetik. In Cannabis und Cannabinoide. Grotenhermen, F., Ed., Hans
Huber Verlag, Bern, 2001, pp 87-92.
[11] Harvey, D.J., Absorption, distribution, and biotransformation of the cannabinoids. In Marihuana
and medicine. Nahas, G.G., Sutin, K.M., Harvey, D.J., and Agurell, S., Eds., Humana Press,
Totowa, NJ, 1999, pp 91-103.
[12] Speich, A., Heroin-Flüssiginhalation und Heroin-Pulverinhalation, Dissertation, University of Bern
(1998).
[13] Kleiber, D. and Kovar, K.A., Auswirkungen des Cannabiskonsums. Wissenschaftliche
Verlagsgesellschaft, Stuttgart, 1997, pp 14ff.
[14] Clarke, R.C. and Watson, D.P., Die Botanik natürlicher Cannabismedikamente. In Cannabis und
Cannabinoide. Grotenhermen, F., Ed., Hans Huber Verlag, Bern, 2001, pp 21-32.
[15] Stearn, W.T., The Cannabis plant: Botanical characteristics. In The botany & chemistry of
Cannabis. Joyce, C.R.B. and Curry, S.H., Eds., J. & A. Churchill, London, 1970, pp 1-10.
Referneces 104
____________________________________________________________________________________
[16] ElSohly, M.A., Chemische Bestandteile von Cannabis. In Cannabis und Cannabinoide.
Grotenhermen, F., Ed., Hans Huber Verlag, Bern, 2001,pp 45-55.
[17] Kleiber, D. and Kovar, K.A., Auswirkungen des Cannabiskonsums. Wissenschaftliche
Verlagsgesellschaft, Stuttgart, 1997, pp 85ff.
[18] Brenneisen, R., Cannabis profiling project, University of Bern, Unpublished data (2003).
[19] Bundesgesetz vom 3. Oktober 1951 über die Betäubungsmittel und die psychotropen Stoffe
(Betäubungsmittelgesetz, BetmG), SR 812.121.1, Confoederatio Helvetica, Die Bundesbehörden
der Schweizerischen Eidgenossenschaft.
[20] Verordnung vom 29. Mai 1996 über die Betäubungsmittel und die psychotropen Stoffe
(Betäubungsmittelverordnung, BetmV), SR 812.121.1, Confoederatio Helvetica, Die
Bundesbehörden der Schweizerischen Eidgenossenschaft.
[21] Verordnung des Schweizerischen Heilmittelinstitutes vom 12. Dezember 1996 über die
Betäubungsmittel und psychotropen Stoffe (Betäubungsmittelverordnung Swissmedic, BetmV-
Swissmedic). SR 812.121.2, Confoederatio Helvetica, Die Bundesbehörden der
Schweizerischen Eidgenossenschaft.
[22] Verordnung des EDI vom 26. Juni 1995 über die Fremd- und Inhaltsstoffe in Lebensmitteln
(Fremd- und Inhaltsstoffverordnung FIV), SR 817.021.23, Confoederatio Helvetica, Die
Bundesbehörde der Schweizerischen Eidgenossenschaft.
[23] Verordnung des BLW über den Sortenkatalog für Getreide, Kartoffeln, Futterpflanzen, Oel- und
Faserpflanzen sowei Betarüben (Sortenkatalog-Verordnung) SR 916.151.6, Confoederatio
Helvetica, Die Bundesbehörden der Schweizerischen Eidgenossenschaft.
[24] Mechoulam, R., Devane, W.A., and Glaser, R., Cannabinoid geometry and biological activity. In
Marihuana and medicine. Nahas, G.G., Sutin, K.M., Harvey, D.J., and Agurell, S., Eds., Humana
Press, Totowa, NJ, 1999, pp 65-90
[25] Budavari, S., O'Neil, M.J., Smith, A., and Heckelman, P.E., Eds., The Merck Index. 11th ed.
Merck & Co., Inc., Rahway, NJ, 1989.
[26] Garret, E.R. and Hunt, C.A., Physicochemical properties, solubility, and protein binding of delta-
9-tetrahydrocannabinol. J Pharm Sci, 63(2): 1056-1064 (1074).
[27] Thomas, B.F., Compton, D.R., and Martin, B.R., Characterization of the lipophilicity of natural
and synthetic analogs of delta-9-tetrahydrocannabinol and its relationship to pharmacological
potency. J Pharmacol Exp Ther, 255(2): 624-630 (1990).
[28] Unimed Pharmaceuticals Inc., Physicians information for Marinol‚ (dronabinol). Deerfield, IL,
2001.
[29] Grotenhermen, F., Clinical pharmacokinetics of cannabinoids. J Cann Ther, 2(1): 3-51 (2003).
[30] Brenneisen, R., Egli, A., ElSohly, M.A., Henn, V., and Spiess, Y., The effect of orally and rectally
administered delta-9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin
Pharmacol Ther, 34(10): 446-452 (1996).
Referneces 105
____________________________________________________________________________________
[31] Wall, M.E. Sadler, B.M., Brine, D., Taylor, H., and Perez-Reyes, M., Metabolism, disposition, and
kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther, 34(3): 352-
363 (1983).
[32] Hunt, C.A. and Jones, R.T., Tolerance and disposition of tetrahydrocannabinol in man. J
Pharmacol Exp Ther, 215(1): 35-44 (1980).
[33] Lemberger, L., Tamarkin, N.R., Axelrod, J., and Kopin, I.J., Delta-9-tetrahydrocannabinol:
metabolism and disposition in long-term marihuana smokers. Science, 173(991): 72-74 (1971).
[34] Watanabe, K., Matsunaga, T., Yamamoto, I., Funae, Y., and Yoshimura, H., Involvement of
CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman.
Biol Pharm Bull, 18(8): 1138-1141 (1995).
[35] Bornheim, L.M., Lasker, J.M., and Raucy, J.L., Human hepatic microsomal metabolites of delta-
1-tetrahydrocannabinol. Drug Metab Dispos, 20: 241-246 (1992).
[36] Pertwee, R.G., Cannbinoid receptors and their ligands in brain and other tissues. In Marihuana
and medicine, Nahas, G.G., Sutin, K.M., Harvey, D.J., and Agurell, S., Eds., Humana Press,
Totowa, NJ, 1999, pp 177-185.
[37] Pertwee, R.G., Angriffspunkte und Wirkungsmechanismen., In Cannabis und Cannabinoide,
Grotenhermen, F., Ed., Hans Huber Verlag, Bern, 2001, pp 93-107.
[38] Walker, J.M., Huang, S.M., Strangman, N.M., Twou, K., and Sanudo-Pena, C.M., Pain
modulation by release of the endogenous cannabinoid anandamide, Symposium on the
Cannabinoids, Burlington Vermont: International Cannabinoid Research Society (ICRS),
Acapulco, 1999.
[39] Grotenhermen, F., Uebersicht über die therapeutischen Wirkungen. In Cannabis und
Cannabinoide, Grotenhermen, F., Ed., Hans Huber Verlag, Bern, 2001, pp 141-164.
[40] Grotenhermen, F., Uebersicht über die unerwünschten Wirkungen von Cannabis und THC. In
Cannabis und Cannabinoide, Grotenhermen, F., Ed., Hans Huber Verlag, Bern, 2001, pp 259-
273.
[41] Bergeret, I., Papageorgiou, C., Verbanck, P., and Pelc, I., Cannabis and physical health. In
Cannabis 2002 Report, Spruit, I.P., Ed., Ministry of Public Health, Brussels, 2002, pp 55-61.
[42] Miller, L.L., Marihuana: Acute effects on human memory. In Marihuana and medicine, Nahas,
G.G., Sutin, K.M., Harvey, D.J., and Agurell, S., Eds., Humana Press, Totowa, NJ, 1999, pp 227-
231.
[43] Swift, W. and Hall, W., Abhängigkeit. In Cannabis und Cannabinoide, Grotenhermen, F., Ed.,
Hans Huber Verlag, Bern, 2001, pp 283-294.
[44] Lichman, A.H., and Martin, B.R., The selective cannabinoid antagonist SR 141716A blocks
cannabinoid-induced antinociception in rats. Pharmacol Biochem Behav, 57(1/2): 7-12 (1997).
[45] Smith, F.L., Cichewicz, D., Martin, Z.L., and Welch, S.P., The enhancement of morphine
antinociception in mice by delta-9-tetrahydrocananbinol. Pharmacol Biochem Behav, 60(2): 559-
566 (1998).
Referneces 106
____________________________________________________________________________________
[46] Milstein, S.L., MacCannell, K., Karr, G., and Clark, S., Marijuana-produced changes in
paintolerance. Experienced and non-experienced subjects. Intern Pharmacopsych, 10: 177-182
(1975).
[47] Greenwald, M.K. and Stitzer, M.L., Antinociceptive, subjective and behavioural effects of smoked
marijuana in humans. Drug Alcohol Depend, 59(3): 261-275 (2000).
[48] Zeidenberg, P., Crawford, C.W., Jeffe, J., Anderson, S.W., Chin, S., and Malitz, S., Effect of oral
administration of delta-9-tetrahydrocannabinol on memory, speech, and perception of thermal
stimulation: results with four normal human volunteer subjects. Preliminary report. Comprehens
Psych, 14(6): 459-556 (1973).
[49] Hill, S.Y., Schwin, R., Goodwin, D.W., and Powell, B.J., Marihuana and pain. J Pharmacol Exp
Ther, 188(2): 415-418 (1974).
[50] Campbell, F.A., Tramer, M.R., Carroll, d., Reynolds, D.J., Moore, R.A., and McQuay, H.J., Are
cannabinoids an effective and safe treatment option in the management of pain? A qualitative
systematic review. Br Med J, 323(7303): 13-16 (2001).
[51] Noyes, R. Jr., Brunk, S.F., Baram, D.A., and Canter, A., Analgesic effect of delta-9-
tetrahydrocannabinol. J Clin Pharmacol, 15(2-3): 139-143 (1975).
[52] Noyes, R.J., Brunk, S.F., Avery, D.H., and Canter, A., The analgesic properties of delta-9-
tetrahydrocannabinol and codeine. Clin Pharmacol Ther, 18(1): 84-98 (1975).
[53] Raft, D., Grefgg, J., Ghia, J., and Harris, L., Effects of intravenous tetrahydrocannabinol on
experimental and surgical pain. Psychological correlates of the analgesic response. Clin
Pharmacol Ther, 21(1): 26-36 (1977).
[54] Holdcroft, A., Smith, M., Jacklin, A., Hodgson, H., Smith, B., Newton, M., and Evans, F., Pain
relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia, 52(5): 483-486 (1997).
[55] Lynch, M.E., Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. J Pain
Sympt Manage, 25(6): 496-498 (2003).
[56] Joy, J.E., Watson, S.J., and Benson, J.A., Marijuana and medicine, Assessing the science base.
Institute of Medicine, National Academic Press, Washington D.C., 1999, pp 1-14.
[57] Grinspoon, L. and Bakalar, J.B., Marihuana, the forbidden medicine. Yale University Press, New
Haven, London, 1997.
[58] Wachtel, S.R., ElSohly, M.A., Ross, S.A., Ambre, J., and de Wit, H., Comparison of the
subjective effects of delta-9-tetrahydrocannabinol and marijuana in humans.,
Psychopharmacology (Berlin), 161(4): 331-339 (2002).
[59] Zuardi, A.W., Shirakawa, I., Finkelfarb, E., and Karniol, I.G., Action of cannabidiol on the anxiety
and other effects produced by delta-9-THC in normal subjects. Psychopharmacology (Berlin),
76(3): 245-250 (1982).
[60] Zuardi, A.W., Morais, S.L., Guimaraes, F.S., and Mechoulam, R., Antipsychotic effect of
cannabidiol. J Clin Psych, 56(10): 485-486 (1995).
Referneces 107
____________________________________________________________________________________
[61] Notcutt, W., Price, M., Miller, R., Newport, S., Samsom, C., and Simmons, S., Medicinal
Cannabis extracts in chronic pain: (4) Cannabidiol modification of psycho-active effects of delta-
9-THC. Proceed. Congress of the International Association of Cannabis as Medicine (IACM),
Berlin, 2001.
[62] Partland, J.M. and Russo, E.B., Cannabis and Cannabis extracts: greater than the sum of their
parts? J Cann Ther, 1: 103-132 (2001).
[63] Mechoulam, R., Parker, L.A., and Gallily, R., Cannabidiol: an overview of some pharmacological
aspects. J Clin Pharmacol, 42(11 Suppl): 11S-19S (2002).
[64] Douglas, R.B., The physiology of the lung. In Drug delivery to the respiratory tract. Ganderton, D.
and Jones, T.M., Eds., VCH Ellis Horwood Ltd., Cambridge, 1987, pp 13-26.
[65] Damani, L.A., Metabolism of drugs in the respiratory tract, In Drug delivery to the respiratory
tract. Ganderton, D. and Jones, T.M., Eds., VCH Ellis Horwood Ltd., Cambridge, 1987, pp 46-57.
[66] Padfield, J.M., Principles of drug administration to the respiratory tract, In Drug delivery to the
respiratory tract. Ganderton, D. and Jones, T.M., Eds., VCH Ellis Horwood Ltd., Cambridge,
1987, pp 75-86.
[67] Newman, S.P., Pavia, D., Garland, N., and Clarke, S.W., Effects of various inhalation modes on
the deposition of radioactive pressurized aerosols. Eur J Respir Dis Suppl, 119: 57-65 (1982).
[68] Smart, J.R., A brief overview of novel liquid-based inhalation technologies. Drug delivery
systems & sciences, 2(3): 67-71 (2002).
[69] Voigt, R., Pharmazeutische Technologie. 8th ed. Ullstein Mosby, Berlin, 1985, pp 86ff
[70] Martin, A.N., Swabrick, J., and Cammarata, A., Physikalische Pharmazie. 3rd ed. Stricker, H.,
Ed., Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1987, pp 96, 515ff
[71] Pfleger, K., Maurer, H.H., Weber, A., Mass spectral and GC data of drugs, poisons, pesticides,
pollutants and their metabolites (on-line-library for Hewlett Packard Chemstation).
[72] ElSohly, M.A., Little, T.L. Jr., Hikal, A., Harland, E., Stanford, D.F., and Walker, L., Rectal
bioavailability of delta-9-tetrahydrocannabinol from various esters. Pharmacol Biochem Behav,
40(3): 497-502 (1991).
[73] Brennum, J., Kjeldsen, M., Jensen, K., and Jensen, T.S., Measurements of human pressure-pain
thresholds on fingers and toes. Pain, 38(2): 211-217 (1989).
[74] Brennum, J.; Arendt-Nielsen, L., Secher, N.H., Jensen, T.S., Bjerring, P., Quantitative sensory
examination in human epidural anaesthesia and analgesia: effects of lidocaine. Pain, 51(1): 27-
34 (1992).
[75] Petersen-Felix, S., Arendt-Nielsen, L., Bak, P., Bjerring, P., Breivik, H., Svensson, P., and
Zbinden, A.M., Ondansetron does not inhibit the analgesic effect of alfentanil. Br J Anaesth,
73(3): 326-330 (1994).
[76] Fruhstorfer, H., Lindblom, U., Schmidt, W.C., Method for quantitative estimation of thermal
thresholds in patients. J Neurol Neurosurg Psych, 39(11): 1071-1075 (1976).
Referneces 108
____________________________________________________________________________________
[77] Arendt-Nielsen, L., Nielsen, L., Petersen-Felix, S., Schnider, T.W., and Zbinden, A.M., Effect of
racemic mixture and the (S+)-isomer of ketamine on temporal and spatial summation of pain. Br
J Anaesth, 77(5): 625-631 (1996).
[78] Jones, S.F., McQuay, H.J., Moore, R.A., and Hand, C.W., Morphine and ibuprofen compared
using the cold pressor test. Pain, 34(2): 117-122 (1988).
[79] Sindrup, S.H., Poulsen, L., Brosen, K., Arendt-Nielsen, L., and Gram, L.F., Are poor
metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers? Pain,
53(3): 335-339 (1993).
[80] Arendt-Nielsen, L., Brennum, J., Sindrup, S., and Bak, P., Electrophysiological and
psychophysical quantification of temporal summation in the human nociceptive system. Eur J
Appl Physiol Occup Physiol, 68(3): 266-273 (1994).
[81] Curatolo, M., Petersen-Felix, S., Gerber, A., and Arendt-Niesen, L., Remifentanil inhibits
muscular more than cutaneous pain in humans. Br J Anaesth, 85(4): 529-532 (2000).
[82] Bourquin, D., Bundeli, P., Lehmann, T., and Brenneisen, R., Diacetylmorphine and its
metabolites in plasma by HPLC with diode-array and atmospheric pressure ionization mass
spectrometric detection. J Liq Chromatogr & Rel Technol, 22(17): 2663-2674 (1999).
[83] Feng, S., ElSohly, M.A., Salamone, S., and Salem, M.Y., Simultaneous analysis of delta-9-THC
and its major metabolites in urine, plasma, and meconium by GC-MS using an immunoaffinity
extraction procedure. J Anal Toxicol, 24(6): 395-402 (2000).
[84] Heinzel, G., Woloszczak, R., and Thomann, P., Topfit -Pharmacokinetic and pharmacodynamic
data analysis system for the PC. G. Fischer, Stuttgart, 1983.
[85] Pfleger, K., Maurer, H.H., and Weber, A., Mass spectral and GC data of drugs, poisons,
pesticides, pollutants and their metabolites, 2nd ed. vol. 3, VCH, Weinheim, 1992.
[86] Brenneisen, R. and ElSohly, M.A., Chromatographic and spectroscopic profiles of Cannabis of
different origins: Part I. J Forens Sci, 33(6): 1385-1404 (1988).
[87] Voigt, R., Pharmazeutische Technologie. 8th ed. Ullstein Mosby, Berlin, 1985, pp 154ff
[88] Leuenberger, H., Mathemtische Versuchsplanung und Optimierungsstrategien. In
Pharmazeutische Technologie. Sucker, H. and Fuchs, P., Eds., Georg Thieme Verlag, Stuttgart,
1991, pp 125-144.
[89] European Pharmacopeia, 4th ed., vol 1, Deutscher Apothekerverlag Stuttgart, 2002.
[90] Olsen, J.L., Makhani, M., Davis, K.H., and Wall, M.E., Preparation of delta-9-
tetrahydrocannabinol for intravenous injection. J Pharm Pharmacol, 25(4): 344 (1973).
[91] Moeller, M.R., Doerr, G., and Warth, S., Simultaneous quantitation of delta-9-
tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH) in
serum by GC/MS using deuterated internal standards and its application to a smoking study and
forensic cases. J Forens Sci, 37(4): 969-983 (1992).
[92] PKAnalyst‚, MicroMath Scientist Software, Salt Lake City, UT.
Referneces 109
____________________________________________________________________________________
[93] Petersen-Felix, S., Luginbuhl, M., Schnider, T.W., Curatolo M., Arendt-Nielsen, L., and Zbinden,
A.M., Comparison of the analgesic potency of xenon and nitrous oxide in humans evaluated by
experimental pain. Br J Anaesth, 81: 742-747 (1998).
[94] Enggaard, T.P., Poulsen, L., Arendt-Nielsen, L., Hansen, S.H., Bjornsdottir, I., Gram, L.F., and
Sindrup, S.H., The analgesic effect of codeine as compared to imipramine in different human
experimental pain models. Pain, 92(1-2): 277-282 (2001).
[95] Luginbuhl, M. Schnider, T.W., Petersen-Felix, S., Arendt-Nielsen, L., and Zbinden, A.M.,
Comparison of five experimental pain tests to measure analgesic affects of alfentanil. Anaesth,
95(1): 22-29 (2001).
[96] Clark, W.C., Janal, M.N., Zeidenberg, P., and Nahas, G.G., Effects of moderate and high doses
of marihuana on thermal pain: a sensory decision theory analysis. J Clin Pharm, 21: 299S-310S
(1981).
[97] Pertwee, R.G., Cannabinoid receptors and pain. Prog Neurobiol, 63(5): 569-611 (2001).
[98] Siegling, A., Hofman, H.A., Denzer, D., Mauloer, F., and De Vry, J., Cannabinoid CB(1) receptor
upregulation in a rat model of chronic neuropathic pain. Eur J Pharmacol, 415(1): R5-R7 (2001).
[99] Elsner, F., Radbruch, L., and Sabatowski, R., Tetrahydrocannabinol zur Therapie chronischer
Schmerzen - Tetrahydrocannabinol for treatment of chronic pain. Schmerz, 15(3): 200-204
(2001).
[100] von Graffenried, B., Adler, R., Abt, K., Nuesch, E., and Spiegel, R., The influence of anxiety and
pain sensitivity on experimental pain in man. Pain, 4(3): 253-263 (1978).
[101] Gralla, R.J., Cannabinoids and the control of chemotherapy-induced nausea and vomiting. In
Marihuana and medicine. Nahas, G.G., Sutin, K.M., Harvey, D.J., and Agurell, S., Eds., Humana
Press, Totowa, NJ, 1999, pp 599-610.
[102] Gyr, E., Brenneisen, R., Bourquin, D., Lehmann, T., Vonlanthen, D., and Hug, I.,
Pharmacodynamics and pharmacokinetics of intravenously, orally and rectally administered
diacetylmorphine in opioid dependents, a two-patient pilot study within a heroin-assisted
treatment program. Int J Clin Pharmacol Ther, 38(10): 486-491 (2002).
[103] Buetler, T.M., Wilder-Smith, O.H., Wilder-Smith, C.H., Aebi, S., Cerny, T., and Brenneisen, R.,
Analgesic action of i.v. morphine-6-glucuronide in healthy volunteers. Br J Anaesth, 84(1): 97-99
(2000).
[104] Magalini, S.C., Nanni, G., Agnes, S., Citterio, and Castagneto, M., Anaphylactic reaction to first
exposure to cyclosporine. Transplantation, 42(4): 443-444 (1986).
[105] Naef, M., Curatolo, M., Petersen-Felix, S., Arendt-Nielsen, L., Zbinden, A.M., and Brenneisen,
R., The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-
morphine combination in healthy subjects under experimental pain conditions, Pain, 105(1-2):
79-88 (2003).
[106] Tashkin, D.P., Reiss, S., Shapiro, B.J., Calvarese, B., Olsen, J.L., and Lodge, J.W., Bronchial
effects of aerosolized delta-9-tetrahydrocannabinol in healthy and asthmatic subjects. Am Rev
Respir Dis, 115(1): 57-65 (1977).
Appendices I
____________________________________________________________________________________
APPENDICES
I. Study protocol (incl. volunteer information) and VAS questionnaire of the pain study
II. Study protocol (incl. volunteer information) and VAS questionnaire of the
pharmacokinetic study
III. Typical chromatogram of the determination of THC and its metabolites in plasma of
the pain study
IV. Typical chromatogram of the determination of THC and its metabolites in plasma of
the pharmacokinetic study
V. Paper pain study
VI. Paper pharmacokinetic study
Appendices II
____________________________________________________________________________________
I. Study protocol (incl. volunteer information) and VAS questionnaire of the pain study
Department of Clinical Research, University of Bern
and
Department of Anaesthesiology and Intensive Care,
University Hospital of Bern
The analgesic effect of delta-9-tetrahydrocannabinol
alone and in combination with morphine
in healthy subjects
S T U D Y   P R O T O C O L L
Prof. Dr. pharm. Rudolf Brenneisen, Bern
Prof. Dr. med. A. Zbinden
Dr. med. M. Curatolo
2Introduction
Cannabis (Cannabis sativa L., Cannabaceae) has been used as medicinal plant for thousands of
years against pains, muscle spasms, rheuma, malaria, opstipation etc. (see ref. 1-3 for lit.
reviewing the therapeutic potential of Cannabis and cannabinoids). Some anecdotal reports about
Cannabis as analgesic exist from the 19th century. Reynolds, a famous British neurologist and
physician of Queen Victoria, was enthousiastic about Cannabis as pain medicament: „In almost
all painful maladies I have found it is by far the most useful of drugs... It is especially so in cases
of...neuralgia of the fifth nerve...tumor of brain...thickening of spinal meninges...the lithning pains
of the ataxia patient... and migraine.“ The US Pharmacopeia of 1888 recommended the use of
Cannabis as analgesic.
Among the more than 400 identified Cannabis constituents the cannabinoids (about 60) are the
compounds of pharmacological interest. Most research in animals and humans has been done
with (-)-delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the dominating
cannabinoid of „Drug-Type Cannabis“ and responsible for its psychoactivity, whereas CBD is
the dominating cannabinoid in „Fiber-Type Cannabis“. It is not psychactive. Synthetic THC has
been registered by FDA under the international name of Dronabinol for the treatment of anorexia
of AIDS patients and nausea/vomiting associated with cancer chemotherapy. It is sold in the US
under the trade name of Marinol“ as 5, 10 and 15 mg capsules. The medicinalisation of THC in
the US lead to a rescheduling by WHO and UN, allowing the therapeutic use of THC under
medicinally strictly controlled conditions. The Swiss Narcotic Law did not (yet) follow and only
allows today the use of THC for clinical research with a special permit of the Federal Office of
Public Health. Such a study is ongoing at the Rehabilitation Center for Paralyzed Patients in
Basel (Rehab). The clinical use of Cannabis plant products is still forbidden in Switzerland.
Until 1987 the mechanism of action of THC was attributed to unspecific membrane binding and
interaction with the serotonin and prostaglandin synthesis. The first cannabinoid receptor  (CB-
1) has been discovered in the rat (and later also in mammalians) [4]. It is mainly located in the
brain (substantia nigra, cerebellum etc.). A peripheral cannabinoid receptor system (CB-2) was
then detected 1993 in rat spleen [5]. THC has among the natural cannabinoids as agonist the
highest binding affinity to CB-1. An endogenous ligand („Anandamide-I“) was first identified in
1992 [6], followed by other arachidonic acid ethanolamides binding to the receptor [7, 8]. The
3physiological role of the cannabinoid receptors and ligands is not yet clear. One speculates, that
they might play a role in the coordination of psychomotoric functions, memory, emotions,
immunomodulation, sleep rhythm, antiinflammation and analgesia.
Several animal studies have shown the analgesic effect of THC [9-13], some only with very high
doses (10-40 mg/kg). In rodents THC was equipotent with morphine or even 3 times more
effective. In a recent animal study a low inactive dose of THC (20 mg/kg) was co-administered
orally with morphine to mice resulting in enhanced morphine-induced anti-nociception, i.e. 7.6-
fold shift in ED50. In the tail-flick latency test codeine, methadone, oxymorphone and
hydromorphone showed significant ED50 shifts with potency ratios of 25.8, 4.1, 5.0 and 12.6,
respectively [14]. In a study with rhesus monkeys THC (0.1-10 mg/kg i.m.) dose-dependently
increased antinociception, which was reversable by the specific cannabinoid receptor antagonist
SR 141716A [15]. A recent study with rats showed that analgesia produced by a synthetic THC
derivative and morphine involves similar brainstem circuitry (rostral ventro-medial medulla,
RVM) and that cannabinoids are indeed centrally acting analgesics but with a new mechanism of
action [16].
The number of controlled clinical trials with THC is limited and the results somewhat
equivocal. Oral THC (5-20 mg) and placebo were compared in 10 cancer patients with moderate
chronic pains. 15 and 20 mg THC produced significant pain relief, but with more central side-
effects (drowsiness, mental clouding) than small doses. The effect peaked at 3 h and was still near
maximum after 6 h [17]. Oral THC (10, 20 mg) and codeine (60, 120 mg) were compared in 36
patients with cancer pain. Analgesic efficacy was equivalent with the two drugs and both THC
20 mg and codeine 120 mg gave significant pain relief compared with placebo [18]. The
conclusion was that THC is not suited as standard pain medicament but can be used in small
doses for co-medication. In a placebo-controlled study 54 outclinic patients with tumor-induced
pains received THC orally. The majority of patients were sedated, relaxed, less depressive but
did not report pain reduction [19]. Oral THC had an analgesic effect vs. placebo in healthy
subjects after thermally induced pain [20]. No significant analgesic effects from 2 doses of i.v.
THC (0.22, 0.44 mg/kg) were found in 10 subjects undergoing dental surgery [21]. The pain level
was increased after pressure- and electrostimulation when THC was administered i.v. The side-
effects were anxiety and dysphoria [22]. No analgesic effect could be observed in healthy
subjects after i.v. doses of 1.5 and 3 mg THC; 10 mg diazepam and placebo were used as control
[23]. End-stage cancer patients reported no significant reduction of pain after 0.15 and 0.3 mg
4THC per kg b.wt. [24]. Pain relief and reduction of analgesics-co-medication could be observed in
a paralyzed patient with spasticity after the oral and rectal administration of 10 and 5 mg THC,
respectively [25]. A patient with chronic pain resulting from familial mediterranean fever
obtained in a double-blind placebo-controlled crossover trial 50 mg oral THC (as standardized
Cannabis preparation) daily and 10 mg morphine. The difference in daily analgesic consumption
between active and placebo phase was found to be highly significant [26]. For further literature
reviewing the analgesic potency of THC and Cannabis see ref. [27-30].
Aim and relevance of study, hypothesis
Morphine as clinically well established hypno-analgesic may produce relevant dose-dependent
acute (respiratory depression etc.) and chronic side-effects (opstipation etc.), tolerance and
psychic and physic dependence. It shows poor efficacy on pain syndromes associated with
nerve damage. It is postulated from animal data that the combination with THC increases the
efficacy of morphine allowing to reduce the dosage and therefore the risk of side-effects and
tolerance development. After single oral, sub-psychotropic doses of THC, morphine and a
combination of these two substances the analgesic potency will be measured in healthy subjects
using standardized pain tests as well as patient monitors and visual analog scales (VAS) to record
potential CNS, respiratory and cardiovascular side-effects. Pharmacokinetic parameters will be
acquired for correlating plasma concentrations and effects including also metabolites. If the
hypotheses of this study are confirmed, therapeutic strategies including THC could be
developed, particularly for the treatment of pain states in which the currently available therapies
either are ineffective or cause unacceptable side-effects.
Methods
Study design
The study will be performed as double-blind, cross-over trial. Each volunteer will be tested a 4
different sessions, separated by a minimum 7-days-interval. Each subject receives one oral dosage
of THC, morphine, THC plus morphine and placebo in a random order. The analgesic potency is
tested by using 4 pain tests. Psychotropic side-effects are monitored by a standar-dized
5questionnaire. For the pharmacokinetic profiling blood samples are collected imme-diately before
each pain test series through an intravenous catheter inserted in a large vein in the cubital fossa.
Subjects
15 paid healthy volunteers, male and female medical students will participate in the study.
Exclusion criterias are: existing or earlier drug abuse (including alcohol and medicaments), known
or suspected hypersensibility to cannabinoids or opioids, pregnancy. Subjects are not allowed to
use non-steroidal antiinflammation drugs, paracetamol and other analgesics 48 h before and during
the study. Written informed consent will be obtained from all subjects.
Substances and dosages
Each subject receives orally (empty stomach) on each experimental session either placebo, 20 mg
THC (Marinol“), 30 mg morphine sulfate (MST Continus“) or 20 mg THC plus 30 mg morphine
sulfate.
Pharmacodynamics
Experimental pain tests (order randomised)
All tests will be applied to the right side. Each test series includes heat, ice water, pressure and
transcutaneous electrical stimulation (single and repeated stimulation). These tests will be
performed within each series in a randomized order. The volunteers will first try all tests for
training. When they are familiar with the testing procedure, baseline recordings of all tests will be
performed. Then the test drug will be administered. The test series will be performed every hour,
from 1 to 10 h after administration of the drug.
Heat Stimulation. The heat stimulation [31] will be applied to the volar surface of the forearm,
in the middle of a line joining the elbow to the wrist fold. Heat pain thresholds will be determined
using a computerized version of the Thermotest (Somedic AB, Stockholm, Sweden). The
thermode consists of series-coupled Peletier elements and measures 25 mm x 50 mm. A baseline
temperature of 30ºC (± 0.2ºC) and a 2.0ºC/s rate of change (heating and return to baseline) will be
used. To avoid skin damage a maximum limit of 52ºC will be set. The volunteer will be informed
6to press a button when he/she begins to perceive the heat as painful (pain detection threshold)
and when he/she finds the heat intolerable and does not want the heat to be further increased
(pain tolerance threshold). These temperatures are recorded, and the thermode automatically
cools to the baseline temperature. Three consecutive measurements will be performed for both
detection and tolerance thresholds. The average of the last two values will be computed and
considered for the data analysis.
Ice water test. A two minutes ice water test [32] will be used. The hand is immersed in ice
saturated water (1.5 ± 1.0°C). If the pain is considered intolerable before two minutes have
elapsed, the volunteer can withdraw the hand, and the elapsed time will be noted. Perceived pain
intensity will be continuously rated with an electronic visual analogue scale (VAS) coupled to a
pen recorder. The area under the pain intensity/time curve will be determined. If the hand is
withdrawn before the end of the two minutes, the pain intensity will be considered to be maximal
until the end of the period.
Pressure Pain. Pressure stimulation [33] will be applied to the center of the pulpa of the 2nd and
3rd toe. An electronic pressure algometer (Somedic AB, Stockholm, Sweden), whose probe has a
surface area of 64 mm2, will be used. The pressure will be increased from 0 at a rate of 30 kPa/s
to a maximum pressure of 1500 kPa. The volunteer will be informed to press a button when
he/she begins to perceive the pressure as painful (pain detection threshold) and when he/she finds
the pressure intolerable and does not want the pressure to be further increased (pain tolerance
threshold). If the threshold will be above 1500 kPa, this value will be considered as threshold.
The mean of 2 determinations of both pain detention and tolerance thresholds from the 2nd and
3rd toe will be considered for data analysis.
Transcutaneous Electrical Stimulation. Two bipolar surface Ag/AgCl-electrodes (inter-electrode
distance approximately 2 cm) will be placed in the innervation area of the sural nerve (foot, just
distal to the lateral malleolus). Electrophysiological (flexion reflex) and psychophysical
(perception of pain) thresholds will be determined. The electrophysiological signal produced by
the flexion reflex will be recorded from bipolar Ag/AgCl-electrodes placed over the middle of the
biceps femoris and the rectus femoris muscles. A 25 ms, train-of-five, 1 ms, square-wave impulse
(perceived as a single stimulus) will be delivered from a computer-controlled constant current
7stimulator (University of Aalborg, Denmark). The current intensity will be increased from 1 mA
in steps of 1 mA until a pain sensation (psychophysical threshold) or a flexion reflex
(electrophysiological threshold) will be evoked. These thresholds will be defined as single
stimulus thresholds. The above-mentioned stimulus burst will be repeated 5 times with a
frequency of 2 Hz [34] to elicit temporal summation. Temporal summation occurs when the
repetition of a stimulus causes increased pain perception, probably as a result of sensitization of
spinal cord neurons [35]. The current intensity will be increased from 1 mA in steps of 1 mA
until the summation threshold will be reached. Summation threshold will be defined as the
stimulus intensity eliciting an increase in perception of current intensity (psychophysical
threshold) or an increase in amplitude of the last 1 or 2 reflexes (electrophysiological threshold)
during the 5 stimulations.
For all the above measurements, if the threshold will be above a maximal current of 80 mA, the
threshold will be defined as 80 mA. Three consecutive measurements will be performed, and the
average of the last two values will be considered for data analysis.
Side effects
A 10 cm visual analog scale (VAS) will be used to assess sedation, psychotropic effects and
nausea. The episodes of vomiting will be noted. Hemoglobin oxygen saturation (pulse oximetry),
expired CO2 (via nasal catheter), blood pressure and heart rate will be recorded. To determine the
reaction time, a 1000 Hz tone will be delivered from a computer with randomized intervals of 3
to 8 seconds, and a timer will be simultaneously started. The volunteer will be instructed to press
a button as fast as possible after the tone. The reaction time will be defined as the time from the
tone until the volunteer presses the button. The mean of five consecutive measurements will be
calculated. All the above parameters will be recorded immediately before each test series.
Pharmacokinetics
Plasma profiles of THC and THC metabolites (11-carboxy-THC, 11-hydroxy-THC) will be
performed by gas-chromatography/mass spectrometry (GC/MS) [25]. Plasma profiles of
morphine and morphine metabolites (morphine-6-glucuronide, morphine-3-glucuronide) will be
performed by HPLC [36]. The pharmacokinetic data evaluation includes Cmax, tmax, t1/2, V and
CL.
8Ethical Aspects, Permits
The toxicity of THC is extremely low. Fatal intoxications after either recreational or therapeutic
use have never been reported. According to the manufacturer of Marinol“, the human lethal dose
after i.v. injection is estimated to be 30 mg/kg. CNS side-effects (sedation, dysphoria, anxiety
etc.) only occur after oral doses of THC higher than 20 mg [37]. A psychic dependence may
develop only after long-term use and high dosages [37]. The study requires a special THC permit
of the Federal Office of Public Health.
Bern, 25. November 1998 / cannabis / ifai-studienprotokoll.doc
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Die analgetische Wirkung von delta-9-Tetrahydrocannabinol
allein und in Kombination mit Morphin
VersuchsteilnehmerInnen-Information, Einverständniserklärung
Einleitung, Zielsetzung
Die Cannabispflanze wird seit Jahrtausenden u.a. gegen Schmerzen und Muskelkrämpfe
eingesetzt. In der Schweiz ist in den letzten Jahren eine zunehmende volksmedizinische (illegale)
Verwendung von Cannabisprodukten zu beobachten. Der Hauptwirkstoff ist das delta-9-
Tetrahydrocannabinol (THC), welches in den USA als Marinol® registriert ist. Der
schmerzhemmende Effekt von THC und die Potenzierung der Morphinwirkung ist in
verschiedenen Tierstudien gezeigt worden, während die Resultate aus den wenigen kontrollierten
Humanversuchen kontrovers sind. Das Ziel dieser doppelblind und placebokontrolliert
durchgeführten Studie an gesunden ProbandInnen ist die Messung der Schmerzhemmung von oral
verabreichtem THC allein oder in Kombination mit Morphin anhand von verschiedenen
standardisierten Schmerztests.
Versuchsablauf
Am jeweils rund 12 Stunden (08.00-20 h) dauernden Versuch könne MedizinstudentInnen sowie
Angehörige des DKF teilnehmen, welche nicht Alkohol-, Medikamenten-, Opiat- oder Cannabis-
abhängig sind/waren, keine Überempfindlichkeit gegenüber Cannabinoiden und Opiaten aufweisen
2und nicht schwanger sind. Jede(r) VersuchsteilnehmerIn erhält an 4 verschiedenen Tagen nüchtern
eine orale Dosis von 20 mg THC, 30 mg Morphin, eine Kombination von 20 mg THC und 30 mg
Morphin oder Placebo. Zwischen den einzelnen Versuchen liegen mindestens 7 Tage. Gemessen
wird während 10 Stunden der schmerzstillende Effekt nach Hitze-, Druck-, Kälte- und
Elektrostimulation. Gleichzeitig werden anhand von Befragungsprotokollen und Monitoren
allfällige psychische und physische Nebenwirkungen aufgezeichnet. Vor jedem Schmerztest wird
zur Bestimmung der Blutspiegel und Metaboliten von THC und Morphin über einen
Venenkatheter eine Blutprobe entnommen. Während des ganzen Versuches ist ein Arzt/eine
Ärztin und eine Pflegeperson anwesend. Selbstverständlich werden Sie während der gesamten
Versuchsdauer von uns verpflegt. Der Versuch findet im Schmerzlabor des Institutes für
Anästhesie und Intensivmedizin (IFAI) statt. Die aus dem Versuch gewonnenen medizinischen
und persönlichen Daten werden anonymisiert verarbeitet, sind vertraulich und nicht öffentlich
zugänglich. Die persönlichen Daten können von den zuständigen Behörden und von befugten
Personen während einer Inspektion eingesehen und geprüft werden.
Nebenwirkungen
Die Toxizität des THC ist extrem niedrig. Allenfalls auftretende kardiovaskuläre Neben-
wirkungen (Blutdruck- und Pulsveränderungen) sind harmlos (falls Probleme in der Nacht nach
dem Versuch auftreten ‡  Tel. Versuchsleiter). Unerwünschte psychische, reversible Effekte
(Sedation, Angst etc.) treten erst in höheren Dosen auf. Ein Abhängigkeitsrisiko besteht nur bei
Langzeitanwendung. Morphin kann Übelkeit, Verstopfung, Blutdruck- und Stimmungs-
veränderungen sowie eine Atemdepression verursachen. Ein Abhängigkeitsrisiko besteht ebenfalls
nur nach längerem Einsatz.
Verpflichtung
Sie haben das Recht, jederzeit vom Versuch zurückzutreten. 48 h vor und während den einzelnen
Sitzungen dürfen keine nichsteroidalen Entzündungshemmer und Analgetika sowie kein Alkohol
eingenommen werden. Bis 12 h nach dem Versuch darf kein Fahrzeug geführt werden.
3Versicherung
Für klinische Versuche an gesunden Probanden besteht eine pauschale Haftpflichtversicherung
der Universität Bern.
Entschädigung
Sie werden für die Versuchsteilnahme mit insgesamt 1000.-- Franken entschädigt (250.-- pro
Sitzung).
Einverständniserklärung
Ich habe die VersuchsteilnehmerInnen-Information gelesen und Sinn und Inhalt der
Studie verstanden. Ich erhielt Gelegenheit, Fragen zum Versuchsablauf und zu
allfälligen Nebenwirkungen zu stellen.
Bern, den .................... ....................................................
Unterschrift VersuchsteilnehmerIn
Unterschriften Versuchsleiter:
....................................................
Prof. Dr. A. Zbinden
....................................................
Prof. Dr. R. Brenneisen
....................................................
Dr. M. Curatolo
THC/Morphin-Analgesie-Studie
Proband/in: Nr.
Versuchsdatum: / /
Session:
Messzeitpunkt: t 0 (Baseline)
Nebenwirkungen-0
Bitte beantworten Sie folgende Fragen durch Markierung der skalierten Linie
mit einem Strich:
1. Ich fühle mich angenehm ruhig und entspannt.
0% 100%
überhaupt nicht sehr stark
2. Ich kann mich gut konzentrieren.
0% 100%
überhaupt nicht sehr stark
3. Ich fühle mich schläfrig.
0% 100%
überhaupt nicht sehr stark
4. Ich fühle mich euphorisch.
0% 100%
überhaupt nicht sehr stark
25. Ich fühle mich verstimmt.
0% 100%
überhaupt nicht sehr stark
6. Ich habe Angstgefühle.
0% 100%
überhaupt nicht sehr stark
7. Ich fühle mich innerlich gespannt, aggressiv.
0% 100%
überhaupt nicht sehr stark
8. Ich fühle mich verwirrt, desorientiert.
0% 100%
überhaupt nicht sehr stark
9. Ich nehme mich selbst als verändert wahr.
0% 100%
überhaupt nicht sehr stark
10. Ich nehme meine Umgebung als verändert wahr.
0% 100%
überhaupt nicht sehr stark
311. Ich habe optische, akustische oder andere Halluzinationen.
0% 100%
überhaupt nicht sehr stark
12. Ich nehme Stimmungen, Gedanken, innere Bilder wahr,
die mir nicht vertraut sind.
0% 100%
überhaupt nicht sehr stark
13. Ich empfinde Übelkeit.
0% 100%
überhaupt nicht sehr stark
14. Ich habe Kopfschmerzen.
0% 100%
überhaupt nicht sehr stark
15. Ich habe Atembeschwerden.
0% 100%
überhaupt nicht sehr stark
16. Ich habe Herzbeschwerden (z.B. Herzrasen, Herzstechen).
0% 100%
überhaupt nicht sehr stark
417. Ich habe Magen-, Darmbeschwerden.
0% 100%
überhaupt nicht sehr stark
18. Ich empfinde Mundtrockenheit.
0% 100%
überhaupt nicht sehr stark
19. Ich habe Schwindelgefühle.
0% 100%
überhaupt nicht sehr stark
20. Ich habe andere Beschwerden, nämlich:
thc/ifai-studie-vas.doc / 15.9.99
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pharmacokinetic study
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Pharmakokinetik und –dynamik des pulmonal
applizierten delta-9-Tetrahydrocannabinols        (THC-
Flüssigaerosol)
Studienprotokoll
1. Einführung
Bei der geplanten pharmakokinetischen und -dynamischen Studie handelt
es sich um die Fortsetzung des inzwischen abgeschlossenen Projektes
„The analgesic effect of delta-9-tetrahydrocannabinol alone and in
combination with morphine in healthy subjects“. Für den allgemeinen
Background zu THC und Analgesie sei deshalb auf dieses am 7.12. 1998
bewilligten Sudienprotokolls (Gesuch Nr. 195/98) verwiesen.
Nachdem sich im Rahmen dieser Schmerzlaborstudie gezeigt hat, dass die
orale Applikation von THC in Form von Marinol“-Kapseln in pharmako-
kinetischer Hinsicht nicht ideal ist (intensiver Lebermetabolismus, tiefe
Bioverfügbarkeit etc.), drängt sich die klinische Prüfung anderer Anwen-
dungsformen auf. Alternativ bieten sich Suppositorien, welche allerdings
auch einem First-Pass-Effekt unterliegen, Lungenaerosole, Sublingual-
sprays (zur Zeit in klinischer Erprobung bei GW Pharmaceuticals, GB),
Hautpflaster (eher für Depotanwendung geeignet, klinische Versuche
laufen in den U.S.A.) sowie Injektionslösungen an. Cannabiszigaretten
sind medizinisch-ethisch nicht vertretbar und im Gegensatz zu den USA in
der Schweiz für die Forschung nicht zugelassen. Bereits kommerziell
2zugänglich sind einige Inhalatoren (z.B. Vapormed“ Vaporizer Volcano).
Diese Geräte sind allerdings wissenschaftlich nicht oder nur ungenügend
validiert und eignen sich nur zur „heissen“ (Heissluft, Infrarotlampe etc.)
Verdampfung von Cannabis. Aus toxikologischen (keine Bildung von
Pyrolyseprodukten), galenischen (definierte Partikelgrösse etc.) und
technischen Gründen (validierte Inhalatorgeräte auf dem Markt) ist die
„kalte“ Inhalation in Form von THC-Flüssigaerosolen zu bevorzugen. Die
Aerosolproduktion erfolgt dabei mittels Pressluft oder Ultraschall.  Die
intravenöse Applikation von THC wurde bereits an Tieren und Menschen
getestet. Dabei stellte die, wie bei der Herstellung der Flüssigaerosole,
extrem schlechte Wasserlöslichkeit des THC (0.003 mg/mL) ein zu
lösendes galenisches Problem dar.
2. Ziel der Studie, Studiendesign
Im Rahmen des geplanten Projektes soll nun ein bereits in unserem Labor
entwickeltes und in vitro validiertes THC-Flüssigaerosol pulmonal an 8
gesunden ProbandInnen im Vergleich mit i.v. appliziertem THC getestet
werden. Diese Phase-I-Pilotstudie, bestehend aus insgesamt 3 Sessionen
(Flüssigaerosol-Verum, Flüssigaerosol-Placebo, Injektionslösung) umfasst
primär pharmakokinetische Messungen (Plasmaspiegel, AUC, Bioverfüg-
barkeit, Halbwertszeit etc.) sowie ein Nebenwirkungs-Monitoring
(Lungen-verträglichkeit, Vitalfunktionen). Zur Beurteilung der
analgetischen Potenz soll ein einfacher Schmerztest (Eisbad)
durchgeführt  werden,  was e ine P lacebokontro l le  und
Doppelblindbedingungen erfordert.
3. Methoden
3.1 Probanden
•  4 männliche und 4 weibliche, freiwillige, bezahlte ProbandInnen,
welche bereits an der Schmerzlaborstudie teilgenommen haben und
3dem Stud ien le i te r  bekannt  s ind  (DKF-Angehör ige ,
MedizinstudentInnen). Die ProbandInnen werden vor Versuchsbeginn
in der Abteilung für Pneumologie (Prof. Bachofen) einem
Lungenfunktionstest unterworfen.
• Einschlusskriterien: die ProbandInnen müssen gesund sein, über intak-
te Lungenfunktionen verfügen und dürfen 48 h vor, während und 24 h
nach dem Versuch keinen Alkohol, keine Drogen und Medikamente
konsumieren. Bis 24 h nach dem Versuch sind das Führen von Fahr-
zeugen und das Bedienen von Maschinen nicht erlaubt. Die Proband-
Innen müssen die Einverständniserklärung unterschreiben, dies nach-
dem sie ausführlich über die Studie informiert worden sind und die
ProbandInnen-Information gelesen haben.
•  Ausschlusskriterien: Konsum von Alkohol, Drogen oder Medikamenten
(insbesondere Analgetica) vor und/oder während der Studie; positiver
Cannabisnachweis im Urin (Test jeweils kurz vor Sessionsbeginn);
Schwangerschaft (Test kurz vor Studienbeginn).
3.2 Versicherung
Die VersuchsteilnehmerInnen sind durch die Universität Bern pauschal-
versichert.
3.3 Testsubstanzen, Dosierungen
• THC-Flüssigaerosol:
-  Rezeptur: 30.0 mg THC (THC Pharm, D-Frankfurt/Main; Analysen-
zertifikat des Herstellers vorhanden; Nachkontrolle im DKF), 500.0
mg Cremophor RH 40 (Emulgator; BASF; Toxizitätsdaten
vorhanden), 5.0 mg Natriumascorbat (Vit. C, Antioxydans;
Pharmakopöe-Qualität), 100.0 mg Benzylalkohol (Konservierungs-
mittel; Pharmakopöe-Qualität), Phosphatpuffer pH 7.4 ad 10.0 mL.
Die 0.3%-Flüssigaerosole werden jeweils unter GMP-Bedingungen
4in der Inselspital-Apotheke frisch hergestellt und sterilfiltriert. Die
Qualitätskontrolle (THC-Gehaltsbestimmung) erfolgt im DKF.
- Dosierung: 0.053 mg THC pro kg KG (4 mg THC pro 75 kg) in Form
von 2.2 mL THC-Flüssigaerosol.
• Placebo-Flüssigaerosol:
Mit Ausnahme des Wirkstoffes THC identische Zusammensetzung wie
THC-Flüssigaerosol. Herstellung unter GMP-Bedingungen in der Insel-
spital-Apotheke.
Die Verblindung der beiden Flüssigaerosole übernimmt ebenfalls die Insel-
spital-Apotheke.
• THC-Injektionslösung:
- Rezeptur: 10 mg THC, 150.0 mg Polysorbatum 80 (Tween“ 80), 10.0
mg Natriumascorbat, Ethanol abs. 500 mL, NaCl 0.9% pH 7.4 ad
10.0 mL. Die 0.1%-Injektionslösungen werden jeweils kurz vor den
Versuchen unter GMP-Bedingungen in der Inselspital-Apotheke
frisch hergestellt und sterilfiltriert. Die Qualitätskontrolle (THC-
Gehaltsbestimmung) erfolgt im DKF.
- Dosierung: 0.053 mg THC pro kg KG (4 mg THC  pro 75 kg).
3.4 Studienablauf
•  Die Studie wird in den Räumlichkeiten der Clinical Investigation Unit
(CIU) am Inselspital Bern unter der Überwachung eines Arztes und
einer Forschungsschwester durchgeführt. Eine Session dauert jeweils
9h (8-17h).
•  Session 1: Trainingsversuch (Instruktion Inhalationsinstrument/          
-technik) mit Placebo-Flüssigaerosol; anschliessend Verum- oder
Placeboversuch mit 0.053 mg THC pro kg KG (4 mg THC pro 75 kg)
pulmonal in Form von 2.2 mL THC-Flüssigaerosol oder 2.2 mL Placebo-
Flüssigaerosol. Die standardisierte Applikation (1 Zug/10 sec, 10 min
Inhalationsdauer) erfolgt mittels eines druckluftbetriebenen Vernebler-
gerätes (PariMaster“-LC Plus). 5 min vor (Basislinie), 5, 10, 20, 40, 60,
5120, 240 und 480 min nach Applikation werden mittels eines Venen-
katheters 5-10 mL Blut entnommen, zentrifugiert und sofort tiefgefro-
ren. Zum Zeitpunkt der Blutentnahmen werden jeweils ein Analgesie-
Test (Eiswasser) sowie ein Nebenwirkungs-Monitoring (Vitalfunktionen,
Lungenverträglichkeit, psychotrope Effekte etc. !  Beilage) durch-
geführt.
• Session 2: 0.053 mg THC pro kg KG (4 mg THC pro 75 kg) pulmonal in
Form von 2.2 mL THC-Flüssigaerosol oder 2.2 mL Placebo-
Flüssigaerosol. Blutentnahmen und Messungen wie bei Session 1.
• Session 3: 0.053 mg THC pro kg KG (4 mg THC pro 75 kg) in Form einer
intravenösen Injektionslösung (10 mg THC/10 mL). Blutent-nahmen
und Messungen wie bei Session 1.
• Bioanalytik und pharmakokinetisches Profiling: Quantifizierung des THC
und seiner Hauptmetaboliten (11-Hydroxy-THC, 11-Nor-Carboxy-THC)
in Plasma mittels Gaschromatographie-Massenspektrometrie. Auf Basis
der resultierenden THC-Plasmakonzentrations-Zeit-Profile werden
dann dessen Areas Under the Curve (AUC), Bioverfügbarkeit (F),
Plasma-peaks (Cmax), Zeitpunkt der Plasmapeaks (tmax), terminale
Plasmahalb-wertszeiten (t1/2z), Verteilung (V) und Clearence (CL)
berechnet.
Bern, den   /   / 2002 Prof. Dr. pharm. R. Brenneisen
DKF
(Studienleiter)
Bern, den   /   / 2002 Dr. med. S. Russmann
CIU
(Prüfarzt)
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Zusammenfassung
1. Einleitung
Bei der geplanten Phase-I Studie mit 2 neuen THC-Applikationsformen
handelt es sich um die Fortsetzung der Schmerzlaborstudie „The
analgesic effect of delta-9-tetrahydrocannabinol alone and in combination
with morphine in healthy subjects“ (Projekt Nr. 195/98, 7.12.1998).
Nachdem sich im Rahmen dieser Schmerzlaborstudie gezeigt hat, dass die
orale Applikation von THC in Form von Marinol“-Kapseln (synthetisches
THC) in pharmakokinetischer Hinsicht nicht ideal ist (intensiver
Lebermetabo-lismus, niedrige Bioverfügbarkeit etc.), drängt sich die
klinische Prüfung anderer, bevorzugt nicht invasiver Anwendungsformen
auf.
2. Ziel der Studie, Fragestellungen
Im Rahmen des geplanten Projektes soll nun ein in unserem Labor ent-
wickeltes THC-Flüssigaerosol pulmonal an 8 gesunden ProbandInnen im
Vergleich mit i.v. THC getestet werden. In den 3 Sessionen (Aerosol-
Verum, -Placebo, Injektionslösung) werden primär ein pharmakokineti-
sches Profiling sowie Nebenwirkungs-Monitoring durchgeführt. Mittels
Eisbadtest wird zudem doppelblind und vs. Placebo die analgetische
Wirkung gemessen.
23. Versuchsplan, -dauer
An dieser Phase-I Pilotstudie werden in 3 je 9-stündigen Sessionen 4
gesunde Probandinnen und 4 Probanden teilnehmen. Der klinische
Versuch findet in der Clinical Investigation Unit (CIU) des Inselspitals
unter Dauerüberwachung eines Arztes und einer Krankenschwester statt.
Die ProbandInnen erscheinen um 8 h nüchtern in der CIU, werden nach
der Trainingsphase (Instruktion Inhalationsgerät/-technik) venenkathetri-
siert und an den Monitor zur Messung der Vitalfunktionen (Blutdruck, Puls,
Sauerstoffsättigung) angeschlossen. Bei Probandinnen wird vor Versuchs-
beginn ein Schwangerschaftstest und bei allen VersuchsteilnehmerInnen
vor jeder Session ein Cannabis-Urintest durchgeführt. Um 8:30 h, nach
Sammeln der 1. Blutprobe (Baseline) sowie Ausfüllen der Nebenwirkungs-
protokolle (Visual Analog Scales, VAS), inhalieren die ProbandInnen unter
Doppelblindbedingungen und nach vorgängiger Anleitung mittels
Druckluft-Vernebler ein THC-Aerosol enthaltend 0.053 mg THC pro kg KG
(4 mg THC pro 75 kg) oder ein Placebo-Aerosol oder erhalten eine intra-
venöse Injektion von 0.053 mg THC pro kg KG (4 mg THC pro 75 kg). Über
einen Venenkatheter werden insgesamt 9 Blutproben zu je rund 10 mL
gesammelt, Nebenwirkungen mittels VAS erfasst und die Vitalfunk-tionen
aufgezeichnet. Zum Zeitpunkt der Blutentnahmen wird jeweils auch ein
Schmerztest (Eiswasser) durchgeführt.
Die Studie dauert voraussichtlich 8 Monate und soll im Juli 2002 oder
sofort nach Vorliegen der Bewilligungen (inkl. Swissmedic, BAG) beginnen.
4. Einschluss-, Auschlusskriterien
•  4 männliche und 4 weibliche, freiwillige, bezahlte ProbandInnen,
welche bereits an der Schmerzlaborstudie teilgenommen haben und
dem Studienleiter bekannt sind (DKF-Angehörige, Medizin-
studentInnen).
•  Einschlusskriterien: die ProbandInnen müssen gesund sein, über
intakte Lungenfunktionen verfügen und dürfen 48 h vor, während und
24 h nach dem Versuch keinen Alkohol, keine Drogen und Medikamente
3konsumieren. Bis 24 h nach dem Versuch sind das Führen von Fahr-
zeugen und das Bedienen von Maschinen nicht erlaubt. Die Proband-
Innen müssen die Einverständniserklärung unterschreiben, dies nach-
dem sie ausführlich über die Studie informiert worden sind und die
ProbandInnen-Information gelesen haben.
•  Ausschlusskriterien: Konsum von Alkohol, Drogen oder Medikamenten
(insbesondere Analgetica) vor und/oder während der Studie; positiver
Cannabisnachweis im Urin, Schwangerschaft.
5. Risikoabschätzung
Die Toxizität des THC ist extrem niedrig. Allenfalls auftretende Blutdruck-
und Pulsschwankungen sind harmlos. Unerwünschte psychische Effekte
(Sedation, Angst etc.) sind reversibel und treten erst in höheren Dosen
auf. Ein Abhängigkeitsrisiko besteht nur bei Langzeitanwendung hoher
Dosen und missbräuchlichem Konsum zu Rauschzwecken. Dies gilt auch
für das (seltene) Auftreten von Entzugssymptomen.
6. Studienleitung
Prof. Dr. pharm. Rudolf Brenneisen, Leiter Labor „Phytopharmakologie,
Bioanalytik und Pharmakokinetik“, Departement Klinische Forschung
(DKF).
Bern, den 13.6.2002 Prof. Dr. pharm. R. Brenneisen
DKF
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VersuchsteilnehmerInnen-Information
Einleitung und Zielsetzung
Die Cannabispflanze wird seit Jahrtausenden u.a. gegen Schmerzen und
Muskelkrämpfe eingesetzt. In der Schweiz, anderen europäischen
Ländern sowie in den USA ist in den letzten Jahren eine zunehmende
volksmedi-zinische Verwendung von Cannabisprodukten zu beobachten.
Eine ausreichende klinische Datenlage besteht allerdings nur für das in
den USA als Marinol“ registrierte Dronabinol (synthetisches delta-9-
Tetrahydro-cannabinol, THC). Nachteil der Marinol“-Kapseln ist der sehr
intensive, nach Resorption aus dem Darmtrakt rasch einsetzende Abbau
des THC in der Leber. Aus diesem Grunde sind alternative galenische
Applikations-formen notwendig, bei denen dieser Lebereffekt nicht
vorhanden oder weniger ausgeprägt ist. Die klinische Studie mit einem
pulmonal appli-zierten THC-Flüssigaerosol und einer intravenösen THC-
Injektionslösung, an der Sie nun teilnehmen, ist eine Folgestudie zur
2abgeschlossenen Schmerzstudie mit oral verabreichtem THC (Marinol“).
Sie soll primär dazu dienen, die Blutspiegel des THC und seiner
Metaboliten nach Inhalation und Injektion zu vergleichen, die
schmerzhemmende Wirkung anhand eines Kältetests zu messen sowie
allfällige psychische und physische Nebenwirkungen zu erfassen.
Versuchsablauf
An den jeweils 9 h (8-17 h) dauernden Versuchssessionen können
MedizinstudentInnen sowie Angehörige des DKF teilnehmen, welche nicht
alkohol-, medikamenten- oder drogenabhängig sind/waren und nicht
schwanger sind (Urintest). Vor Studienbeginn werden Sie in der Abteilung
für Pneumologie einem Lungenfunktionstest unterworfen. Vor jeder
Session wird ein Cannabis-Urintest durchgeführt.
Vor dem ersten Versuch durchlaufenen Sie eine Trainingsphase, die dazu
dient, Sie mit dem Inhalationsinstrument und der Inhalationstechnik
vertraut zu machen. Nach Anweisung inhalieren Sie dann unter standardi-
sierten Bedingungen (1 Zug/10 sec, 10 min Inhalationsdauer) mittels
eines druckluftbetrieben Verneblergerätes eine Lösung von 0.053 mg THC
pro kg Körpergewicht (entsprechend 4 mg THC pro 75 kg) oder eine
Lösung ohne Wirkstoff (Placebo) oder man injiziert Ihnen intravenös eine
Lösung von 0.053 mg THC pro kg (4 mg THC pro 75 kg). Zur Bestimmung
der Blutspiegel von THC und dessen Metaboliten werden über einen
Venenkatheter zu definierten Zeitpunkten pro Session insgesamt 9
Blutproben zu je 5-10 mL entnommen. Die Messung des schmerzhem-
menden Effektes erfolgt mittels Eiswasser-Test jeweils zum Zeitpunkt der
Blutentnahmen. Gleichzeitig werden anhand von Befragungsprotokollen
und Monitoren allfällige psychische und physische Nebenwirkungen
aufgezeichnet.
Während des ganzen Versuches ist ein Arzt und eine
Forschungsschwester anwesend. Selbstverständlich werden Sie während
3der gesamten Versuchsdauer von uns verpflegt. Der Versuch findet in der
Clinical Investigation Unit (CIU) des Inselspitals Bern statt.
Die aus dem Versuch gewonnenen medizinischen und persönlichen Daten
werden anonymisiert verarbeitet, sind vertraulich und nicht öffentlich
zugänglich. Die persönlichen Daten können aber von den zuständigen
Behörden und von befugten Personen während einer Inspektion
eingesehen und geprüft werden.
Nebenwirkungen
Die Toxizität des THC ist extrem niedrig. Allenfalls auftretende kardio-
vaskuläre Nebenwirkungen (Blutdruck- und Pulsveränderungen) sind
harmlos. Falls Probleme in der Nacht nach dem Versuch auftreten ! Tel.
Versuchsleiter: 031-352 41 25 od. 079-300 83 29. Unerwünschte
psychische, reversible Effekte (Sedation, Angst etc.) treten meist erst in
höheren Dosen auf. Ein Abhängigkeitsrisiko kann bei zweimaliger Appli-
kation ausgeschlossen werden.
Verpflichtung
Sie haben das Recht, jederzeit vom Versuch zurückzutreten. 48 h vor und
während des Versuches dürfen kein Alkohol sowie keine Medikamente
und Drogen eingenommen werden. Bis 24 h nach dem Versuch darf kein
Fahr-zeug gelenkt und keine Maschinen bedient werden.
Versicherung
Der Versuchsleiter Prof. Dr. R. Brenneisen ersetzt Ihnen Schäden, die Sie
gegebenenfalls im Rahmen des klinischen Versuchs erleiden. Zu diesem
Zweck hat Prof. Dr. R. Brenneisen zu Ihren Gunsten im Rahmen der
„Probandenversicherung der Universität Bern“ eine Versicherung bei der
„Allianz Suisse Versicherungen“ abgeschlossen.
4Entschädigung
Sie werden für die Versuchsteilnahme nach Beendigung der Session 3 mit
insgesamt 750 Franken entschädigt.
Bern, den 13. Juni 2002 Prof. Dr. R. Brenneisen
DKF
Versuchsleiter
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E I N V E R S T Ä N D N I S E R K L Ä R U N G
? Bitte lesen Sie dieses Formular sorgfältig durch.
? Bitte fragen Sie, wenn Sie etwas nicht verstehen oder wissen möchten.
Nummer der Studie :
Titel der Studie : Pharmakokinetik und -dynamik des pulmonal applizierten
delta-9-Tetrahydrocannabinols (THC-Flüssigaerosol)
Ort der Studie : Dep. Klinische Forschung (DKF), Universität Bern und Clinical
Investigation Unit (CIU), Inselspital Bern
Stud.leiter, Prüfarzt : Prof. Dr. pharm. R. Brenneisen, Dr. med. S. Russmann
Versuchsperson :
Geburtsdatum : Geschlecht :
? Ich wurde vom unterzeichnenden Arzt mündlich und schriftlich über die Ziele, den Ablauf der
Studie mit THC-Aerosolen und -Injektionslösungen, über die zu erwartenden Wirkungen,
über mögliche Vor- und Nachteile sowie über eventuelle Risiken informiert.
? Ich habe die zur oben genannten Studie abgegebene schriftliche Information vom 13.6.2002
gelesen und verstanden. Meine Fragen im Zusammenhang mit der Teilnahme an dieser
Studie sind mir zufriedenstellend beantwortet worden. Ich kann die schriftliche Information
behalten und erhalte eine Kopie meiner schriftlichen Einverständniserklärung.
? Ich hatte genügend Zeit, um meine Entscheidung zu treffen.
? Ich bin darüber informiert, dass eine Versicherung Schäden deckt, falls solche im Rahmen
der Studie auftreten.
? Ich bin einverstanden, dass die zuständigen Fachleute des Studienauftraggebers, der
Behörden und der Ethikkommission zu Prüf- und Kontrollzwecken in meine Originaldaten
Einsicht nehmen dürfen, jedoch unter strikter Einhaltung der Vertraulichkeit.
? Ich nehme an dieser Studie freiwillig teil. Ich kann jederzeit und ohne Angabe von Gründen
meine Zustimmung zur Teilnahme widerrufen, ohne dass mir deswegen Nachteile bei der
weiteren medizinischen Betreuung entstehen. In diesem Fall werde ich zu meiner
Sicherheit abschliessend medizinisch untersucht.
?  Ich bin mir bewusst, dass während der Studie die in der Information genannten
Anforderungen und Einschränkungen einzuhalten sind. Im Interesse meiner Gesundheit
kann mich der Prüfarzt jederzeit von der Studie ausschliessen.
Bern, den Unterschrift der Versuchsperson
Bern, den Unterschrift des Studienleiters
Bern, den Unterschrift des Prüfarztes
thc-neurol/kek-informedconsent/9.8.2002
THC-Kinetik-Studie
Proband/in: Nr.
Versuchsdatum:
Session:
Messzeitpunkt: t 0
Nebenwirkungen-0
Bitte beantworten Sie folgende Fragen durch Markierung der skalierten
Linie mit einem Strich (falls 0% oder 100% zutreffen, bitte entsprechend
einkreisen):
1. Ich fühle mich angenehm ruhig und entspannt.
0% 100%
überhaupt nicht sehr stark
2. Ich kann mich gut konzentrieren.
0% 100%
überhaupt nicht sehr stark
3. Ich fühle mich schläfrig.
0% 100%
überhaupt nicht sehr stark
4. Ich fühle mich euphorisch.
0% 100%
überhaupt nicht sehr stark
25. Ich fühle mich verstimmt.
0% 100%
überhaupt nicht sehr stark
6. Ich habe Angstgefühle.
0% 100%
überhaupt nicht sehr stark
7. Ich fühle mich innerlich gespannt, aggressiv.
0% 100%
überhaupt nicht sehr stark
8. Ich fühle mich verwirrt, desorientiert.
0% 100%
überhaupt nicht sehr stark
9. Ich nehme mich selbst als verändert wahr.
0% 100%
überhaupt nicht sehr stark
10. Ich nehme meine Umgebung als verändert wahr.
0% 100%
überhaupt nicht sehr stark
311. Ich habe optische, akustische oder andere Halluzinationen .
0% 100%
überhaupt nicht sehr stark
12. Ich nehme Stimmungen, Gedanken, innere Bilder wahr,
die mir nicht vertraut sind.
0% 100%
überhaupt nicht sehr stark
13. Ich empfinde Übelkeit.
0% 100%
überhaupt nicht sehr stark
14. Ich habe Kopfschmerzen.
0% 100%
überhaupt nicht sehr stark
15. Ich habe Atembeschwerden.
0% 100%
überhaupt nicht sehr stark
16. Ich habe Husten / Hustenreiz.
0% 100%
überhaupt nicht sehr stark
417. Meine Atemwege sind irritiert / gereizt / brennen.
0% 100%
überhaupt nicht sehr stark
18. Ich habe Herzbeschwerden ( z.B. Herzrasen, Herzstechen)
0% 100%
überhaupt nicht sehr stark
19. Ich habe Magen-, Darmbeschwerden .
0% 100%
überhaupt nicht sehr stark
20. Ich empfinde Mundtrockenheit.
0% 100%
überhaupt nicht sehr stark
21. Ich habe Schwindelgefühle.
0% 100%
überhaupt nicht sehr stark
22. Ich habe andere Beschwerden, nämlich :
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III. Typical chromatogram of the determination of THC and its metabolites in plasma of
the pain study
Appendix III: Typical chromatogram of the determination of THC and its metabolites in plasma of the pain study.
A: blank plasma, ion 371; B: real sample (oral 60 min), ion 371; C: blank plasma spiked with internal
standard, ion 374.
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IV. Typical chromatogram of the determination of THC and its metabolites in plasma of
the pharmacokinetic study
Appendix IV: Typical chromatogram of the determination of THC and its metabolites in plasma of the kinetic study.
A: blank plasma, ion 371; B: real sample (i.v. 10 min), ion 371; C: blank plasma spiked with internal
standard, ion 374.
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V. Paper pain study
The analgesic effect of oral delta-9-tetrahydrocannabinol (THC),
morphine, and a THC-morphine combination in healthy
subjects under experimental pain conditions
Myrtha Naefa, Michele Curatolob, Steen Petersen-Felixb, Lars Arendt-Nielsenc,
Alex Zbindenb, Rudolf Brenneisena,*
aDepartment of Clinical Research, University of Bern, Murtenstrasse 35, CH-3010 Bern, Switzerland
bDepartment of Anaesthesiology, University Hospital of Bern, Murtenstrasse 35, CH-3010 Bern, Switzerland
cCenter for Sensory-Motor Interaction, University of Aalborg, DK-9220 Aalborg, Denmark
Received 27 September 2002; received in revised form 5 March 2003; accepted 4 April 2003
Abstract
From folk medicine and anecdotal reports it is known that Cannabis may reduce pain. In animal studies it has been shown that delta-9-
tetrahydrocannabinol (THC) has antinociceptive effects or potentiates the antinociceptive effect of morphine. The aim of this study was to
measure the analgesic effect of THC, morphine, and a THC-morphine combination (THC-morphine) in humans using experimental pain
models. THC (20 mg), morphine (30 mg), THC-morphine (20 mg THC þ 30 mg morphine), or placebo were given orally and as single
doses. Twelve healthy volunteers were included in the randomized, placebo-controlled, double-blinded, crossover study. The experimental
pain tests (order randomized) were heat, cold, pressure, single and repeated transcutaneous electrical stimulation. Additionally, reaction time,
side-effects (visual analog scales), and vital functions were monitored. For the pharmacokinetic profiling, blood samples were collected. THC
did not significantly reduce pain. In the cold and heat tests it even produced hyperalgesia, which was completely neutralized by THC-
morphine. A slight additive analgesic effect could be observed for THC-morphine in the electrical stimulation test. No analgesic effect
resulted in the pressure and heat test, neither with THC nor THC-morphine. Psychotropic and somatic side-effects (sleepiness, euphoria,
anxiety, confusion, nausea, dizziness, etc.) were common, but usually mild.
q 2003 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
Keywords: Delta-9-tetrahydrocannabinol; Morphine; Experimental pain; Antinociception; Plasma levels; Pharmacokinetics
1. Introduction
From the folk medicine and anecdotal reports it is known
that Cannabis may reduce pain. It is widely used in self-
medication to relieve pain of different origins such as back
pain, headache, and migraine (Ogborne et al., 2000).
Several animal studies have shown the analgesic effect of
delta-9-tetrahydrocannabinol (THC) in different pain
models (Lichtman and Martin, 1997; Smith et al., 1998a;
Vivian et al., 1998). In mice, subcutanously (s.c.) and orally
(p.o.) administered THC enhanced the antinociceptive
effect of s.c. and p.o. morphine in the tail-flick and also in
the paw-pressure test (Smith et al., 1998b). Again in mice,
an inactive p.o. dose of THC (20 mg/kg) enhanced the
antinociception of opioids 2.2- (for morphine) to 25.8-fold
(for codeine, shift in ED50) in the tail-flick test (Cichewicz
et al., 1999).
Few human trials have been conducted and the results
were equivocal (Campbell et al., 2001). Oral doses of 15 and
20 mg THC resulted in a significant reduction of cancer pain
(Noyes et al., 1975a). In another clinical study, the analgesic
potency of THC in cancer pain was compared with codeine.
The analgesic effect of 20 mg p.o. THC corresponded to that
of 120 mg p.o. codeine (Noyes et al., 1975b). Intravenously
administered THC did not affect pain tolerance thresholds in
dental surgical pain (Raft et al., 1977). In a double-blind,
placebo-controlled, crossover trial on a chronic pain patient
suffering from familial Mediterranean fever five doses of
10 mg p.o. THC (as standardized Cannabis preparation,
0304-3959/03/$20.00 q 2003 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
doi:10.1016/S0304-3959(03)00163-5
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containing 5.75% THC) per day did not reduce pain
(Holdcroft et al., 1997). However, it significantly reduced
the need for morphine (10 mg per dose) given as escape
medication indicating an additive effect of THC on morphine.
Some patients claim that Cannabis is more effective than
THC (e.g. dronabinol, Marinolw) for a variety of symptoms,
including nausea and vomiting, wasting syndrome, and
muscle spasticity (Grinspoon and Bakalar, 1997; Joy et al.,
1999). However, most of these claims are based on patient
reports and surveys, and have not been verified by
controlled clinical trials (Wachtel et al., 2002). To the best
of our knowledge, no comparative data exist of the analgesic
effect of THC and Cannabis. A recent study compared the
subjective effects of orally administered and smoked THC
alone and THC within Cannabis preparations (brownies,
cigarettes) (Wachtel et al., 2002). THC and Cannabis in both
application forms produced similar, dose-dependent sub-
jective effects, and there were few reliable differences
between the THC-only and whole-plant conditions. In
studies on volunteers and a multiple sclerosis patient it was
shown that cannabidiol (CBD) reduces the psychotropic
effects of THC (Zuardi et al., 1982, 1995) and a Cannabis
based medicinal extract (Notcutt et al., 2001), respectively.
This could explain anecdotal reports from patients who
prefer the milder forms of Cannabis containing significant
levels of CBD (Notcutt et al., 2001). A review of the
antianxiety effects and the pharmacology of CBD is given in
Partland and Russo (2001) and Mechoulam et al. (2002).
In experimental pain the results are controversial.
Smoked Cannabis increased pressure pain tolerance in
Cannabis-naı¨ve and Cannabis-experienced subjects com-
pared to placebo (THC-extracted Cannabis) (Milstein et al.,
1975). In a radiant heat test experienced Cannabis users
reported a mild antinociceptive effect when smoking
Cannabis cigarettes (Greenwald and Stitzer, 2000). In
thermal pain p.o. THC showed in healthy subjects with
moderate side-effects a reduction of pain and in subjects
experiencing a ‘bad trip’ hyperalgesia (Zeidenberg et al.,
1973). In the transcutaneous electrical stimulation pain
model, smoked Cannabis had no analgesic effect, it even
produced a slight hyperalgesia (Hill et al., 1974).
It was the aim of the present study to test the anti-
nociceptive effects of oral THC and THC combined with
morphine (THC-morphine) versus morphine and placebo in
healthy subjects and under experimental pain conditions.
Plasma profiles were acquired to study the pharmaco-
kinetics of THC and look for a possible correlation with
analgesia and side-effects.
2. Materials and methods
2.1. Subjects and study design
Twelve healthy, Cannabis-naı¨ve volunteers (six
females, age 25 ^ 7 years, weight 70 ^ 8 kg; six males,
27 ^ 11 years, 74 ^ 7 kg; all right handed) participated in
this randomized, placebo-controlled, double-blind, cross-
over study which was carried out in the pain laboratory
of the Department of Anaesthesiology at the University
Hospital of Bern. All pain tests were performed by the
same investigator. The subjects were informed about the
risks of the study, gave their written informed consent, and
were paid for participating. Exclusion criteria were past or
existing drug abuse (including alcohol and drugs; Cannabis
and opiate urine tests before each session), known or
suspected hypersensibility to cannabinoids or opioids,
pregnancy (urine test before first session). The subjects
were not allowed to take analgesics, alcohol, and
caffeinated beverages 48 h before and during the study
and were asked to refrain from driving up to 12 h after the
study. The study has been approved by the Ethics
Committee of the Faculty of Medicine, University of
Bern. Each subject received either 20 mg THC (dronabi-
nol, Marinolw soft gelatine capsules; Unimed Pharmaceu-
ticals, Inc., Deerfield, IL, USA), 30 mg morphine
hydrochloride (Schweizerhall Pharma, Basel, Switzerland),
a mixture of 20 mg THC and 30 mg morphine hydrochlo-
ride, or placebo as a single oral dose on empty stomach.
The blinding of the test medications was performed by
enclosing the 20-mg or placebo Marinolw capsules in
another, dark-colored gelatine capsule and adding either
30 mg mannitol or 30 mg morphine hydrochloride. The 30-
mg morphine capsules were similarly prepared. Caffeine-
free beverages were allowed 1 h, and light, but not
standardized meals 3 h post-dosing.The between-session
washout phases were at least 7 days. To get the subjects
familiar and comfortable with the testing procedures, each
session began with a training phase. Then the baselines
were recorded and the pain tests performed in a random
order every hour up to 8 h post drug. Pressure and heat pain
were not determined at timepoints 5,6 and 7h post drug to
present skin damage. Side-effects were monitored before
each set of pain tests. Blood (5–10 ml) was collected in all
four sessions through a peripheral vein catheter at baseline,
0.5, 1, 2, 4, and 8 h post drug. The heparinized blood
samples were centrifuged and the plasma instantly deep-
frozen and stored at 2208C until analysis.
2.2. Pain tests
2.2.1. Pressure
Pressure pain tolerance thresholds were determined on
the center of the pulp of the second and third finger of the
right hand with an electronic pressure algometer (Somedic
AB, Stockholm, Sweden) (Brennum et al., 1989, 1992;
Petersen-Felix et al., 1994). A probe with a surface area of
0.28 cm2 was used, and the pressure increase was set to
30 kPa s21. Pain tolerance was defined as the point when the
subject felt the pain as intolerable. For determination of the
tolerance thresholds, the mean of two consecutive measure-
ments was used.
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2.2.2. Heat
The computer-driven Thermotest (Somedic AB, Stock-
holm, Sweden) was used (Fruhstorfer et al., 1976;
Arendt-Nielsen et al., 1996). A thermode with a surface of
25 £ 50 mm was applied to the volar surface of the forearm,
in the middle of a line joining the elbow to the wrist fold.
The temperature of the thermode was continuously
increased from 30 to a maximum of 528C at a rate of
2.08C s21. The subject was asked to press a button when
perceiving the heat as painful (pain detection) and when
feeling the heat as intolerable and not wanting the heat to be
further increased (pain tolerance). At that point the tem-
perature was recorded and the thermode cooled to 308C. The
thermode was also cooled to 308C in the case when the
tolerance threshold was not reached at 528C. 528C was then
considered as pain tolerance threshold. Three consecutive
measurements were performed for both pain detection and
tolerance thresholds. The average of the last two values
were computed and evaluated for data analysis.
2.2.3. Cold
A 2-min ice cold immersion test was used (Jones et al.,
1988; Sindrup et al., 1993; Petersen-Felix et al., 1994).
Before immersion, the skin temperature on the thenar of the
left hand was measured. The left hand was then immersed in
ice-saturated water (0.6 ^ 0.28C). If pain was felt as
intolerable (pain tolerance) before 2 min had elapsed, the
subject could withdraw the hand. Perceived pain intensity
was rated continuously with an electronic visual analogue
scale (VAS) and recorded on a personal computer. Peak
pain, area under the pain intensity-time curve, and mean
pain were determined. If the hand was withdrawn before the
end of 2 min, pain intensity was considered to be maximal
until the end of the 2-min period (for calculation of area
under the curve).
2.2.4. Transcutaneous electrical stimulation
(single, repeated)
Two bipolar surface Ag/AgCl-electrodes (Dantec, Skov-
lunde, Denmark) were placed on the shaved skin of the shin,
14 cm distal to the patella. The electrode surface was
7 £ 4 mm, and the distance between the two electrodes was
1.5 cm. A train of five square-wave impulses was delivered
from a computer-controlled constant current stimulator
(University of Aalborg, Denmark). Each of these impulses
lasted 1 ms. The whole duration of the train of five impulses
was 25 ms, so they were perceived as a single stimulus. For
the single electrical stimulation this train was given once,
and for the repeated electrical stimulation this train was
repeated five times, at the same intensity and a frequency of
2 Hz (i.e. every 0.5 s) (Arendt-Nielsen et al., 1994; Curatolo
et al., 2000). The current intensity was increased stepwise
1 mA until the stimulus was perceived as painful. For the
single electrical stimulation the pain detection threshold
was defined as the minimum stimulus intensity eliciting a
subjective pain. For the repeated electrical stimulation
the pain detection threshold was defined as the minimum
stimulus intensity eliciting a subjective increase in
perception during the five stimulations, so that the last one
to two impulses were perceived as painful.
2.3. Monitoring of side-effects and vital functions
A 10-cm VAS was used to assess psychological
(euphoria, hallucinations, disorientation, altered perception,
etc.) and somatic side effects (heart and digestive problems,
etc.). The episodes of vomiting were noted. Hemoglobin
oxygen saturation (pulse oximetry), blood pressure, and
heart rate were recorded. To determine the reaction time, a
1000 Hz tone was delivered from a computer with random
intervals of 3–8 s, and simultaneously a timer was started.
The volunteer was told to press a button as fast as possible
after the tone. The reaction time was defined as the time
from the tone until the subject pressed the button. The mean
value of five consecutive measurements was calculated.
2.4. Bioanalytics
Plasma concentrations of THC and its metabolites
11-nor-9-carboxy-THC (11-COOH-THC) and 11-hydroxy-
THC (11-OH-THC) were determined by gas-chromato-
graphy/mass spectrometry (GC/MS) according to the
method of Feng et al. (2000). Plasma concentrations of
morphine and its metabolites morphine-6-glucuronide
(M-6-G) and morphine-3-glucuronide (M-3-G) were deter-
mined by high performance liquid chromatography (HPLC)
using a modified method described previously (Bourquin
et al., 1999). Major modifications involved: (i) the washing
(20 ml of 0.005 M carbonate buffer pH 9.3, 0.4 ml of
bidistilled water and 0.25 ml of acetonitrile-0.01 M phos-
phate buffer pH 2.1 40:60 v/v) and elution steps (1.0 ml of
acetonitrile-0.01 M phosphate buffer pH 2.1 10:90, fol-
lowed by 1.2 ml of acetonitrile-0.01 M phosphate buffer
pH 2.1 70:30) in the solid-phase sample extraction pro-
cedure; (ii) the HPLC column (125 £ 2 mm i.d. column and
a 8 £ 3 mm i.d. precolumn, both packed with Spherisorb-80
ODS-1 3 mm (Macherey-Nagel, Oensingen, Switzerland);
(iii) the multi-step gradient (0–5.5 min, 4% B, isocratic;
5.5–9 min, 4–15% B, linear; 9–9.2 min, 15–25% B linear;
9.2–18 min, 25% B, isocratic; 18–19 min, 25–100% B,
linear; 19–21 min, 100% B, isocratic; 21–22 min, 100–4%
B, linear. (A) Bidistilled water, containing 0.05% (v/v)
trifluoro acetic acid (TFA), (B) acetonitrile, containing
0.05% (v/v) TFA; reconditioning time 15 min, flow rate
300 ml/min); and (iv) detection and quantitation with a
fluorescence detector at 343 nm (excitation wavelength of
227 nm; 220 Hz; response time 0.5 s). The limit of
quantification (LOQ) for THC and its metabolites was
2 ng/ml for THC and 11-OH-THC and 10 ng/ml for
11-COOH-THC, respectively. The LOQ for morphine and
its metabolites was 10 ng/ml.
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2.5. Statistics
Statistical analysis was performed independently for
each pain test. Differences of the baseline values in the four
different sessions of each volunteer were excluded with
the Friedman’s test. Then we calculated for each session
the mean results of all subjects and time-points. The three
verum sessions were then compared to the placebo session
using the Wilcoxon signed ranks test. P , 0:05 was
considered as significant.
3. Results
3.1. Pain tests
3.1.1. Pressure test
In the pressure test, where pain tolerance thresholds were
measured, no significant analgesic effect of THC and THC-
morphine was observed compared to placebo (Fig. 1). On
the other hand, morphine alone increased the pain tolerance
significantly compared to placebo (P ¼ 0:01).
3.1.2. Heat test
THC did not produce any analgesic effect in the heat test,
neither alone nor in combination with morphine (data not
shown). Morphine alone had no effect.
3.1.3. Cold test
Fig. 2 represents the area under the pain-intensity time
curve (total pain) in the cold test (ice cold immersion test).
The area under the pain-intensity time curves of THC and
THC-morphine showed no significant difference compared
to placebo. Morphine alone significantly (P ¼ 0:014)
reduced the cold pain (AUC). THC alone showed an
increase of the pain (AUC), which was completely
neutralized when combining with morphine. This hyper-
algesia was not significant. The same effect was observed
for the mean pain value. The peak pain value was signi-
ficantly reduced by morphine (P ¼ 0:017) and THC-
morphine (P ¼ 0:046) but not with THC alone.
3.1.4. Transcutaneous electrical stimulation
In the single mode of the transcutaneous electrical
stimulation (Fig. 3A), no significant analgesic effect of THC
and THC-morphine was observed. However, a slight addi-
tive effect of THC-morphine compared to morphine alone at
most of the measuring time points could be seen. Morphine
significantly increased the pain detection threshold
(P ¼ 0:008). In the repeated mode (Fig. 3B) THC-morphine
was again additively effective in the pain detection com-
pared to morphine alone and even produced a statistically
significant analgesic effect compared to placebo
(P ¼ 0:042). THC alone did not significantly reduce pain.
It again caused a slight, not significant hyperalgesia in
the second part of the session (timepoint 4 h up to 8 h post
drug) compared to placebo.
3.2. Side-effects and vital functions
The side-effects, summarized in Table 1, were usually
mild. Most of the subjects felt sleepy (Fig. 4) and confused
after the administration of THC and THC-morphine. They
also reported altered inner (Fig. 5) and outer perception,
feelings of anxiety and aggression. Interestingly, the
euphorigenic and hallucinogenic effects of THC were
reduced when combining with morphine. Other side-effects
were nausea and vomiting, dizziness, headache, reduced rate
of breathing, tachycardia, and dry mouth. The reaction time
was not significantly impaired with any of the test substances.
Fig. 1. Pain tolerance of THC, morphine, THC-morphine, and placebo in the pressure test; values.100% of baseline (mean ^ SEM) indicate analgesia, values
,100% hyperalgesia. The effect of morphine was statistically significant versus placebo.
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Systolic (116 ^ 4–101 ^ 3 mmHg) as well as diastolic
blood pressure (65 ^ 3–54 ^ 2 mmHg) decreased signifi-
cantly only after THC-morphine compared to placebo. With
63 ^ 3–87 ^ 4 THC alone increased significantly the heart
rate, whereas the hemoglobin oxygen saturation was only
significantly reduced after THC-morphine.
3.3. Plasma levels
Fig. 6 shows the plasma profiles of THC and its main
metabolites after 20 mg oral THC. The THC plasma
levels ranged from 1.1 ^ 0.8 to 7.2 ^ 2.0 ng/ml (mean ^
SEM), with the maximum concentrations at 60 or
120 min. The 11-OH-THC plasma levels were
0.3 ^ 0.3 – 19.7 ^ 2.0 ng/ml, mostly peaking at
120 min, and the 11-COOH-THC levels 1.7 ^ 1.8–
241.4 ^ 21.1 ng/ml, peaking at 120 or 240 min. After
administration of THC-morphine the THC, 11-OH-THC
and 11-COOH-THC levels were 4.0 ^ 1.4–6.7 ^ 2.1,
0.2 ^ 0.2–7.9 ^ 2.4 and 0–134.7 ^ 18.8 ng/ml, respect-
ively. THC and metabolites were not detectable in any of
the baseline samples.
Fig. 2. Pain tolerance of THC, morphine, THC-morphine, and placebo in the cold test (ice cold immersion test); values .100% of baseline (mean ^ SEM)
indicate hyperalgesia, values ,100% analgesia. The effect of morphine was statistically significant versus placebo.
Table 1
Psychological and somatic side-effects (peak VAS %, mean ^ SEM of all subjects) after THC, morphine, THC-morphine, and placebo
Side effects Placebo THC Morphine THC-morphine
n VAS (%) n VAS (%) n VAS (%) n VAS (%)
Sleepiness 12 70 ^ 31 12 82 ^ 20 12 64 ^ 33 12 85 ^ 20
Euphoria 1 66 ^ 0 9 54 ^ 34 3 16 ^ 11 5 21 ^ 29
Irritation 1 12 ^ 0 5 44 ^ 34 1 6 ^ 0 5 28 ^ 31
Anxiety 0 4 54 ^ 43 0 – 3 22 ^ 32
Tenseness and aggressiveness 1 10 ^ 0 4 57 ^ 39 2 14 ^ 5 2 49 ^ 66
Confusion and disorientation 1 2 ^ 0 7 58 ^ 31 0 – 8 13 ^ 9
Change of inner perception 2 16 ^ 4 10 66 ^ 30 5 19 ^ 9 9 61 ^ 37
Change of outer perception 0 8 53 ^ 28 0 – 4 41 ^ 36
Hallucinations 0 6 64 ^ 29 0 – 5 39 ^ 37
Strange thoughts, ideas, moods 0 7 51 ^ 40 1 13 ^ 0 3 43 ^ 50
Nausea 0 5 25 ^ 17 3 27 ^ 7 6 11 ^ 8
Headache 2 23 ^ 8 6 63 ^ 28 5 33 ^ 33 5 36 ^ 29
Difficulties in breathing 0 6 30 ^ 33 2 18 ^ 17 4 22 ^ 23
Heart problems (tachycardia) 0 6 48 ^ 37 0 – 1 97 ^ 0
Digestive problems 0 5 25 ^ 19 3 13 ^ 12 4 8 ^ 6
Dry mouth 5 21 ^ 20 12 76 ^ 28 8 31 ^ 22 10 51 ^ 37
Vertigo 3 6 ^ 2 11 51 ^ 35 5 12 ^ 10 9 34 ^ 33
Vomiting 0 0 4 – 2 –
Orthostatic disorder 0 0 1 – 2 –
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As can be seen in Fig. 7 morphine undergoes like THC an
extensive metabolism resulting in the formation of the two
glucuronides M-6-G and M-3-G. Morphine plasma levels
of 0–11.2 ^ 1.8 ng/ml were measured after 30 mg of oral
morphine, with a peak at 60 min. M-6-G plasma con-
centrations were 10.5 ^ 5.2–97.5 ^ 15.1 ng/ml, mostly
peaking at 120 min. M-3-G plasma levels were 98.7 ^
25.5–707.9 ^ 67.3 ng/ml, with peaks from 60 to 120 min.
After administration of THC-morphine the morphine,
M-6-G, and M-3-G levels were 0–36.3 ^ 24.4, 13.2 ^
5.7–143.2 ^ 12.3 and 129.5 ^ 16.3–561.8 ^ 46.5 ng/ml,
respectively. Morphine and metabolites were not detectable
in any of the baseline samples.
4. Discussion
The multimodel, well established experimental pain test
battery (Petersen-Felix et al., 1998; Enggaard et al., 2001;
Luginbuhl et al., 2001) was used to cover different types of
pain. On one hand the more superficial pain in the electrical
stimulation and in the heat test, and on the other hand
Fig. 3. Pain detection of THC, morphine, THC-morphine, and placebo after (a) single and (b) repeated transcutaneous electrical stimulation; values.100% of
baseline (mean ^ SEM) indicate analgesia, values ,100% hyperalgesia. The effect of morphine was statistically significant versus placebo.
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the more deep pain in the pressure and cold test. Although
from a pharmacokinetic point of view not ideal, THC
encapsulated in sesame oil was used, as this oral formulation
is registered in some countries. The 8-h study period
enabled to register also effects at timepoints where mainly
the metabolites were present in the plasma.
THC did not produce analgesia to pressure stimulation.
Oddly, it seems to antagonize morphine analgesia. This
could be the result of a hyperalgesic effect of THC that has
not been detected with THC alone, but appeared when THC
was combined with morphine.
In the heat test (pain tolerance threshold) THC produced
a significant hyperalgesia. One problem in this test was the
temperature limit of 528C. There were some volunteers who
had already a baseline of 528C for the pain tolerance
threshold. A similar hyperalgesic effect of THC on thermal
pain was also reported in habitual marihuana users
participating in a pain study carried out with Cannabis
cigarettes (Clark et al., 1981). We recently found heat pain
to be inadequate for detecting opioid induced analgesia
(Luginbuhl et al., 2001). Hyperalgesia after THC was also
observed with the cold test. Interestingly, the combination
with morphine totally reversed this effect to an analgesic
effect, which was comparable to that of morphine. The cold
test is well-established to measure opioid-induced anal-
gesia, but it is unclear whether it is also suited for non-
opioid analgesics. Jones et al. showed the opiate sensitivity
of the cold test but also the apparent insensitivity of the
model for non-steroidal anti-inflammatory drugs (Jones
et al., 1988). We assume that hyperalgesia measured in the
cold test was due to an outlier which also caused the wide
variability.
Our findings indicate that the analgesic effect of
THC and morphine, which was in all our experiments
gender-independent, is much depending on the pain model
used. Luginbuhl et al. (2001) also reported that the experi-
mental pain profile differed in substances like alfentanil,
xenon, and nitrous oxide. This illustrates the benefit of a
multimodel stimulation in the investigation of the analgesic
properties of new drugs. None of the experimental pain tests
used in this study produces inflammation or tissue damage.
Different animal studies have shown an increased analgesic
effect of THC in models of inflammatory pain (Pertwee,
2001). It has previously been reported that in rats
Fig. 4. Side effect ‘sleepiness’ measured by visual analog scales (VAS %, mean ^ SEM) after THC, morphine, THC-morphine, and placebo.
Fig. 5. Side effect ‘change of inner perception’ (VAS %, mean ^ SEM) after THC, morphine, THC-morphine, and placebo.
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cannabinoid CB1 receptors are upregulated in chronic
neuropathic pain and therefore could lead to an increased
analgesic effect of THC in chronic pain (Siegling et al.,
2001). In a retrospective study with patients suffering from
chronic pain of different origins, three out of six patients
could reduce their pain to a satisfactory level with a dose of
THC of 5–20 mg/day, whereas the other three patients had
to stop the medication due to lack of analgesia or intolerable
side-effects (Elsner et al., 2001). Therefore, we cannot rule
out that THC would have an analgesic effect after induction
of inflammation, tissue or nerve damage.
The side-effects of THC were common and normally not
severe. There was one volunteer out of 12 who reported
disliking very much the psychotropic effects of THC. We
assume that a strong aversion to the psychotropic effect
leads to a discomfort and therefore possibly also to
increased sensitivity to pain. This phenomenon could be
observed in the ice cold immersion test where one subject
showed a nice correlation between hyperalgesia and
anxiety. Von Graffenried et al. (1978) found anxiety (and
also other psychological factors, like mood) to be a factor
that might be responsible for the unreliable results obtained
in experimentally induced pain in man especially for mild
analgesics. If anxiety towards pain tests played a role even
when not using psychotropic drugs, anxiety feelings
produced by the psychotropic THC could have an additional
influence on the outcomes of pain tests. Many of the
psychotropic side-effects of THC (e.g. euphoria, halluci-
nations, confusion) were lowered by combining with
morphine. On the other hand THC was also influencing
the side-effects of morphine. Nausea and vomiting was
decreased in the combination session compared to the
morphine session. This could be due to the antiemetic effect
of THC (Gralla, 1999; Soderpalm et al., 2001; Trame`r et al.,
Fig. 6. Plasma profiles (ng/ml, mean ^ SEM) of THC, 11-OH-THC and 11-COOH-THC after 20 mg oral THC.
Fig. 7. Plasma profiles (ng/ml, mean ^ SEM) of morphine, M-6-G and M-3-G after 30 mg oral morphine.
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2001). The reduction of this common side-effect of opioids
would be a great benefit in the therapy of chronic pain. The
typical psychotropic side-effects of THC made the true
blinding of the study impossible.
Although THC is almost completely absorbed (90–
95%) after oral administration (Wall et al., 1983; Unimed
Pharmaceuticals, 2001) the plasma profiles after 20 mg
THC are characterized by very low levels of THC and
high concentrations of the two main metabolites 11-OH-
THC and 11-COOH-THC. The levels were similar to
those measured in an earlier study after administration of
oral THC (Brenneisen et al., 1996). Due to the combined
effects of extensive first pass hepatic metabolism, pre-
systemic elimination in the gut, and high lipid solubility
(volume of distribution, V ¼ 10 l/kg), only 10–20% of a
dose is reaching the systemic circulation (Wall et al.,
1983; Unimed Pharmaceuticals, 2001; Brenneisen, 2002).
The metabolites are detectable already 30 min post drug
indicating the rapid liver first pass metabolism. The
microsomal hydroxylation is catalyzed by cytochrome
P450 isoenzymes (Harvey, 1999). 11-OH-THC is psy-
choactive whereas the dominating metabolite 11-COOH-
THC is inactive. In glucuronidated form the latter is the
main urinary excretion product of THC (Harvey 1999). A
correlation between the THC plasma levels and the
pharmacological profiles could only be observed related
to the side-effects. It is not known whether 11-OH-THC
has analgesic properties, too. It should be tested if another
application form of THC with a better bioavailability, for
example a pulmonally administered aerosol, could
increase the analgesic effect of THC. By avoiding or at
least reducing the first pass effect and thus the formation
of the psychotropic 11-OH-THC the unpleasant side-
effects of THC could be decreased. The plasma profiles
after the administration of 30 mg morphine showed only
low levels of morphine, but high (M-6-G) to very high
(M-3-G) concentrations of its metabolites. Like THC,
biotransformation by first pass metabolism starts within
min after administration. M-3-G is the dominating urinary
excretion product of morphine (Gyr et al., 2000), but only
M-6-G exhibits analgesic effects (Buetler et al., 2000).
In conclusion, in this study oral THC did not significantly
reduce experimentally-induced pain in healthy subjects.
Some analgesic effects were only observed when combining
THC with morphine. Psychotropic and somatic side-effects
were common, but not severe. The hypothesis that the
analgesic effectiveness of THC is increased by using
alternative application forms resulting in a better bioavail-
ability deserves further investigation.
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ABSTRACT: The aim of the present study was to develop a physiologically compatible
inhalation solution of delta-9-tetrahydrocannabinol (THC), and to compare the pharma-
cokinetic and analgesic properties of pulmonal THC versus pulmonal placebo and
intravenous (iv) THC, respectively. Eight healthy volunteers were included in this
randomized, double-blind, crossover study. The aqueous THC formulations were prepar-
ed by using a solubilization technique. iv THC (0.053mg/kg bodyweight), pulmonal THC
(0.053 mg/kg), or a placebo inhalation solution was administered as single dose. At
defined time points, blood samples were collected, and somatic and psychotropic side
effects aswell as vital functionsmonitored. An icewater immersion testwas performed to
measure analgesia. Using a pressure-driven nebulizer, the pulmonal administration of
the THC liquid aerosol resulted in high THC peak plasma levels within minutes. The
bioavailability of the pulmonal THC was 28.7 8.2% (meanSEM). The side effects
observedafter pulmonalTHCwere coughingand slight irritation of theupper respiratory
tract, verymild psychotropic symptoms, andheadache. The side effects after ivTHCwere
much more prominent. Neither pulmonal nor iv THC significantly reduced experimen-
tally induced pain.  2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm
Sci 93:1176–1184, 2004
Keywords: delta-9-tetrahydrocannabinol; pulmonary aerosol; injection; pharmacoki-
netics; analgesia
INTRODUCTION
Numerous indications for cannabis preparations
and delta-9-tetrahydrocannabinol (THC) have
been postulated, with marked differences in the
available supporting data. For applications such
as nausea and vomiting associated with cancer
chemotherapy, anorexia, and cachexia in HIV/
AIDS, and spasticity in multiple sclerosis and
spinal cord injury, there is strong evidence for
medical benefits.1–4 Relatively well-confirmed
effects were described related to painful condi-
tions, especially neurogenic pain, movement dis-
orders, asthma, and glaucoma.1 In folk medicine,
cannabis is widely used to relieve pain of differ-
ent origins, such as back pain, headache, and
migraine.5 Few human trials have been con-
ducted so far and the outcomes were equivocal.6
Fifteen to twenty milligrams of oral THC reduced
cancer pain significantly, with 20 mg of THC
corresponding to 120 mg of oral codeine.7,8
Intravenous (iv) THC did not affect pain tolerance
in dental surgical pain.9 Analgesia could not be
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confirmed in a previous pain study with healthy
subjects using oral THC (dronabinol, Marinol1)
and experimental pain models.10 Extensive first-
pass metabolism by the liver was observed lead-
ing to early and high THC metabolite plasma
levels. Additionally, the THC plasma peak con-
centrations showed a high interindividual var-
iability between 30 and 120 min.10 The
bioavailability of orally administered THC is
known to be low (6–20%) and to depend on the
vehicle and co-ingested food.11 The peak plasma
levels, occurring at 1–5 h after administration,
show a strong, also vehicle- and food-dependent
variability.11 After eating cannabis cookies, the
bioavailability of THC was 6%,12 whereas when
using THC dissolved in sesame oil in soft gelatin
capsules, it was 11 (women) to 19% (men).13
These factors make it very difficult to dose oral
THC. There is a need for alternative application
forms with better pharmacokinetic properties.
Ohlsson et al.12 studied the pharmacokinetic
behavior of THC and its clinical effects after iv
administration, oral ingestion of cannabis cookies,
and smoking cannabis cigarettes. Plasma levels
after smoking and iv injection were similar, but
low and irregular after ingestion. Peak plasma
levels after smoking occurred rapidly and the bio-
availabilitywas found to bemuchhigher (18–50%)
than after oral (6–20%) administration.11,12 For a
rapid onset of action, theUnited States Institute of
Medicine recommended the development of reli-
able, and safe THC delivery systems for clinical
trials with cannabinoid drugs for symptom man-
agement.14 To the best of our knowledge, there are
neither pharmacokinetic data of pulmonally admi-
nistered THC in humans, except for smoked
cannabis, nor data from cannabis-naı¨ve subjects.
Therefore, the aim of the present study was to
develop and validate in vitro and in vivo a
physiologically tolerable inhalation solution that
could be administered with a commercially avail-
able nebulizer. In addition, this new application
form should be easy to handle, lead to a higher
bioavailability as well as early peak plasma levels
of THC, and consequently show a rapid onset of
action.
EXPERIMENTAL
Materials
The clinical test compound THC (dronabinol) was
supplied by THC Pharm GmbH (Frankfurt am
Main, Germany). Cremophor1 RH 40 was pro-
vided from BASF AG (Ludwigshafen, Germany);
all other chemicals were of pharmaceutical qual-
ity obtained by the pharmacy of the University
Hospital of Bern. THC and THC-d3 used for
plasma analysis were obtained from Lipomed
(Arlesheim, Switzerland), and ()-11-hydroxy-
D9-THC (11-OH-THC), ()-11-hydroxy-D9-THC-
d3 (11-OH-THC-d3), ()-11-nor-9-carboxy-D9-THC
(11-COOH-THC), and ()-11-nor-9-carboxy-D9-
THC-d3 (11-COOH-THC-d3) were from Radian
(Austin, TX). All solvents were of high-perfor-
mance liquid chromatography (HPLC) grade and
purchased either fromMerck (Basel, Switzerland)
or Fluka Chemie (Buchs, Switzerland). Bac-
terial b-glucuronidase (Escherichia coli, type
IX-A) and N,O-bis(trimethylsilyl) trifluoraceta-
mide (BSTFA) containing 1% trimethylsilyl chlor-
ide (TMCS) were obtained from Sigma-Aldrich
(Buchs, Switzerland) and Fluka Chemie, re-
spectively. The solid phase extraction columns
(Bakerbond SPE octadecyl cartridges) were pur-
chased from Stehelin (Basel, Switzerland). Roche
OnTrak TesTstiks (Roche Diagnostics, Rotkreuz,
Switzerland) with a cut-off of 50 ng/mL were used
for urine cannabis testing.
Subjects and Study Design
Eight healthy, cannabis-naı¨ve, nonsmoking vol-
unteers (four women, aged 26–35 years, body
weight 60 8 kg; four men, 27–50 years, 80
5 kg) were accepted for this randomized, placebo-
controlled, double-blind, crossover study which
was performed at the Clinical Investigation Unit
of the University Hospital of Bern. The subjects
were informed about the risks of the study, gave
their written informed consent, and were paid
for participating. Exclusion criteria were past or
existing drug abuse (including alcohol and pre-
scription drugs; cannabis urine test before each
session), pregnancy (urine test before first session),
positive past history of any psychiatric disorders,
and lung diseases. Each subject had to pass lung
function tests including vital capacity and forced
expiratory volume in 1 s. The subjects were not
allowed to take analgesics, alcohol, and caf-
feinated beverages 48 h before and during the
study and were asked to refrain from driving up to
24 h after the end of the study. The study was
approved by the Regional Ethics Committee,
the Swiss Agency for Therapeutic Products
(Swissmedic), and the Swiss Federal Office for
Public Health. In the first and second session, each
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subject received randomly and double-blinded
either the THC (0.053 mg/kg body weight) or the
placebo inhalation aerosol. In the third session,
THC was administered iv (0.053 mg/kg body
weight) over a time period of 2 min. The
between-session washout phases were at least
7 days. To familiarize the subjects with the pain
test and visual analog scales (VAS), each session
began with a training phase, during which the
subjects performed a pain test and a 5-min
inhalation training with the placebo aerosol. This
was followed by recording the baseline of vital
functions, side effect scores (VAS), and pain test.
After administration of the THC and placebo
preparations, vital functions and side effects were
recorded and ice water pain determined at 20, 40,
60, 120, 240, and 480 min. Blood (5 mL per time
point, corresponding to 45 mL per session, and
135 mL per study) was collected in all three
sessions through a peripheral venous catheter
from a forearm vein at baseline, 5, 10, 20, 40, 60,
120, 240, and 480 min after administration of the
test medications. The heparinized blood samples
were centrifuged and the plasma instantly deep-
frozen and stored at 208C until analysis.
Preparation and Validation of the
Test Medications
TheTHC inhalation solution consisted of 0.3% (w/
v) of THC, 5.0% (w/v) Cremophor1 RH 40, 1.0%
(v/v) benzyl alcohol, 0.05% (w/v) sodium ascor-
bate, and 84.2 mM sodium phosphate buffer (pH
7.4). THC and Cremophor1 RH 40 were heated in
a water bath at 638C for 10 min. Two-third of the
phosphate buffer, also heated at 638C, was then
incorporated in the mixture by shaking. After
cooling to room temperature, benzyl alcohol,
sodium ascorbate, and the remaining phosphate
buffer were added to the mixture. The clear,
yellowish solution was then sonicated for 30 s and
finally filtrated through a 0.22-mm filter under
aseptic conditions. The placebo inhalation solu-
tion was prepared like the THC solution. The
THC content and the stability of THC in the
inhalation solution, stored at 48C and protected
from light, was controlled by HPLC with diode
array detection (HPLC-DAD). The THC content
had to be within a range of 5% of the initial
value. Osmolality, viscosity, pH, and sterility
were measured according to the standards of the
European Pharmacopeia.15 For the in vitro vali-
dation of the nebulizer system and the liquid
aerosol, the pressure-driven PARI1Master appa-
ratus (Labhardt, Basel, Switzerland) was con-
nected to the tubing followed by the interrupter
and the PARI1 LC-Plus nebulizer equipped with
an inspiratory valve. The nebulizer itself was
connected to a PARI1 filter set containing a filter
pad collecting the aerosol. The filter set was then
connected to a 3-L calibration hand pump (3-L
Calibrated Syringe; Sensor Medics Corporation,
Yorba Linda, CA). Samples of 2 and 3 mL
(n¼ 3 each) were nebulized. The inhalation was
simulated manually with the hand pump (velocity
1 pull/10 s). The aerosol absorbed on the filter pad
was then extracted with ethanol, lyophilized,
redissolved in ethanol, and analyzed by HPLC-
DAD. The particle size distribution was de-
termined by using a Malvern Mastersizer X
equipped with a 100-mm lens and Malvern Soft-
ware, Malvern, UK (using the algorithm for
volume distribution, polydisperse aerosol, and
the 2QAA-model representing water in air). To
minimize light scattering, the room was darkened
during the measurements. Temperature and
humidity were kept constantly at 238C and 40%,
respectively. For the sample analysis, the inhala-
tion solution was nebulized continuously into the
laser beam and continuously removed by a
vacuum cleaner. The obscuration was held on a
value of approximately 10–30%. The particle size
distribution was measured in the vehicle (n¼ 10)
and in the THC liquid aerosol (n¼ 5). The
injection solution consisted of 0.1% (w/v) of THC,
1.5% (w/v) Tween1 80, 5.0% (v/v) ethanol abso-
lute, 0.1% (w/v) sodium ascorbate, and sodium
chloride solution (0.9%).16 Sodium ascorbate was
added to prevent the oxidation of THC to
cannabinol. THC was dissolved in ethanol and
Tween1 80, then added to the sodium ascorbate
dissolved in 1 mL of the sodium chloride solution.
The remaining sodium chloride solution was
finally added to the mixture. The clear, yellowish
solution was then sonicated for 30 s and filtrated
through a 0.22-mm filter under aseptic conditions.
Inhalation Procedure
The pressure-driven inhalation device PARI1
Master and the PARI1 LC-plus nebulizer with
interrupter were used. The subjects were
instructed to inhale deeply with a breath fre-
quency of 1 breath per 10 s waiting for 3–5 s
before expiration. The subjects were instructed to
continue until all the inhalation solution had been
inhaled. Inhalation time and any residue left in
the nebulizer compartment were measured.
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Pain Test
A standardized 2-min ice water test (ice cold
immersion test) was used as model for acute
pain.17–19 The right hand was immersed in ice-
saturated water (1.6 0.048C) and if pain was
considered as intolerable before 2 min had
elapsed, the subject could withdraw the hand.
Perceived pain intensity was rated continuously
with an electronically controlled VAS system and
recorded on a computer. Peak pain, area under
the pain intensity-time curve, and mean pain
were determined. If the hand was withdrawn
before the end of 2 min, pain intensity was
considered to be maximal until the end of the
2-min period (for calculation of the area under the
curve).
Monitoring of Side Effects
A VAS was used to asses psychological and
somatic side effects, such as sedation, euphoria,
anxiety, nausea, vertigo, headache, irritation of
airways, etc. The volunteers were instructed to
report how they felt at the moment of answering
the VAS questionnaire. On the 10-cm VAS scale,
0 cm (0%) represented ‘‘not at all,’’ 10 cm (100%)
represented ‘‘very strong.’’ Hemoglobin oxygen
saturation (pulse oximetry), blood pressure, and
heart rate were recorded by using an HP 78352C
patient monitoring system from Hewlett Packard.
Statistical Analysis
The Wilcoxon matched-pairs signed-rank test for
nonparametric data was used for comparison of
the side effects in the pulmonary application ses-
sions. p< 0.05 was considered as significant. No
statistical comparison was made with the results
from the iv session because this THC application
was not blinded. Analyses were performed in
STATA, version 8.1 for MacOS X (STATA Corp.,
College Station, TX).
Analysis of Plasma Samples
Plasma concentrations of THC and its metabolites
11-OH-THC and 11-COOH-THC were determin-
ed by gas chromatography/mass spectrometry.
Extraction of the 0.5-mL plasma aliquots was
performed automatically by using an ASPEC XL
(Automatic Sample Preparation with Extraction
Columns) system equipped with a Dilutor 402
(Gilson, Villiers Le Bel, France) and applying the
method of Moeller et al.20 Hydrolyzation, deriva-
tization, and gas chromatography/mass spectrom-
etry analysis were performed according to the
method of Feng et al.21 The method was linear in
the following calibrated ranges: from 0.4 to 20 ng/
mL for THC in the lower concentration levels,
from 20 to 300 ng/mL for THC in the higher
concentration levels, and from 0.4 to 100 ng/mL
for the two metabolites 11-OH-THC and 11-
COOH-THC. Samples exceeding the linearity
range were diluted with blank plasma, re-
extracted, and again analyzed. The limit of quanti-
fication for THCand itsmetabolites was 0.4 ng/mL
plasma.
Pharmacokinetic Calculations
Plasma concentrations versus time were used to
calculate pharmacokinetic parameters, including
plasma peak concentrations (Cmax), time to reach
peak plasma concentrations (tmax), and area
under the concentration-time curve (AUC). Based
on a noncompartmental model, all pharmacoki-
netic parameters were assessed by use of stan-
dard calculation procedures performed by the
TopFit (version 2.0) computer software.22 AUC
from time 0 to infinity (AUC0–1) or the time
corresponding to the last measurable concentra-
tion (AUC0–x) was calculated by numeric integra-
tion using the linear trapezoidal rule. Values for
C0 (extrapolated) were determined by linear
regression of the logarithmically transformed
concentration values back to the time point 0.
RESULTS
The results of the quality assurance of the test
medications, which allowed their clinical use, are
listed in Table 1. Figures 1 and 2 show the plasma
profiles of THC and the two metabolites 11-OH-
THC and 11-COOH-THC after pulmonal and iv
administration, respectively. None of the baseline
samples showed measurable concentrations of
THC or THC metabolites. The mean plasma level
of pulmonal THC after 10 min was 18.7 7.4 ng/
mL (meanSEM) with a mean duration of the
inhalation procedure of 23 3 min. The peak
plasma levels of 18.9 5.0 ng/mL were measured
at 20 min (Fig. 1). Then, the plasma concentra-
tions decreased rapidly. Peak plasma levels of the
two main metabolites 11-OH-THC and 11-COOH-
THC were 1.4 0.3 ng/mL occurring at 40 min
and 10.0 2.9 ng/mL at 120 min, respectively.
The plasma levels 5 min after the iv injection of
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THC (0.053 mg/kg body weight) ranged from 81.6
to 640.6 ng/mL (271.5 61.1 ng/mL; Fig. 2). After
that, the plasma levels decreased rapidly. Peak
plasma levels of 11-OH-THC and 11-COOH-THC
were 9.1 0.8 ng/mL occurring at 5 or 10 and
36.7 3.8 ng/mL occurring at 60 min, respec-
tively. The ratio of the AUC0–480 of THC to the
AUC0–480 of its psychoactive metabolite 11-OH-
THC was 4.4 to 1 and 6.6 to 1 after pulmonal
and iv THC, respectively. Tables 2 and 3 sum-
marize the pharmacokinetic parameters for pul-
monal and iv THC. The approximate half-lives
for iv and pulmonal THC were 73 and 46 min,
respectively.
The observed psychological and somatic side
effects are depicted in Table 4 and Figure 3. After
pulmonal THC, the symptoms irritation of the
throat and upper respiratory tract, and coughing
were highly significant compared with placebo.
These side effects were reversible within 30min of
finishing inhalation. In contrast to iv THC, the
psychotropic effects after pulmonal THC were
usually very mild. A significant difference versus
pulmonal placebo was observed for pulmonal THC
concerning euphoria, confusion and disorienta-
tion, and change of inner perception. Blood
pressure was not changed by THC, whereas both
pulmonal and iv THC increased heart rate sig-
nificantly as compared with placebo (data not
shown).
As after oral THC,10 pulmonal THC produced
hyperalgesia in the ice water pain test, an effect
which was significant versus pulmonal placebo
only after 20 min (Table 5).
DISCUSSION
It was possible to develop an aqueous inhalation
solution of the very hydrophobic THC. The output
rate of the nebulizer device was sufficient to
deliver the required dose of THC within an in-
halation time of 20–25 min. The resulting droplet
size should allow the aerosolized THC to reach
the lower compartments of the lung, thus enabl-
ing a high absorption rate. The quality assurance
of the pulmonal and iv formulation showed good
stability and physiological compatibility. The pul-
monal application of nebulized THC, therefore,
seems to be a promisingmode for the clinical use of
THC. The pulmonal bioavailability of
28.5 23.1% (0.4–60.6%) was higher than after
oral administration, where the bioavailability was
found to be 5–20%.11–13 Some volunteers even
Table 1. In Vitro Validation and Quality Assurance of the Test Medications
Test Inhalation Solution Injection Solution
Stability 3 months 3 weeks
Osmolality 550 mOsm/kg 321 mOsm/kg
Viscosity 1.478 mPas Not determined
pH value 7.40 7.40
Output rate 63.5 4.4% (meanSD) Not determined
Particle size distribution 3.8 0.32 mm (medianSD) Not determined
Sterility Not determined Passed
Figure 1. Plasma concentrations (meanSEM;
n¼ 8) of THC and its main metabolites 11-OH-THC
and 11-COOH-THC after pulmonal THC.
Figure 2. Plasma concentrations (meanSEM;
n¼ 8) of THC and its main metabolites 11-OH-THC
and 11-COOH-THC after iv THC.
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showed a bioavailability of >40%. A study com-
paring the bioavailability of oral and pulmonal
THC in individual volunteers would lead to more
conclusive results. Most of the subjects reached
plasma levels comparable to those of iv THC at
10 and 20 min. Peak plasma levels of THC
were observed before the end of the inhalation
procedure.
Regarding the plasma concentrations of the
THC metabolites 11-OH-THC and 11-COOH-
THC, similar patterns for pulmonal and iv THC
were observed. The THC to 11-OH-THC-ratios
found in the present study for iv THC, and in an
earlier study10 for oral THC, confirm the findings
reported by Wall et al.13 for iv THC. The signifi-
cantly lower formation of the psychoactive 11-OH-
THC after pulmonal THC, due to the absence of
first-pass metabolism, results in remarkably less
intensive psychotropic side effects compared with
oral THC. This is an important fact regarding the
development of future THC application forms.
The plasma concentration-time plot of the iv
administration showed first a distribution phase
with a very rapid decrease of the THC plasma
levels followed by the elimination phase with a
much longer terminal plasma elimination half-
life. This pattern is compatible with two-compart-
ment elimination kinetics described previously by
Wall et al.13 and Huestis.11
The placebo aerosol was very well tolerated
indicating a good tolerability of the vehicle with
the adjuvants used for solubilization and stabiliza-
tion of the formulation. Nevertheless, irritation of
the airwaysand coughingafter pulmonalTHCwas
observed for all subjects, meaning that THC itself
caused these adverse effects (p¼ 0.01). Coughing
Table 2. Pharmacokinetic Parameters of Pulmonal Versus iv THC
Subject Pulmonal THC iv THC
No. Gender
Dose
(mg)
AUC0–1
(ng min mL1)
Bioavailability
F (%)
Elimination Rate
Constant lz
(102)
Dose
(mg)
AUC0–1
(ng min mL1)
1 F 3.71 2528 38.8 1.600 3.30 5792
2 M 2.98 694 28.5 1.500 4.20 3437
3 M 4.08 2607 59.4 1.090 4.24 4559
4 M 4.56 1257 21.4 1.710 4.53 5827
5 F 2.34 68 0.4 3.890 2.40 20103
6 F 2.97 528 15.3 1.570 2.92 3406
7 F 3.29 367 3.7 0.823 3.50 10506
8 M 4.03 1581 60.5 0.225 4.00 2592
MeanSD 1203 969 28.5 23.1 1.550 1.070 7028 5829
F, female; M, male.
Table 3. Pharmacokinetic Parameters of iv THC
Subject iv THC
No. Gender
Distribution Volume
Vss/kg Body Weight
(Steady State) (L/kg)
Clearance CL/kg
Body Weight
(mL/min kg)
Elimination Rate
Constant lz (102)
1 F 0.847 8.14 0.578
2 M 0.598 15.44 1.370
3 M 0.403 12.08 1.400
4 M 0.300 9.03 1.500
5 F 0.324 3.41 0.566
6 F 0.668 15.30 1.320
7 F 0.431 5.37 0.813
8 M 1.120 20.26 1.280
MeanSD 0.586 0.285 11.13 5.69 1.100 0.390
F, female; M, male.
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Table 4. Psychological and Somatic Side Effects (VAS) after Pulmonal THC and Placebo and iv THC
Symptom on VAS
Median of Maximum Values on VAS
p Valuea (Pulmonal THC
vs. Pulmonal Placebo)iv THC
Pulmonal
THC
Pulmonal
Placebo
Sleepiness 89 64 22.5 0.12
Euphoria 62.5 20.5 0 0.02
Irritation 25 2 0 0.05
Anxiety 26.5 0 0 0.45
Tenseness and aggressiveness 18.5 1 0 0.45
Confusion and disorientation 80 2 0 0.03
Change of inner perception 85.5 9.5 0 0.03
Change of outer perception 72.5 0 0 0.09
Hallucinations 35 0 0 0.16
Strange thoughts, ideas, moods 34 0 0 0.32
Nausea 25 8 0 0.05
Headache 43 16.5 0 0.11
Difficulties in breathing 27.5 8.5 0 0.03
Irritation of the throat, coughing 0 75 2 0.01
Irritation of the upper respiratory tract 1.5 79.5 0 0.01
Heart problems (tachycardia) 34.5 0 0 0.16
Digestive problems 7.5 0 0 0.93
Dry mouth 100 3 3 0.48
Vertigo 76 30.5 0 0.03
aWilcoxon matched-pairs signed-rank test.
Figure 3. Psychological and somatic side effects after pulmonal and iv THC and
pulmonal placebo. Box and whisker plots according to VAS showing median, inter-
quartile range, lower and upper adjacent values, and outside values.
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impaired the inhalation procedure, and therefore,
most likely also the interindividually most vari-
able bioavailability, which would probably be
higher with a less irritating formulation of THC.
The irritations were reversible within a short time
after the end of inhalation indicating no lasting
damage to the mucosa. This particular effect of
THC was also demonstrated by Tashkin et al.23
Because the micellar formulation used in this
study did not prevent mucosal irritation, other
techniques should be tested, for example the use of
liposomes or microencapsulation. A higher mean
Cmax and very rapid increase in concentration in
the central nervous system were responsible for
the more pronounced adverse effects of iv THC,
which were mainly of a psychotropic nature. THC
did not reduce pain in the ice water test after
pulmonal administration. This confirms the ice
water test results obtained in our previous study
with oral THC. As postulated before,10 this in-
dicates that the low oral bioavailability of THC
is not responsible for the lack of analgesia. It is
assumed that the ice water test is not the right
model to determine an analgesic effect of THC.
In conclusion, the pulmonal administration of a
liquid THC aerosol leads to rapid and high plasma
levels of THC, with a metabolic pattern similar to
that of iv THC. Although the bioavailability was
much higher than after oral THC, no significant
analgesic effect was measured with an acute pain
test. Because appropriate experimental chronic
pain models are currently not available, the
analgesic effect of pulmonal THCshould be further
tested in pain patients. In addition, other solubi-
lization techniques should be evaluated to improve
the physiological tolerability of pulmonal THC
aerosols.
ACKNOWLEDGMENTS
The authors thank THC Pharm (Frankfurt/M.,
Germany) for the supply of THC, the Swiss
Federal Office for Public Health for sponsoring the
study (grant 02.000330/2.24.02-150), and the staff
of the Clinical Investigation Unit for assistance.
REFERENCES
1. Grotenhermen F. 2002. Review of therapeutic
effects. In: Grotenhermen F, Russo E, editors.
Cannabis and cannabinoids: Pharmacology, toxi-
cology, and therapeutic potential. New York: The
Haworth Press, pp 129–142.
2. Baker D, Pryce G, Giovannoni G, Thompson AJ.
2003. The therapeutic potential of cannabis. Lancet
Neurol 2:291–298.
3. Croxford JL. 2003. Therapeutic potential of canna-
binoids in CNS disease. CNS Drugs 17:179–202.
4. Smith PF. 2002. Cannabinoids in the treatment of
pain and spasticity in multiple sclerosis. Curr Opin
Investig Drugs 3:859–864.
5. Ogborne AC, Smart RG, Weber T, Birchmore-
Timney C. 2000. Who is using cannabis as medicine
and why: An exploratory study. J Psychoactive
Drugs 32:435–443.
6. Campbell FA, Trame`r MR, Carroll D, Reynolds
DJM, Moore RA, McQuay HJ. 2001. Are cannabi-
noids an effective and safe treatment option in the
management of pain? A qualitative systematic
review. Br Med J 323:13–16.
7. Noyes RJ, Brunk SF, Baram DA, Canter A. 1975.
Analgesic effect of delta-9-tetrahydrocannabinol.
J Clin Pharmacol 15:139–143.
8. Noyes RJ, Brunk SF, Baram DA, Canter A. 1975.
The analgesic properties of delta-9-tetrahydrocan-
nabinol and codeine. Clin Pharmacol Ther 18:84–89.
Table 5. Pain Tolerance in the Ice Cold Immersion Test after Pulmonal THC
and Placebo
Time (min)
Median AUC Pain Test
(Difference from Baseline)
p Valuea (Pulmonal THC
vs. Pulmonal Placebo)Pulmonal THC Pulmonal Placebo
20 127 26 0.03
40 54 34 0.21
60 129 80 0.53
120 170 62 0.12
240 160 127 0.89
480 235 99 0.67
aWilcoxon matched-pairs signed-rank test.
CHARACTERIZATION OF DELTA-9-TETRAHYDROCANNABINOL 1183
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 93, NO. 5, MAY 2004
9. Raft D, Gregg J, Ghia J, Harris L. 1977. Effects of
intravenous tetrahydrocannabinol on experimental
and surgical pain. Psychological correlates of the
analgesic response. Clin Pharmacol Ther 21:26–36.
10. Naef M, Curatolo M, Petersen-Felix S, Arendt-
Nielsen L, Zbinden A, Brenneisen R. 2003. The
analgesic effect of oral delta-9-tetrahydrocannabi-
nol (THC), morphine, and a THC–morphine com-
bination in healthy subjects under experimental
pain conditions. Pain 105:79–88.
11. Huestis M. 1999. Pharmacokinetics of THC in in-
haled and oral preparations. In: Nahas GG, Harvey
D, Agurell S, editors. Marihuana and medicine.
Totowa, NJ: Humana Press, pp 105–116.
12. Ohlsson A, Lindgren JE, Wahlen A, Agurell S,
Hollister LE, Gillespie HK. 1980. Plasma delta-9-
tetrahydrocannabinol concentrations and clinical
effects after oral and intravenous administration
and smoking. Clin Pharmacol Ther 28:409–416.
13. Wall ME, Sadler BM, Brine D, Taylor H, Perez-
Reyes M. 1983. Metabolism, disposition, and
kinetics of delta-9-tetrahydrocannabinol in men
and women. Clin Pharmacol Ther 34:352–363.
14. Joy JE, Watson SJ, Benson JA. 1999.
Marijuana and medicine, assessing the science
base. Washington DC: National Academic Press,
pp 1–14.
15. European Pharmacopeia, 4th ed., Vol. 1. 2002.
Stuttgart, Germany: Deutscher Apotheker Verlag.
16. Olsen JL, Makhani M, Davis KH, Wall ME. 1973.
Preparation of 9-tetrahydrocannabinol for intrave-
nous injection. J Pharm Pharmacol 25:244.
17. Jones SF, McQuay HJ, Moore RA, Hand CW. 1988.
Morphine and ibuprofen compared using the cold
pressor test. Pain 34:117–122.
18. Sindrup SH, Poulsen L, Brosen K, Arendt-Nielsen
L, Gram LF. 1993. Are poor metabolisers of
sparteine/debrisoquine less pain tolerant than
extensive metabolisers? Pain 53:335–339.
19. Petersen-Felix S, Arendt-Nielsen L, Bak P, Bjer-
ring P, Breivik H, Svensson P, Zbinden AM. 1994.
Ondansetron does not inhibit the analgesic effect of
alfentanil. Br J Anaesth 73:326–330.
20. Moeller MR, Doerr G,Warth S. 1992. Simultaneous
quantitation of delta-9-tetrahydrocannabinol
(THC) and 11-nor-9-carboxy-delta-9-tetrahydro-
cannabinol (THC-COOH) in serum byGC/MS using
deuterated internal standards and its application
to a smoking study and forensic cases. J Forensic
Sci 37:969–983.
21. Feng S, ElSohly MA, Salamone S, SalemMY. 2000.
Simultaneous analysis of delta-9-THC and its
major metabolites in urine, plasma, and meconium
by GC-MS using an immunoaffinity extraction
procedure. J Anal Toxicol 24:395–402.
22. Heinzel G, Woloszczak R, Thomann P. 1993. Topfit:
Pharmacokinetic and pharmacodynamic data ana-
lysis system for the PC. Stuttgart, Germany: G.
Fischer.
23. Tashkin DP, Reiss S, Shapiro BJ, Calvarese B,
Olsen JL, Lodge JW. 1977. Bronchial effects
of aerosolized delta-9-tetrahydrocannabinol in
healthy and asthmatic subjects. Am Rev Respir
Dis 115:57–65.
1184 NAEF ET AL.
JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 93, NO. 5, MAY 2004
